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Alterations in RNA and proteins observed at birth may have long-term effects on 
early life. Perinatal asphyxia (PA) accounts for a quarter of all global neonatal deaths. 
Early intervention is critical for developing strategies to improve long-term outcome. 
Early identifiers for infants at risk of HIE is prone to subjective-bias or poorly objective 
biochemical measurements. The umbilical cord blood (UCB) can give a snapshot of 
both the newborn and the in-utero environment. It is non-invasive to both mother 
and infant and contains microRNA (miRNA), messenger RNA (mRNA) and circulating 
proteins that can exist stably in the circulation. This thesis aims to progress further 
the knowledge of UCB biomarkers using low-throughput techniques in both RNA and 
protein analyses, and to explore and validate proposed and potential biomarkers in 
HIE. 
Methods 
This thesis utilised three distinct, well-defined cohorts throughout, the BiHIVE1 
cohort (2009-2011), the BiHiVE2 cohort (2012-1015), and the BASELINE longitudinal 
birth cohort (2008-2016). The BiHIVE1 cohort was recruited in Cork, Ireland (7500 
live births per annum), this study included full-term infants with PA enrolled at birth. 
This cohort recruited 112 cases (40 developed HIE - 24 mild, 6 moderate and 10 
severe), of these 52 had neurodevelopmental follow-up, and 7 died in infancy. For 
this cohort, healthy controls were recruited from the BASELINE cohort. The BiHiVE2 
validation cohort was recruited in Cork, Ireland and Karolinska Huddinge, Sweden 
(4400 live births per annum), this study included infants with PA along with healthy 
control infants. This cohort recruited 353 cases (48 developed HIE - 32 mild, 14 
moderate and 2 severe) and 289 controls, 449 had neurodevelopmental follow-up, 
and no deaths occurred in infancy. 
Infants with perinatal asphyxia had matched inclusion criteria across both BiHiVE1 
and BiHiVE2. Infants were assigned a modified Sarnat score at 24 hours and were 
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followed-up with neurological assessment and neurodevelopmental outcome at 18-
36 months of age. Umbilical cord serum, plasma and whole blood were processed 
and biobanked across all cohorts at delivery and stored at -80°C.  
Techniques employed throughout the thesis include blood processing, RNA isolations 
of whole blood miRNA and mRNA, and subsequent cDNA synthesis and quantitative 
real-time polymerase chain reaction (qPCR). Protein expression measurements were 
conducted with sandwich enzyme-linked immunosorbent assays (ELISA) on cord 
serum samples. All statistical analyses were conducted using IBM SPSS Statistics 24, 
graphical representation of data was generated using GraphPad Prism 8. 
Results 
miRNA Panel: One-hundred and sixty infants had miRNA qPCR analyses across both 
BiHiVE1 and BiHiVE2. In BiHIVE1, 12 candidate miRNAs were identified, and 7 of these 
miRNAs were chosen for validation in BiHIVE2. The BiHIVE2 cohort showed 
consistent alteration of 3 miRNAs; miR-374a-5p was decreased in infants diagnosed 
as having HIE compared with healthy control infants (P = 0.009), miR-376c-3p was 
decreased in infants with PA compared with healthy control infants (P = 0.004), and 
miR-181b-5p was decreased in infants eligible for therapeutic hypothermia (TH) 
(P = 0.02). 
Predicted mRNA Targets: One-hundred and twenty-six infants had mRNA analyses. 
In the grade of HIE severity, the level of mFZD4 was increased in severe HIE vs mild 
HIE (P = 0.004), and severe HIE vs moderate HIE (P = 0.003). Fifty-six infants were 
included in the neurodevelopmental outcome analysis; Levels of mNFAT5 were 
increased in severely abnormal vs normal outcome (P = 0.036), and in severely 
abnormal vs mildly abnormal outcome (P = 0.013). Levels of mFZD4 were increased 
in severely abnormal vs normal outcome (P = 0.004), and in severely abnormal vs 
mildly abnormal outcome (P = 0.026). 
Interleukin-16: One-hundred and thirteen infants were included in the final analyses. 
Cord blood-based IL-16 was increased in infants with perinatal asphyxia and HIE 
relative to controls (P = 0.025). IL-16 was also increased in the HIE group relative to 
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controls (P = 0.042). There was no significant difference in IL-16 across grades of HIE 
or in those with abnormal outcomes at 2-years of age. 
Activin A and mACVR2B: Serum activin A analyses included 101 infants. No 
differences were observed across the groups (P = 0.693). The HIE group included 23 
infants; a combination of mild and moderate HIE, without infants with a severe 
grade. No differences were observed across the grades of HIE (P = 0.115). Whole 
blood mACVR2B analyses included 68 infants, and no differences were observed 
across the groups (P = 0.746). The HIE group included 22 infants, and no differences 
were observed across the grades of HIE (mild and moderate only) (P = 0.468). No 
differences were observed in infants followed up to 18-36 months in serum activin A 
or in whole blood mACVR2B, (P = 0.550) and (P = 0.881) respectively. 
Conclusions 
This thesis has identified and validated the decreased expression of UCB miRNA (miR-
181b, 374a and miR-376c), increased expression of UCB mRNA (mNFAT5 and mFZD4) 
and increased UCB cytokine expression (IL-16) across two cohorts in HIE. It validates 
previous miRNA whole blood biomarkers of PA (miR-376c) and HIE (miR-374a) and 
proposes novel whole blood mRNA biomarkers as assessors for both HIE severity 
(mFZD4) and long-term neurodevelopmental outcome (mNFAT5 and mFZD4), which 
can outperform current measurements. These miRNA and mRNA could aid current 
measures as objective diagnostic and prognostic markers of HIE. It has further 
explored the strengths of cytokines and proteins and confirmed their inability as 
biomarkers across HIE groups and grades. This work has an important role in further 
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Early life is a period of profound change, and potentially altered transcript expression 
may lead to long-term alterations in growth and development. This thesis will 
examine the ability of microRNA (miRNA) and messenger RNA (mRNA) expression in 
umbilical cord blood (UCB) to predict the occurrence of hypoxic-ischaemic 
encephalopathy (HIE) in infants. 
Perinatal asphyxia (PA) occurs when the fetal blood flow through the umbilical cord 
is impaired reducing the supply of oxygen and glucose supply to the neonate; if this 
impairment is prolonged the newborn will develop an injury to the brain called HIE. 
Therapeutic hypothermia (TH) is the only treatment for HIE to date that can improve 
outcome, but only if initiated within the first 6 hours of delivery (1-4). Accurate HIE 
diagnosis within this limited window is difficult, and current biochemical and clinical 
identifiers are poor positive predictors (5-8). More specific objective biomarkers 
need to be explored and validated urgently. 
In recent years, biomarker research in HIE has explored small non-coding molecules 
including miRNAs that are present in peripheral blood cells and stable in the 
bloodstream by transportation within extracellular vesicles including membrane 
fragments, exosomes, microvesicles, and microparticles (9-11). Conducting analyses 
in UCB allows us to examine miRNA transcripts and mRNA expression and answer 
questions about conditions where the prediction of outcome is important. 
Furthermore, in HIE, reliable biomarkers would have the potential to change 
management and improve outcome. This thesis uses state of the art approaches to 
examine the ability of alterations in UCB miRNA and mRNA as biomarkers for early 





1.2 Human Brain Development 
Insults and injuries in the neonatal period are unique due to the rapid development 
of the brain occurring simultaneously, there is a high likelihood that these injuries 
may cause significant alterations to long-term neurodevelopment. The major 
milestones of brain development begin at week 3 of gestation and finishes in the 
adult life. The major developmental events begin with primary neurulation, and 
subsequent to this the development of the prosencephalon, the development of the 
posterior fossa structures, neuronal proliferation, neuronal migration, organisation, 
and myelination (12, 13). 
The formation of the neural tube, together with the development of the 
prosencephalon constitute the embryonic aspects of neural development. The 
development of the prosencephalon occurs predominantly during months 2-3 of 
gestation, particularly around weeks 5-6, and occurs across 3 events, and the most 
important molecular pathways in prosencephalic development are the Sonic 
hedgehog signalling pathway and the nodal pathway (13, 14). 
The development of the posterior fossa structures begins with brain flexure 
development in the anterior neural tube at gestational week 5, which has an 
important role in defining the region of the future rhombencephalon, the pontine 
flexure separates the future fourth ventricular roof, and the mesencephalic flexure 
appears at the border between the mesencephalon and rhombencephalon, which 
will become the future midbrain-hindbrain junction. The mid-hind brain area is 
where patterning events define cerebellar and related structures, these events are 
followed by the development of the fourth ventricle roof and the development of 
the cerebellar hemispheres (13, 15). 
Neuronal proliferation occurs primarily between 3-4 months at the ventricular and 
subventricular zones at the subependymal location across the developing nervous 
system, where neuronal units are produced by progenitor cells. Succeeding this, in 
months 3-5 primarily, neuronal migration occurs, where the neurons migrate from 





forms of migration occur called radial and tangential migration, along with axophilic 
and multipolar migration (13, 16). 
Organisational events in the brain occur from 5 months gestation until the postnatal 
years, and include the formation and differentiation of subplate neurons, alignment, 
orientation, and lamination of cortical neurons, gyral development, expansion of 
dendritic and axonal ramifications, formation of synaptic contacts, cell death and 
selective elimination of neuronal processes and synapses (13, 15). 
Finally, myelination occurs within the first 2 years postnatally, separated into 
oligodendroglial proliferation and differentiation, and myelin deposition around 
axons. The oligodendrocytes develop in waves from distinct brain regions from 
oligodendroglial progenitors to pre-oligodendrocyte to the immature 
oligodendrocyte and finally to mature oligodendrocytes, with the changes from pre-
oligodendrocyte to immature and mature oligodendrocyte occurring predominantly 






1.3 Hypoxic-Ischaemic Encephalopathy 
1.3.1 Overview 
PA is the deprivation of oxygen to the newborn and can have profound effects on the 
majority of the infant’s organs, i.e. brain, heart, lungs, liver, gut, and kidneys. Brain 
injury in PA can have profound and irreparable effects in the newborn, from mild 
cognitive impairment to severe disability or death, and when this occurs, the injury 
is termed HIE (18). HIE may result in a focal, diffuse or both focal and diffuse brain 
injury (19). Central gray matter damage, such as basal ganglia and thalami (BGT) 
lesions are considered the hallmark of HIE in newborns, with severe injury associated 
with lesions in the posterior limb of the internal capsule (PLIC), brainstem, 
hippocampal region, and cortex (20). Both BGT and PLIC lesions from HIE can be 
predictive of motor impairments and cerebral palsy (CP). Severity of BGT lesions are 
associated with presence and severity of motor impairments and PLIC signal intensity 
is associated with walking ability, both of which occur in infants with CP; and injury 
to the brainstem is associated with death (21). Basal ganglia/thalamus patterns of 
injury have been shown to be closely associated with the most severe motor and 
cognitive long-term damage (22). Prolonged partial asphyxia can cause white matter 
injury in HIE which has been linked to cognitive, visual, language, behavioural, and 
seizure problems(23). HIE and neonatal stroke share common mechanisms of injury; 
it can be difficult to differentiate HIE from neonatal stroke, as both present similarly, 
and are two of the most common injuries associated with seizures in the neonatal 
period (13, 24-26). 
Neonatal resuscitation is one of the earliest steps of intervention for PA infants with 
impaired breathing at birth, neonatal resuscitation has been separated into steps and 
standardised across many countries with the neonatal resuscitation programme, 
which uses an evidence-based approach to newborn care. Effective resuscitation and 
support at birth can significantly reduce neonatal deaths (27, 28). Improvements in 
early neonatal care for HIE has been made in high-income countries, including the 
introduction of electrophysiological monitoring and diagnostic imaging techniques, 





resonance imaging (MRI) respectively (22, 29). These techniques can both act as 
powerful tools with high performance in the identification of injury severity, and 
operate in tandem with neurological evaluation for aiding in prognoses; both fall 
short as they carry requirements for expert training in application and interpretation, 
and fail to be cost-effective and time-sensitive for early intervention. 
A significant advance in HIE was made two decades ago, following successful HIE 
sheep models, when pilot studies treating HIE infants with therapeutic hypothermia 
(TH) were delivered into the clinical setting, and these were subsequently followed 
by randomised controlled trials (30-32). A few years later, meta-analyses of these 
studies, demonstrated TH was associated with reduced neurological impairments in 
outcome and decreased death rates in infants with HIE; these findings progressed TH 
into standard care of infants with moderate-severe grade of HIE (33). However, 
cooling needs to be implemented rapidly after diagnosis as timing of cooling beyond 
6 hours has shown to be ineffective and needs to commenced within 3 hours of 
delivery to ensure improvement in outcome (1-4). 
Although there is an understanding of the origin of HIE, and the intricate 
pathophysiology that follows; knowledge gaps still exist leaving a number of open 
questions, including timing of injury onset, understanding the balance between 
injury and recovery, and creating more effective treatments for HIE infants, 
particularly those that go on to develop long-term disabilities. Development of robust 
and reliable biomarkers would create minimally invasive, cost-effective diagnostic 
and prognostic markers that may give insight into the underlying pathophysiology 
and aid current markers in improving the standard of care. 
1.3.2 Incidence 
The majority of child deaths are attributed to the neonatal period, and PA accounts 
for roughly a quarter of all global neonatal deaths with most of these deaths 
occurring in low- and middle-income settings (34, 35). Further to this, although global 
neonatal mortality has declined in the past 50 years, the fear is that this decline is 
coming from late neonatal deaths, and early neonatal deaths have failed to drop at 





The incidence of HIE specifically is estimated at 1.5 per 1000 live births in the 
developed world, with risk factors including antecedent events, growth restriction, 
infection and management during labour and delivery (36). Although the past 15 
years have seen mortality decreasing in neonatal encephalopathy, it has the highest 
global increase in years lived with disability of all ‘communicable, maternal, neonatal, 
and nutritional diseases’. This would indicate that improvements in care and 
treatments are preventing death, but the surviving infants are left with lifelong 
disability (37). 
1.3.3 Pathophysiology 
HIE is a complex process that begins at injury and can continue to develop for days 
postpartum. The initial insult occurs when the brain deprived of blood, is starved of 
oxygen, glucose and other essential nutrients; arising during a critical period in early 
brain development (figure 1.1). 
Cerebral blood flow sends oxygen and glucose across from the placenta to the fetal 
brain. This blood flow helps maintain homeostasis and meet cellular energy demands 
in the brain. Hypoxic events cause a reduction in fetal cardiac output, which reduces 
cerebral blood flow. If the decrease in cerebral blood flow is moderate, the cerebral 
arteries push blood flow from the anterior circulation to the posterior circulation to 
maintain sufficient perfusion to vital brain regions, i.e. the brainstem, cerebellum, 
and basal ganglia. This restricts the damage to the cerebral cortex and watershed 
areas of the cerebral hemispheres; with acute hypoxic events injuring the basal 
ganglia/thalamus (38). 
1.3.3.1 Primary Injury 
The progression of injury that develops after the initial asphyxial event involves 
decreased cerebral blood flow which reduces the delivery of oxygen and glucose to 
the brain, leading to anaerobic metabolism. As a result, production of adenosine 
triphosphate (ATP) decreases causing failure of energy-dependent mechanisms of 
homeostasis, including Na+/K+ ATP dependent pump to fail and for the production of 
lactic acid increases. Following pump failure, neuronal depolarisation occurs, causing 





and water, the cell releases the excitatory amino acid (EAA) glutamate, and calcium 
flows into the cell via N-methyl-D-aspartate (NMDA)-gated channels, resulting in 
cytotoxic oedema. The generation of oxygen free radicals leads to the peroxidation 
of free fatty acids and DNA/RNA fragmentation (39, 40). This culmination of energy 
failure, acidosis, glutamate release, lipid peroxidation, and the toxic effects of nitric 
oxide leads to cell death through both necrosis and apoptosis (41, 42). 
Different neuronal cells are affected by different cell death pathways post insult. In 
immature rodent models, the forebrain cortical and striatal neurons exhibit both 
apoptotic and necrotic cell death; and in the postnatal rodent model, layer-specific 
cell death pathways occur in pyramidal and nonpyramidal neurons, these pathways 
can be dependent on brain maturity (43, 44). In thalamic neurons, apoptosis appears 
to act as the central form of cell death independent of brain maturity (45). Rodent 
and porcine models have shown NMDA receptor excitoxicity to cause apoptosis in 
O4 oligodendrocyte precursors and HI and excitotoxity cause necrosis in astrocytes 
(46, 47). The post-injury release of cellular content due to necrosis causing 
inflammation, leading to an influx of microglia that release inflammatory 
messengers; this inflammation can lead to white matter injury via apoptosis (48). 
Death of immature oligodendrocytes occurs during proliferation, migration and 
maturation, prior to the onset of myelination causing long-term damage (17, 49).  





1.3.3.2 Recovery Phase and Secondary Injury 
Depending on the timing of injury and the degree of medical intervention, a partial 
recovery of the cerebral oxidative metabolism, cytotoxic oedema, and accumulation 
of EAAs occurs over 30-60 minutes, and is followed by a transient latent phase that 
sees the return of high energy phosphates, and hypoperfusion with reduced cerebral 
metabolism and improved tissue oxygenation (50). The latent phase is proceeded by 
a secondary phase of injury (second hit) that is typically associated with seizures, 
cytotoxic oedema, accumulation of excitotoxins, failure of cerebral mitochondrial 
activity and further cell death. 
1.3.3.3 Tertiary Injury 
A tertiary phase occurs during the days, weeks and possibly months after the acute 
insult and involves slow cell death, remodelling of the injured brain, and 
overactivation of astroglia and microglia (51). This may potentially expand to 
neutrophils and lymphocytes, which appear to be unable to mount an immune 
response during the initial insult, but lymphocytes may be implicated in the injury 
days later (52, 53). 
1.3.3.4 Inflammatory Response in HIE 
Inflammation plays a vital role in healthy development, but overactivation can have 
profound effects on the immature brain due to developmental plasticity. Innate and 
adaptive immunity both play an exclusive role in HIE, with a number of components 
involved in the crosstalk between the two, i.e. immune cells, adhesion molecules, 
cytokines, chemokines and oxidative stress (54). 
Attempts to understand the immune system is an ever-evolving research area. 
Further to this, the progression of research in ‘inflammatory responses to HIE’ is 
dependent on our understanding that an inflammatory response may have differing 
effects in the underdeveloped nervous system and developing brain. The 
inflammatory response for HIE occurs within minutes post insult in the neonate, 
compared to within hours in the adult (55, 56). 
Microglia, as resident immune cells of the brain, are the first to respond, followed by 





activation and aggregation of microglia are typical in HIE, particularly in the dentate 
gyrus, periventricular and subcortical white matter where they produce 
inflammatory cytokines, glutamate, NO and ROS, causing oligodendrocyte cell death, 
axonal degeneration and blood-brain barrier (BBB) disruption (58, 59). Resting 
microglia extend and retract the ramified processes while surveying the brain; 
following ischaemic insult the microglia become activated and macrophage-like, i.e. 
phagocytotic, produce inflammatory and anti-inflammatory cytokines, antigen 
presentation and release of matrix metalloproteinases causing breakdown of the BBB 
(60). 
Astrocytes become reactive in the last trimester of pregnancy and have a 
hypertrophic response in HIE. Their activation can be both beneficial and detrimental 
in HIE, by both supporting neurons, but also by producing pro-inflammatory 
cytokines, including interferon (IFN)-γ, interleukin (IL)-1α, IL-1β, IL-6, tumour necrosis 
factor(TNF)-α, which cause cell death in injured cells (61-64). 
Cytokines are produced by neurons, microglia and astroglia, and act as critical 
inflammatory mediators of the immune response. They provide both pro-
inflammatory and anti-inflammatory effects, and studies have seen a rise in cytokines 
in response to HIE (65, 66). Due to the rapid onset of the inflammatory response after 
HIE, cytokine expression levels can be studied at birth using enzyme-linked 
immunosorbent assays (ELISAs) across the cerebrospinal fluid, serum and plasma, 
making these an ideal biomarker for diagnosis and injury severity (65-68).  
Sex-differences also appear to play a role in the inflammatory response according to 
the Rice-Vanucci mouse model where females exhibiting a more robust anti-
inflammatory response were linked to fractalkine, a transmembrane protein and 
chemokine that plays a role in adhesion and migration of leukocytes (69, 70). Also, a 
few days’ post-HIE females were seen to have a smaller infarct size and fewer 
seizures, along with less brain tissue loss and behavioural deficits during the chronic 
stage of HIE. Males have been shown to exhibit a higher infiltration of peripheral 





1.3.4 Diagnosis, Prognosis and Treatment 
Diagnosis of HIE is not an easy task, as the timing, severity, and progression of the 
injury occurring over time can have profound effects on the infant. The timing of 
injury sustained can be antepartum or intrapartum, as the neonate enters into a 
disrupted asphyxia state with an obstruction to placental or pulmonary gas exchange. 
The PA events are caused by any decrease in blood flow including placenta praevia, 
vasa praevia, placental abruption, fetal-maternal transfusion, uterine rupture, cord 
prolapse, and nuchal cord (71, 72), determining the exact cause is difficult, but 
placental analysis may aid in this (38). 
1.3.4.1 Identification and Grading 
Study identification of infants with PA typically involves fulfilment of one or more of 
the following criteria (29, 32, 66, 73): 
• Umbilical cord pH < 7.1 (acidemia) 
• 5-minute Apgar ≤ 6 
• Base deficit ≥ 16 mmol/L 
• Resuscitation in the delivery room 
The low blood pH is due to increased production of hydrogen ions and is normally 
caused by metabolic acidosis; this occurs when the body increases production of 
metabolic acids, i.e. lactic acid, or when the kidneys are unable to excrete acids, i.e. 
accumulation of urea and creatinine. A base deficit is another indicator for the blood 
acidosis. 
Virginia Apgar created the Apgar score in 1952, to evaluate the infant immediately 
post-delivery. It’s a five criteria score, from 0-2 in each category, with a maximum 
total score of 10 (optimal health) and a minimum total score of 0 (requires medical 
attention). Apgar examines skin colour, pulse rate, tone, activity, and respiratory 
effort; it was not intended for long-term outcome, and although there are 
correlations between poor Apgar score and neurological impairment, CP and death, 
it is considered by many to be a poor clinical predictor of long-term outcome (8, 74). 





short-term outcomes in more than 50% of cases, including HIE (75). In a developed 
country randomised infants with Apgar scores, less than 4 at 5-min. were attributed 
to HIE or hypoxic death in 70% of the cases (76). 
Although pH, Apgar and resuscitation can provide an initial assessment of infants 
with PA that may develop HIE, they are poor indicators of insult severity and the 
progression of the HI injury. Timely and costly diagnostic techniques following the 
criteria mentioned above currently accompany neurological examination and Sarnat 
score to determine the infants’ HIE severity and prognoses, such as cEEG and MRI 
both of which require specialised equipment and interpretation. Other biomarkers 
for HIE severity and prognosis are discussed in 1.4.4. 
The Sarnat score is a classification grading scale that group’s infant into Grade I mild, 
Grade II moderate, and Grade III severe. The mild HIE infants are expected to have a 
healthy outcome, with moderate HIE expected to have neurological impairments and 
severe HIE infants expected to have a high disability and mortality rate (77). Although 
recent studies may indicate a poorer long-term outcome associated with mild HIE 
then previously suspected (78, 79). 
Neonatal cEEG acts as a typically non-invasive electrophysiological monitoring 
biomarker; it examines the brains spontaneous electrical activity over a given period, 
and it’s the current gold standard for detecting electrical seizures (80, 81). In HIE, the 
neonatal EEG can be used as an accurate identifier of HIE severity, long-term 
outcome, and can aid in clinical decision making to commence TH (29, 82, 83). 
Normal and delayed EEGs are associated with normal evolutions; and low-voltage 
EEGs, inactivity, and suppression of activity are associated with severe abnormal 
outcomes. The neonatal cEEG can be used to identify HIE severity by classification 
according to background EEG activity, where grades 0 and 1 indicate continuous 
background patterns with either normal physiologic features or slightly abnormal 
activity respectively, grades 2 and 3 indicate discontinuous activity with short and 
long inter burst intervals (IBI) respectively, and grade 4 indicates minimal background 
activity and severe discontinuity with further extended IBIs. To determine HIE 





6, 12, 24 and 48 hours, and it’s been demonstrated that classification at 6 hours can 
be used to predict outcome (29, 83).  
MRI is a robust magnetic imaging technique but has a high running cost, so 
equipment is only available in larger centres and high-resource settings. MRI is 
commonly applied to understand the heterogeneity of brain injury in HIE; previous 
MRI studies have highlighted the vascular watershed damage to the white matter 
associated with prolonged partial asphyxia, and the basal ganglia/thalamus grey 
matter damage associated with severe injury, seizures and impaired long-term motor 
and cognitive outcome (18, 22, 84). 
1.3.4.2 Treatment 
For a long time, treatment options for infants with HIE were quite limited and were 
focused on systemic, respiratory and cardiovascular baseline support immediately 
post-injury, this was until the introduction of TH as standard care. TH is administered 
using either whole body cooling or selective head cooling and involves dropping the 
infant's core temperature to 33.5°C for 72 hours (73). TH reduces injury in both basal 
ganglia/thalamus and white matter injury; it has also been shown to reduce seizure 
burden and disabling neurodevelopmental sequelae in HIE, except in the most severe 
infants (85-88). Although the benefits of TH have been demonstrated, it’s also 
important to recognise the significance of undergoing TH in the neonatal period, 
adverse effects of hypothermia include both sinus bradycardia and 
thrombocytopenia (89). 
Anticonvulsants continue to be used for infants being treated for electrographic and 
clinical seizures in HIE; but questions remain regarding their efficacy and long-term 
effects on the newborn brain in early development (90, 91). 
Emerging therapies for HIE include xenon, erythropoietin, melatonin, and stem cell 








To improve clinical research, there is a need for the use of accurate clinical 
measurement tools to explore disease pathology and human development, i.e. a 
particular biological state. This includes the use of an extensive range of analytical 
tools that can measure biological parameters; these are referred to as biomarkers, 
which the National Institute of Health working group defined as (96): 
“A characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention.” 
These biomarkers have been used across in vitro cell culture, in vivo and clinical 
research, and can be used as: 
1. A diagnostic tool for identification, staging, classification 
2. A prognostic indicator 
3. Monitoring intervention response 
4. A clinical endpoint surrogate 
Biomarkers are readily used in the hospital setting today including blood counts, 
blood glucose, blood pressure, serum low-density lipoproteins (LDL) cholesterol, and 
p53 gene, amongst numerous others (97-99). The earliest use of the term ‘biological 
marker’ dates back to studies in the 1950s, using sex chromatin which was more 
prominent in female tissue. Sex chromatin was used to examine success rates and 
proliferation rates in corneal transplants and bone marrow injections (100, 101). The 
use of biomarkers has increased dramatically over the past decade as ‘omic’ tools 
using high-throughput machines have become more cost efficient (figure 1.2) (102). 
To move novel biomarkers to clinical practice, they need to be readily available and 
efficient with minimal training prerequisites to allow medical staff to implement 
rapidly. They need to discriminate against the disease of interest from the healthy 
patient and possibly provide novel information about severity, progression, 





the biomarker should be both non-invasive with acquisition being non-deleterious to 
the patient. In cases where a single biomarker can assist with the diagnosis, but more 
information is required, it may be more useful to move towards a combined 
biomarker approach. With this, the use of multiple biomarkers that individually 
represent various areas of disease pathways may improve the exploration of 
diagnosis, staging and prognosis (103). Studying complex conditions means 
controlling for and separating out conditions based on the disease and sample-
specific heterogeneity. To develop this area further, the clinical scientist needs to 
work closely with biostatisticians and bioinformaticians, to explore traditional 
statistical models and novel machine learning algorithms respectively (104-107). 
 
Figure 1.2. Omics. The ‘omic’ approaches to biomarker discovery across DNA, RNA, proteins, and 
metabolites. 
High-throughput machines are driving the discovery of large quantities of novel 
biomarkers in multiple areas, but many problems prevent these biomarkers from 
moving from bench to bedside. High-throughput experiments can create large 
volumes of unique data; however, these outputs can be interpreted differently, and 
the clinical scientist and bioinformatician need to optimise the production by 
carefully choosing the method of normalisation, i.e. size factor normalisation vs 
global mean normalisation, and also the introduction of false discovery corrections, 
i.e. Benjamini Hochberg Procedure (108, 109). Following high-throughput discovery, 
these biomarkers need careful validation across independent cohorts, but ever-





biomarkers, represent a bottleneck in their progress. Changing conditions between 
laboratories and methods have proven to have significant implications for the end-
product. Ideally, biomarkers should be reproducible across labs and with this the 
development of standardised protocols, methodologies and assays should be put in 
place. As we move closer towards more molecular and proteomic-based discoveries 
that exist on a significantly smaller platform we need to understand the considerable 
impact minor changes may have on the discovery and validation process. 
1.4.2 Diagnostic Modelling 
Diagnostic modelling is implicit before a diagnostic marker can aid in clinical decision-
making, and the last century has seen significant developments in statistical tools for 
identifying robust biomarkers. It is clear merely demonstrating a statistical difference 
between case and control may not benefit the identification process for a viable 
biomarker. One prediction tool commonly used in diagnostic testing and seen 
throughout this thesis is the receiver-operating-characteristic (ROC), which receives 
two characteristics and plots them, both the true positive rate (TPR) against the false 
positive rate (FPR), at various thresholds. Identifying the area under the ROC 
(AUROC) can provide an optimal value of a model for diagnostic decision-making 
(104). 
Although AUROC can give part of the picture, this can be expanded further by 
indicating the sensitivity (TPR) and specificity (FPR) values, which are measurements 
for ‘diseases correctly identified’ and ‘healthy controls correctly identified’ 
respectively. Following this, further testing can be conducted by establishing the 
positive predictive value (PPV) and negative predictive value (NPV), which are 
measurements of tests positive accuracy and tests negative accuracy respectively 
(110). These similar terms can be easily misclassified, and it is best to think of 
sensitivity and specificity as a measurement of accurate disease classification, and 






Figure 1.3. Diagnostic predictions. Identification of sensitivity and 
specificity, positive predictive value (PPV) and negative predictive value 
(NPV) in diagnostic testing. 
1.4.3 Collection, Processing and Storage 
Biomarker research aims to establish straightforward cost-effective, minimally 
invasive clinical tests with high specificity and sensitivity for early detection. Good 
practice in sample collection, processing, and storage is vital for ‘gold standard’ 
biomarker discovery. Unfortunately, ever-changing methodologies can impede these 
efforts; as significant advances in the field are also accompanied by novel techniques. 
Access to high-quality samples that are collected and handled in an approach that 
minimises potential confounding factors is crucial. Defining and testing standard 
operating procedures during study design and prior to study commencement is 
critical, as minor alterations to sample processing can have profound effects in 
analytical reliability and reproducibility (111, 112). 
Best practice guidelines are needed before commencing the sample collection stage 
of early biomarker work. It is worth the time required to carefully decide on the 
biomarker source as it can have significant implications on the study, as specific 
biomarker sources can introduce a bias before the study begins, i.e. clotting cascades 
effect on cytokines (113, 114). 
The majority of biobanking in clinical research involves the collection of blood over 





other sources are well-recognised. However some of the biobanking required for 
these areas are in their infancy (115, 116). Although CSF is a powerful tool with a 
close relationship to the brain, it falls short of blood due to its invasive nature, often 
meaning that CSF biomarker studies are inadequately powered, and extensive 
collaborative efforts are needed for this field to expand further (117).  
As changes can occur across laboratory-based methods, staffing, collection, storage, 
transport, and analysis, there is a need to develop robust and consistent procedures 
at all stages of biomarker discovery (118). Problems during biofluid collection of 
blood are spread across temperature, processing times, storage, freeze-thaw cycles, 
and haemolysis, all which can affect the biomarker being explored. 
1.4.3.1 Temperature Monitoring 
Temperature monitoring is essential in maintaining good sample quality, with 
changes in temperature affecting samples at any point from collection to long-term 
storage, including sample stability which can be both temperature-dependent and 
temperature-sensitive. For this, the use of both ice and cold storage, and quick and 
efficient processing will minimise sample degradation. The long-term sample storage 
temperature for blood at -80°C has been recommended, although short-term storage 
of DNA and RNA at 4°C and -20°C may be permissible (116, 119, 120). Plasma and 
whole blood-based miRNA stored at -80°C appear stable during long-term storage, 
but unlike plasma whole blood risks degradation after 9 months (121). Alternatively 
from -80°C biobanking, the use of dehydrated samples, dried blood spots, and 
stabilising reagents are all being considered. The storage of dehydrated DNA and RNA 
samples at room temperature is promising, but problems can arise as they can be 
prone to air contamination (122), and dried blood spots currently have issues with 
viscosity and haematocrit levels which can lead to high variability in sample quality 





1.4.3.2 Blood Processing 
Choices in collection type between serum and plasma continue to be debated in 
miRNA, some groups see high correlations between the two mediums, while others 
have cautioned the effect the coagulation process may have on the miRNA profile 
(125 , 126). Blood serum, is blood plasma after clotting, and so does not contain 
fibrinogen or clotting factors, but does contain albumins, globulins, regulatory 
proteins, electrolytes, antibodies, antigens, hormones and exogenous proteins. The 
cells and clotting factors must be removed from the sample by allowing adequate 
clotting time, i.e. 30-60 minutes, without this there’s an increased risk of fibrin clots 
and other cellular contents being present; on the other hand, extended clotting time 
will result in cellular lysis, and may cause the contamination of sample with additional 
cellular content (112, 127). Blood plasma contains the same components as serum 
but also contains fibrinogen and clotting factors. It differs from serum in its collection 
method as plasma collection tubes include anticoagulants, i.e. EDTA, heparin, and 
sodium citrate, which prevent the clotting cascade (112). Centrifugation may be 
required twice to ensure platelet-poor plasma is collected as remaining platelets may 
predominate or mask extracellular RNA-based profiling; centrifugation speed may 
also affect the quantity of miRNA (128-130). 
1.4.3.3 Haemolysis 
Haemolysis is an additional factor that needs to be considered for blood-based 
sampling, as the release of cellular material into the blood due to haemolysis may 
affect the downstream analysis (131). Haemolysis and altered blood cell counts can 
manipulate miRNA biomarker levels (132). For example, in miRNA research, a 
common reference gene, miR-16, can be significantly altered following haemolysis 
due to the high levels of miR-16 present in red blood cells. However miR-16 continues 
to act as a consistent reference gene in non-haemolysed samples, best practice for 
this is confirmed via free haemoglobin measurement (133). The optimal method to 
prevent haemolysis is careful venepuncture at the collection, followed by delicate 
sample handling during processing (134). 
Overall, pre-analytical factors such as sample processing, collection, and storage, 





practice, reduce ‘type I errors’ in biomarker discovery, and enhance the likelihood of 
future biomarker reproducibility. 
1.4.4 Current biomarkers of Hypoxic-Ischaemic Encephalopathy 
Multiple biomarkers are currently used to aid in the identification of HIE infants, that 
detect neonatal seizures, brain function, brain lesions, structural injury, metabolic 
acidosis and anaerobic metabolism; these include both non-biofluid based and 
biofluid-based biomarkers, these are used in tandem with the Apgar score to try and 
evaluate the severity of HIE. The most commonly used biomarkers in clinical practise 
are cEEG, MRI, cord pH, base-deficit and lactate; although these biomarkers have 
advantages, they also have disadvantages which prevent them from acting as the 
perfect robust and reliable biomarker for the diagnosis of HIE (135, 136). 
For  non-biofluid-based biomarkers the cEEG is useful as its the gold-standard tool 
for detecting neonatal seizures and can predict the outcome of infants with HIE at 6 
hours of age, it can also be used as a classification tool for the EEG grade of HIE; but 
the tool is costly, requires training for application of electrodes, requires a trained 
neurophysiologist for interpretation (137-139). The MRI is also a powerful tool for 
identifying the pattern of injury in HIE and is predictive of long-term injury (22, 140). 
However similar to the cEEG is costly and requires specialist training for 
interpretation, further to this it the neonates may not be stationary for the full 
duration of the MRI affecting image quality (135, 141). 
For biofluid-based biomarkers, a number of useful biomarkers are collected from the 
cord blood gas analyser at birth these are all particularly useful due to the short-time 
needed for processing and analysis of the sample; cord pH <7.0 is used to predict 
pathological acidosis, although this can identify acidosis additional information such 
as base deficit >12 mmol/l is needed to confirm metabolic acidosis (142). Although 
both are useful for identifying infants with perinatal asphyxia at risk of developing 
HIE and can act as strong predictors of an adverse outcome, both have difficulty 
predicting severity of HIE or the long-term outcome (143-145). Finally, cord lactate, 
which is an end-product of anaerobic metabolism, and a good indicator of tissue 





complement MRI in identifying infants with poor long-term outcome (146, 147). 
Limitations to lactate are its gestational age-dependent values can prevent suitable 
reference ranges and cut-offs, and its inability similar to differentiate mild HIE from 
moderate HIE (148). 
Pilot biomarker studies, see 1.4.5, have demonstrated the potential of cytokines, 
miRNA, and neuronal-specific molecular markers that could complement current 
biomarkers and aid in the clinical diagnosis, however to date most research has failed 
to recruit a large-scale well-defined validation cohort to confirm the novel findings. 
1.4.5 Biofluid-based Markers of Hypoxic-Ischaemic 
Encephalopathy 
HIE biomarkers have the potential to give the clinician an early diagnosis, prognosis, 
and insight into the severity of the newborns injury. For the past two decades, the 
evolving understanding of HIE pathophysiology has given researchers a focus for 
candidate biomarkers associated with the injury. This research has examined 
different aspects of the injury as potential avenues for biomarker discovery, 
including: 
Breakdown of neuronal cells 
Necrosis and apoptosis occur throughout the various stages of HIE in a “continuum” 
(149). These processes lead to the breakdown of the neuronal cells, causing the 
release of neuronal-specific materials post injury (150). i.e. Brain-derived 
neurotrophic factor (BDNF), Fas ligand, Neuron-specific enolase (NSE), NR2, and 
Ubiquitin-C terminal hydrolase L1 (UCH-L1) (65, 151-154). Breakdown of 
oligodendrocytes can be identified in HIE by measuring myelin basic protein (MBP) 
which can leak into the CSF following acute injury (155). TNF-α when released from 
astrocytes and microglia has also been shown to damage oligodendrocyte progenitor 
cells (OPC) in vitro (156). NMDA receptor excitotoxity can cause apoptosis in OPC and 
both hypoxic insults and excitotoxity will induce necrosis in astrocytes in animal 






Excitotoxic effects of excitatory amino acids (EAAs) 
EAAs act as neurotransmitters and are critical for the generation of action potentials. 
Overactivity of EAAs glutamate, aspartate and EAA agonists can bring an excitotoxic 
effect to the immature brain (157). Multiple EAA receptors in neurons have an 
increased likelihood to be perturbed during HIE. Early life is a critical period for 
receptor development and EAA uptake, and when HIE occurs during this period the 
organisational development and synapse formation may be affected. Additionally, 
increased intracellular calcium through the activation of the NMDA receptor, and 
mitochondrial dysfunction leads to EAA-mediated injury (157, 158). 
Free radicals and Oxidative stress 
Free radicals are atoms with an unpaired electron, i.e. nitric oxide, and reactive 
oxygen species (ROS), are free radicals directly related to oxygen species, i.e. 
superoxide anions, and hydroxyl radicals. Free radicals are generated both 
intracellularly and extracellularly, with complex III mitochondrial ROS production 
acting as the primary intracellular source (159). The release of free radicals can cause 
damage to all components of the cell and is one of the hallmarks of HI, such as nitric 
oxide synthase (NOS) which is a significant source of brain ROS during HIE (160, 161). 
Release of cytokines and inflammatory markers 
Cytokines are proteins secreted by immune cells, endothelial cells and fibroblasts; 
cytokines are categorised as pro-inflammatory, anti-inflammatory and growth 
factors, but all function in intercellular communication and promote recruitment 
across cells. i.e. C-reactive protein, IL-1β, -6, -8, -10, -16, and TNF-α. 
The immature brain is more susceptible to inflammation; Adinolfi and Leviton have 
described the damage caused by cytokine production, such as TNF-α, following 
maternal infection, and how this damage can contribute to both white matter injury 
and preterm birth (162-164). Cytokines can be produced in the placenta, the fetal 
circulation; and in the fetal brain by both microglia and astrocytes; cytokines have 





and permeability, which may have long-term consequences on brain development 
(58, 165-168). 
Inflammation occurs temporally across neonatal brain injury and differs from adult 
injury due the plasticity and development of the immature brain (54). Inflammation 
in the perinatal period can have long-term effects on neurodevelopmental outcome; 
and the inflammatory processes triggered can continue over the postnatal weeks, 
and progress across from proinflammatory, to anti-inflammatory, to reparative and 
resolution/chronic inflammation (54, 169, 170). 
A wide-body of cytokine-related HIE publications began in the 1990s that 
demonstrated the presence of cytokines in both the brain tissue of HIE rodent models 
and in biofluids of neonates with HIE and white matter injury, this research together 
with Leviton’s adapted hypothesis has pushed this field ahead although the 
understanding of newborn inflammation remains incomplete (171). Rodent models 
demonstrated increased expression of both chemokines and cytokines, IL-1β, IL-6, 
MCP-1, MIP-1α, MIP-2 and TNF-α mRNA in hypoxic-ischemic brain tissue (52, 172, 
173). Models have also demonstrated rapid activation of microglia and mast cells and 
the accumulation of leukocytes in areas of injury prior to the initiation of secondary 
injury; innate immune activation is followed by inflammatory injury via the adaptive 
immune response (54). 
Animal models are needed to understand biological processes particularly at the 
molecular levels however, a bioinformatic-based study on neuroinflammation 
comparing humans to mice, demonstrated that only 27% of cytokine-cytokine 
pathway interactions are similar across species; however at the cellular level a higher 
similarity of 62% of interactions was present (174). Animal models of HIE can 
commonly use the endotoxin lipopolysaccharide to induce inflammation but it 
remains difficult to have a faithful animal model of inflammation due to varying 
development of glia, neurons and oligodendrocytes across species; further to this 
current literature is contradictory in the use of mouse models in inflammatory 





Although animal models have continued to display evidence supporting 
inflammation in HIE, largescale clinical validation of the inflammatory process is still 
ongoing. Neonatal biofluid studies in HIE and white matter injury described the 
presence of IL-1β, IL-6, IL-8 TNF-α in amniotic fluid, umbilical cord plasma, and CSF 
(52, 178-183). Dried blood spots have demonstrated elevated Il-1β, IL-6 and IL-8 at 
30 months in HIE infants, cord serum IL-6 was also increased in HIE at 2-year outcome 
(184, 185). More recent publications such as Bartha and Walsh have progressed 
cytokine-related biofluid/biomarker research into larger scale studies using 
chromatography and the Luminex multiplex assay respectively, both of which have 
shown encouraging results and potential, but subsequent validation research is 
needed (66, 185, 186). 
Multiple neuroinflammation therapies have been tested in animal models of HIE, i.e. 
minocycline, melatonin and erythropoietin. The effect size of these treatments has 
been low, and not translated consistently between animal and clinical studies; this 
can be particularly difficult due to negative effective effects on early brain 
development. 
Biomarker pilot studies to date are primarily focused on the first four days of life and 
vary between mediums with most focused-on serum and plasma. Although these 
studies have been conducted temporally throughout the postnatal period, the 
umbilical cord remains an essential resource as a minimally invasive method for 
blood collection, where larger volumes can be collected to allow biomarker discovery 
(table 1.1). 
Multiple biomarker studies have looked beyond the biomarkers used in the initial 
diagnosis and explored its use in long-term prognosis for infants with HIE. These 
studies look at the candidate biomarkers ability to predict normal vs abnormal 
outcomes based on death, development of CP, epilepsy and in less severe cases 
developmental delay. Developmental assessment tools, which screen infant and 
toddler development, i.e. Bayley Scales of Infant and Toddler Development-III (BSID-
III), the Griffiths Developmental Scales and the Denver Developmental Screening Test 





have shown to be increased in infants with poor long-term outcome including 





Table 1.1. Clinical biofluid-based biomarker studies in identification and severity of Hypoxic-Ischaemic Encephalopathy. 
Biomarker Description Effect Time point Medium References 
Activin A Homodimeric TGF-β superfamily cytokine that signals primarily 































0-24 hours (h) Cerebrospinal 
fluid (CSF) 
(194) 
0 h, 12 h, 24 h, 




Transaminase enzyme, the transamination reaction it participates in 
produces pyruvate and L-glutamate.  Found predominantly in the 
liver. 
0-12 h Plasma (196) 
0-6 h Serum (197) 
Amino acids Taurine, alanine, tyrosine, methionine, valine, phenylalanine, leucine, 
isoleucine. 
18 h (cases), 
66 h-4.4 D 
(controls) 
CSF (157) 
Taurine. 16 h (cases) 




Transaminase enzyme, the transamination reaction it participates in 
produces oxaloacetate and glutamate. Found predominantly in the 
liver, cardiac muscle, skeletal muscle, kidneys, brain and 
erythrocytes. 
0-12 h Plasma (196) 
Brain-derived 
neurotrophic factor 
Protein; member of the neurotrophin family of growth factors, 
related to canonical nerve growth. 
Cord Plasma (152) 
Cardiac troponin I Cardiac regulatory protein controlling calcium-mediated interaction 
between actin and myosin. 
0-36 h Serum (199) 
C-reactive protein Pentameric plasma protein produced by the liver that increases in 
response to systemic inflammation. 
Unknown Serum (200) 
Creatinine kinase 
muscle-brain fraction 
Enzyme converting creatine to phosphocreatine. Cord, 2 h, 6 h, 
12 h, 24 h 
Serum (201) 
0-6 h, 48 h Serum (202) 
4 h, 10 h Serum (203) 
Cord, 6-10 h, 
24-30 h, 72-80 
h 
Serum (204) 








































18 h (cases), 
66 h-4.4 D 
(controls) 
CSF (157) 
16 h (cases), 
24 h (controls) 
CSF (198) 
Fas-ligand Type II transmembrane protein. Binding with its receptor induces 
apoptosis. 
0-3 days (D) CSF (206) 
Glial fibrillary acidic 
protein 
Cytoskeleton intermediate filament protein specific to astrocytes. Cord, 6-24 h, 
48-72 h, 78-96 
h 
Serum (65) 
0-6 h, 24 h, 72 
h, 4 D 
Serum (207)  
Interleukin-1β Macrophage produced cytokine that’s act as an important mediator 
of the inflammatory response. 
0-24 h Serum, CSF (208) 
0-24 h CSF (178) 
Cord, D 1, D 3 Plasma (209) 
Interleukin-6 Pro-inflammatory cytokine that actives multiple inflammatory 
pathways by inducing transcription factors. 
6-24 h Serum (65) 
0-3 D CSF (206) 
Cord Plasma (66) 
Cord Serum (184) 
0-24 h Serum, CSF (208) 
Unknown Serum (200) 
0-48 h Plasma, CSF (210) 
Interleukin-8 Inflammatory chemoattractant cytokine that targets neutrophil 
recruitment and degranulation. Increased by oxidative stress. 
6-24 h, 48-72 
h 
Serum (65) 
0-24 h, 48-72 
h 
Serum (67)* 
Cord, D 1 Plasma (209) 
Interleukin-10 Anti-inflammatory cytokine 48-72 h Serum (67)* 
Interleukin-16 Pleiotropic cytokine functioning as chemoattractant and modulator 
of T-cell activation. Processed by caspase-3 and has neuronal-specific 
isoform. 
Cord Plasma (66) 





Lactate Intermediary metabolite, produced in anaerobic metabolism, 
excreted by the kidney. Creatinine Breakdown product of creatinine 






































Enzyme converting lactate into pyruvate. 0-12 h Plasma (196) 
Malondialdehyde Product of lipid peroxidation. 0 h, 48 h Serum (212) 
miR-374a-5p miRNA involved in post-transcriptional modification. Cord Whole blood (213) 
Neuron-specific 
enolase (NSE) 
Dominant enolase-isoenzyme in neuronal and neuroendocrine 
tissues. 
12 h, 24 h Serum (151) 
4-48 h, 5-7 D Serum (214) 
D 1 Plasma (154) 
Neuronal nitric oxide 
synthase (NOS1) 
Synthase that catalyses production of nitric oxide from L-arginine. Cord Plasma (215) 
0-24 h CSF (216) 
NR2 Binding site on NMDA receptor of neurotransmitter glutamate. D 1 Plasma (154) 
Nucleated red blood 
cells (NRBC) 
Progenitors to mature erythrocytes. Present at low levels in infancy. 0-24 h Red blood cells (66) 
Phosphorylated 
axonal neurofilament 
heavy chain (pNF-H) 
Major subunit of neurofilaments, the main component of axonal 
cytoskeleton. 
0-6 h Serum (217) 
Protein carbonyl Oxidative stress marker. 0 h Serum (212) 
Protein S-100β Calcium-binding protein component of cytosol. Predominant in 
astrocytes and Schwann cells. 
Cord, 2 h, 6 h, 
12 h, 24 h 
Serum (151) 
Cord Serum (218) 
Cord Serum (219) 
0 h Saliva (220) 
Soluble intercellular 
adhesion molecule 1 
(sICAM-1) 
Protein involved in trans-endothelial migration of leukocytes during 
inflammation. 
D 3 Plasma (154) 
Troponin T Part of troponin complex expressed in skeletal and cardiac myocytes 0-6 h Serum (197) 
Tumour necrosis 
factor-α 
A major pro-inflammatory cytokine involved in early inflammatory 
events. Triggers series of inflammatory molecules. 
0-24 h Serum, CSF (208) 
Unknown Serum (200) 
0-24 h CSF (178) 









Cord, D 1 Plasma (209) 
Ubiquitin C-terminal 
hydrolase L1 (UCH-L1 
Neuronal and neuroendocrine-specific deubiquitinating enzyme. 
Concentrated in neuronal perikarya and dendrites. 
Cord Serum (221)  
Cord Serum (65) 
0-6 h Serum (217) 
Vascular endothelial 
growth factor (VEGF) 
Inflammatory signal protein associated with increased permeability 
in the blood-brain barrier. 
48-72 h Serum (65) 
0-24 h CSF (216) 
Secretoneurin Highly conserved polypeptide present in large dense-core vesicles of 





Cord [1], 48 h 
[2] 
Serum (222)  
Total serum bilirubin 
(TSB) 
Compound produced from breakdown of heme. Decrease 2-5 D Serum (223) 
*HIE with seizures. 






Francis Crick’s central dogma of molecular biology saw DNA transcribed into RNA, 
and this RNA translated into protein, but this began to change in 1970 when a Nature 
article by an unassigned author wrote, “The central dogma, enunciated by Crick in 
1958 and the keystone of molecular biology ever since, is likely to prove a 
considerable over-simplification” (224). Already researchers were beginning to find 
differences in Crick’s original vision, and discoveries including reverse transcription 
of viral RNA into DNA, identification of small RNA molecules and RNA splicing, which 
continued over the next 20 years (225-227). Following this, in the early 1990s, the 
first miRNA and small interfering RNA (siRNA) was discovered, at this point, it became 
clear that Crick’s central dogma needed to be expanded as these non-coding RNAs 
were acting to fine-tune gene expression and adding new layers to the complexity of 
gene regulation (228, 229). 
The first miRNA discovered was in the Caenorhabditis elegans, a  roundworm model 
for neuronal development (230). It was named lin-4 and mediated temporal control 
of postembryonic development by repressing the lin-14 protein (228, 231). A few 
years later both lin-4 and let-7 in C. elegans, consisting of 22- and 21-nucleotides 
respectively were found to be conserved across a wide range of species, including 
humans, implicating these small RNAs as effectors of human development (230). 
Over the following years, miRNAs were shown to have critical roles as fine-tuning 
gene regulators in both development and physiology, including cell proliferation, cell 
death, fat metabolism, hematopoiesis, circadian rhythm and nervous system 
development (232-235). 
It was initially predicted that over one-third of human regulatory genes were 
conserved targets of miRNA; it’s now believed that over 60% of protein-coding genes 
are targeted (236, 237). In 2004, it was suggested that the total number of human 
miRNAs was over 800, including ~400-500 conserved miRNAs (238), as of 2018 that 
number has been far exceeded with registered human mature miRNA now at 2,654 




As research continued in miRNA, researchers began to explore miRNA in human 
cancers, first described in 2002 (240). Cancer research found miRNA genes were 
located at both fragile sites and genomic regions involved in cancers, and a general 
downregulation of miRNA across cancer tissues when compared with healthy tissue. 
From this, the researchers could classify tumours using miRNA expression profiles, a 
task that could not be completed with mRNA expression profiles, suggesting a novel 
role for miRNA profiling in diagnostics (240, 241). At this time, researchers also 
proposed miRNA had links with genetic diseases, insulin regulation, adipocyte 
differentiation, and viral infection; and in the last two decades, this has expanded 
further into immunity, nervous system disorders, psychiatric disorders and metabolic 
disorders (242-248). 
Although significant work was conducted in miRNA profiling of disease-specific 
tissue, it wasn’t until 2008 when researchers described miRNAs present in serum that 
are stable, reproducible, and consistent in humans that the true diagnostic potential 
of miRNA was revealed (249). This research went on to describe serum-specific 
miRNA expressions unique to several cancers, and diabetes, and with this, a novel 
class of biomarkers were identified (249). In the last decade, this has created an ever-
expanding reservoir of miRNA-based publications and patents trying to establish a 
robust and reliable biomarker that can perform a minimally invasive ‘liquid biopsy’ 
for screening, diagnosis and prognosis across thousands of diseases and disorders. 
1.5.2 Biogenesis and Mechanism of Action 
The mature miRNA sequence that degrades or represses the target mRNA is a short 
non-coding RNA (ncRNA), approximately 21-25 nucleotides in length; but biogenesis 
of the mature miRNA begins in the genome. The miRNA genes need several proteins 
for processing, the main players being RNA polymerase II, RNase III endonucleases 
(Drosha and Dicer), exportin 5 (EXP5) and Argonaute (AGO) proteins (250). These 
proteins progress the miRNA gene from its passive state in the nucleus, to being 
actively involved in the post-transcriptional modification of mRNA targets. The 




in embryonic mice models, which showed lethality when deficient of these proteins 
during embryogenesis due to abnormal placental development (251-254). 
The biogenesis process begins when RNA polymerase II transcribes the miRNA gene 
from introns (or exons occasionally), creating a primary miRNA (pri-miRNA) stem-
loop structure, typically over 1 kb (255). This imperfect stem-loop (hairpin) structure 
is a partially double-stranded RNA molecule with single-stranded overhangs at both 
ends, with each side of the upper portion of double-stranded RNA containing both 
the 5’ and 3’ miRNA end product (250, 256). The next step of processing involves the 
cleavage of the pri-miRNA by the RNase III endonuclease Drosha that removes the 
single-stranded RNA 5’ and 3’ overhangs and part of the double-stranded RNA lower 
stem, creating a pre-miRNA complex (257). The pre-miRNA made up of the remaining 
upper portion of the stem-loop structure approx. 70bp is exported from the nucleus 
by the exportin 5 (XPO5) protein; interestingly export of pre-miRNA is increased 
following DNA damage (250, 258, 259). 
Once the pre-miRNA has left the nucleus, it is cleaved by another RNase III 
endonuclease called Dicer, which removes the loop structure forming a small RNA 
duplex, which is loaded on the AGO protein, in an ATP-dependent step, to create a 
complex called the RNA-induced silencing complex (RISC) (260). After loading, the 
guide strand (be it the 5’ or 3’ miRNA strand) is retained in RISC, and the passenger 
strand is released and quickly degraded, leaving a mature miRNA RISC complex. 
Strand selection between the 5’ and 3’ miRNA can vary, and the less 
thermodynamically stable miRNA is generally chosen as the guide strand (261, 262). 
For mRNA target degradation to occur, the miRNA binds to the 3’UTR of the mRNA 
target with perfect complementarity. However, this is not the standard mechanism 
in mammals. In most cases, human mature miRNA complexes regulate gene 
expression in a sequence-specific manner by binding to the target 3’ untranslated 
region (3’UTR) with imperfect complementarity and function as translational 
repressors; this involves perfect base pairing of nucleotides in the ‘seed region’, i.e. 
nucleotides 2-8 of the miRNA. Additionally, good pairing in miRNA nucleotides 13-16 
will further assist translational repression, along with additional factors (263-265) 




is still unclear (266). Although the functional connection is not clear, it’s been shown 
that the mature RISC complex and translationally repressed mRNA targets are 
localised to processing bodies (P-bodies) for further mRNA degradation (figure 1.4) 
(267). 
miRNA can act on and repress multiple mRNA targets, and multiple miRNAs can act 
on and repress an individual mRNA target (268).  In addition, in some cases, miRNA 
have been shown to upregulate their mRNA targets (269). It is important to recognise 
that miRNAs are suspected to regulate the majority of cellular processes, and change 
in response to injury, developmental or disease processes; miRNA are under complex 
regulation and exist in a tissue-specific and cell type-specific manner (243, 270, 271). 
It is also important to be aware that many unknowns appear across the miRNA field 
in biogenesis, regulation, and function. This is an exciting area of research where each 





Figure 1.4. microRNA biogenesis. RNA polymerase II processes the microRNA (miRNA) 
gene. The RNA Polymerase II enzyme Drosha cleaves the pri-miRNA overhang. The pre-
miRNA is exported from the nucleus by the exportin-5 (XPO5). The stem-loop is cleaved 
from the pre-miRNA by the RNA polymerase II enzyme Dicer. The miRNA duplex is 
loaded into the RNA-induced silencing complex (RISC). The guide strand (mature miRNA) 




1.5.3 Circulating microRNA and mRNA as Biomarkers 
When miRNA are explored beyond the cellular scope in biofluids, we begin to 
appreciate further complexities in the miRNA field. miRNA not only appear to be 
present in biofluids but appear ubiquitous and stable across all fluids, i.e. plasma, 
cerebrospinal fluid, urine, breast milk, colostrum, seminal fluid, tears, saliva, amniotic 
fluid, peritoneal fluid and bronchial lavage (273). Whole blood-based cellular miRNA 
have also been shown to be stable (274). 
Circulating miRNA has been shown to be protected from RNase degradation through 
either protein-binding or extracellular vesicles. Protein-bound miRNAs are the 
predominant form of extracellular miRNA. However a smaller portion of miRNA are 
transported in extracellular vesicles (275, 276). Protein-bound miRNA include those 
bound to AGO proteins, high-density lipoproteins and low-density lipoproteins. 
Extracellular vesicles that contain miRNA include high molecular weight complexes, 
membrane fragments, exosomes, microvesicles, and microparticles (figure 1.5) (9, 
277). Terms for these extracellular vesicles can be confused and merged under one 
umbrella term but they exist in their own right under restrictive ‘size’, ‘marker’ and 
‘function’ definitions (9-11). The extracellular vesicles have been suggested as 
specific cell-to-cell RNA delivery systems (278, 279). Some open questions regarding 
the specific role of circulating miRNA remain: are miRNA actively or passively 
released from the cells? Do miRNA appear in the biofluids due to apoptotic budding? 





Figure 1.5. Circulating microRNAs. The various sources of circulating microRNAs. 
Beyond the potential miRNA mechanisms of transport and circulation, it is their 
stability in biofluids that make miRNA particularly attractive as detectable and 
quantifiable biomarkers for the disease process. In 2008, several groups brought this 
idea forward proposing circulating miRNA may be a viable biofluid biomarker for 
various cancer types (249, 280, 281). Following this, the circulating miRNA biomarker 
field exploded, with the volume of publications increasing each year. Circulating 
miRNA biomarkers have been explored across cancer, fetal programming, birth 
injury, neuropsychiatric disorders, neurodegenerative diseases and non-
communicable diseases (213, 277, 282-284). 
1.5.3.1 Circulating mRNA as Blood-based Biomarkers 
Alongside miRNA, circulating mRNA have also been explored as promising 
biomarkers of injury (285, 286). Both miRNA and mRNA may exchange transcellular 
genetic information via exosome-mediated genetic exchange across cells (278, 287). 
Exosomal mRNA is fragmented making it smaller compared to normal mammalian 
mRNA but longer than both pre- and mature miRNA (288). Whole blood-based 
mRNA, similar to miRNA, includes mRNA from erythrocytes, leukocytes, platelets, 
and circulating via exosomes, meaning mRNA -based biomarker discovery may be 




1.5.4 Techniques and Tools for miRNA Research 
Multiple techniques and tools exist for the study of circulating miRNA profiling, in 
most cases for detection and quantification the miRNA must be isolated from the 
blood sample and go through high-throughput discovery, i.e. next-generation 
sequencing (NGS) and microarray hybridisation. After mass quantities of data are 
produced, these methods require computational and statistical expertise to 
normalise and correct for the large data output. This data output could give insight 
into the altered miRNA expression across a large panel of miRNA, something that can 
prove difficult with low-throughput methods. Low-throughput validation involves 
the qPCR method, this is the more common approach for studying miRNA across 
laboratories, as it is more cost effective, and can bypass discovery work based on 
potential biological significance and previous literature in the field. For terminologies 








Small non-coding 21-25 RNA involved in the post-transcriptional 
modification of mRNA. 
miRNA precursor 
(pre-miRNA) 
Stem-loop miRNA includes two arms, both -5p and -3p, and is cleaved by 
the Dicer enzyme to produce mature miRNA. 
miR-1-5p, miR-1-3p 
 
-5p, -3p indicate sense and antisense arms respectively of miRNA 
precursor before an arm is processed into the mature miRNA; normally 
one arm is processed, but in certain situations, both can be processed and 
functional. 
miR-1a, miR-1b, miR-1c Letters following the number indicate same ‘miRNA family’. 
iso-miR-1 Minor variations of established pre-existing annotated miRNAs. 
Seed region Nucleotides 2-8 from 5’ end of the miRNA; seed region is critical for target 
recognition; matching seed regions between miRNA indicate ‘miRNA 
family’. 
miRNA gene clusters 
 
miRNA genes clustered in tandem within the genome; may collectively 





A large family of RNA molecules that supply ribosomes with genetic 




A region of the mRNA molecule near the poly(A) tail, it’s not translated 
into a protein and can contain regulatory regions that post-
transcriptionally regulate gene expression.  
Microvesicles 
 
Large 50-1000 nanometres (nm) extracellular vesicles in the eukaryotic 
fluid that contain both mRNA, miRNA and proteins. 
Exosomes 
 
Small 30-100 nm cell-derived vesicles in the eukaryotic fluid that can 
contain both mRNA, miRNA and proteins. 
Lipoproteins Lipoproteins that transport lipids around the body; these can also contain 
and transport mRNA and miRNA. 
Serum 
 
The component of blood remaining following clotting post-centrifugation 




A clot formed in blood serum following incomplete clotting prior to 
experiment or storage of serum sample. 
Plasma 
 
The component of blood remaining post-centrifugation after removal of 
erythrocytes and leukocytes (buffy coat); it contains an anticoagulant, 
and so plasma contains inactivated clotting factors. 
Buffy coat 
 
The fraction of blood containing leukocytes in a plasma sample post-
centrifugation; resting between plasma and erythrocytes. 
Whole blood 
 




Rupturing of erythrocytes during serum, plasma or whole blood 
collection, due to incorrect need, tubing, mixing, filling, or excessive 
forces, this can affect experimental testing. 
High-throughput 
 
Large data acquisition, usually from a small sample set; generally used in 
the biomarker discovery stage, as it is both costly and may contain a large 
volume of false positives, i.e. next-generation sequencing and 
microarray. 
Low-throughput Small data acquisition, usually from a large sample set; generally used in 
the biomarker validation stage as it both cheaper and more accurate, i.e. 
qPCR. 






Used for absorbance measurements of a molecule, such as nucleotides, 
RNA and DNA. 
RNase contamination 
 
Environmental and biological ubiquitous ribonucleases that degrade RNA 
samples during RNA extractions. 
260/280 and 260/230 
 
The ratio of absorbance at 260 nm and 280 nm, and at 260 nm and 230 
nm respectively, are used as the primary (260/280) and secondary 
(260/230) measures of nucleic acid purity in DNA and RNA, following DNA 
and RNA extractions. 
RNA integrity number 
(RIN) 
 
The RIN is an algorithm for assigning integrity values to RNA 






The low-throughput method that monitors the amplification of a 
targeted complementary DNA (cDNA) or DNA molecule in real-time. 
TaqMan method Hydrolysis probes designed to increase the specificity of quantitative PCR. 
SYBR Green method A dye for the quantification of double-stranded DNA in quantitative PCR. 
Absolute quantification 
 
Quantification using the exact number of target RNA molecules by 
comparison with RNA standards using a calibration curve. 
Relative quantification 
 
Quantification using reference genes to determine fold-change 




Cellular and extracellular genes with consistent expression under normal 
and pathophysiological conditions.  
RNA spike-in control 
 
Adding a transcript of known sequence and quantity during RNA isolation 
or cDNA step, the spike-in is measured during qPCR to ensure normal 
expression across the sample set. 
Microarray 
 
A high-throughput method where RNA is converted to fluorescently 
labelled cDNA and is hybridised with multiple probes, measurement of 
the hybridised chemiluminescent reaction allows quantification of the 




A high-throughput method where RNA sample is converted to cDNA, 
fragmented, and ligated with an adaptor sequence. Modified cDNA is 
added to a chip with multiple probes and clusters are generated. Next, 
primers and modified fluorescent nucleotides are added. After each 
round of synthesis, the fluorescence is recorded using wavelength to 
identify bases on each parallel sequence. The process is repeated until 
the sample is fully sequenced. 
False discovery rate 
 
A statistical method for correcting false positives on large datasets, but 
is less stringent than more common methods, i.e. Bonferroni correction. 
Fold change 
 
Increase or decrease of times miRNA of interest in the case group 
compared to the control group, i.e. ‘2-fold increase in miR-X’ is equivalent 
to ‘miR-X is 2 times higher in cases than controls’. 
Bioinformatics 
 
Methods and software tools for understanding biological data using 
biology, computer science, mathematics and statistics. 
Gene ontology (GO) 
 
Bioinformatics initiative to conglomerate gene and gene product data 





1.5.4.1 Isolation of RNA 
miRNA extraction and isolation are performed immediately after blood processing, 
or following thawing of the frozen sample. Four universal techniques can accomplish 
the RNA isolation: filter-columns, magnetic beads, organic extractions, and the cell-
lysis method. In some situations, these techniques may be amalgamated to optimise 
and purify the RNA isolate, i.e. chemical extraction followed by filter-columns. These 
techniques each come with strength and weaknesses, for example, the organic 
extraction method can be difficult to automate, and the direct lysis method, once 
correctly optimised may be preferred for NGS, but this sample will not be applicable 
for qPCR as it is reliant on concentration and will not produce a spectrophotometric 
yield (289, 290). Comparisons across quality of different kits can be difficult as 
numerous confounders exist due to events prior to isolation and potential laboratory 
bias. Previous research has suggested that Exiqon miRCURY Biofluids Kit (Exiqon, 
Denmark, following the acquisition; Qiagen, Germany) and Qiagen Serum/Plasma kit 
(Qiagen, Germany) both perform superior to other isolation methods; but other 
groups have drawn alternate conclusions, finding the Macherey-Nagel kit superior 
(Macherey-Nagel, Germany) (128, 291). 
Following RNA isolation RNA quantity and quality is assessed across two mediums, 
both the NanoDrop spectrophotometer for RNA quantity (NanoDrop Technologies, 
Germany) and the Bioanalyser chip for RNA quality, this is completed using an RNA 
integrity number (RIN) value (Agilent, USA). The NanoDrop measures the RNA yield 
but also takes primary and secondary measures of the absorbance ratio at 260 
nm/280 nm, and 260 nm/230 nm for assessing RNA purity(292). The Agilent 
Bioanalyzer is the recommended method for RNA quality which creates a RIN value 
from 1-10, with 10 implying intact and non-fragmented RNA and 0 implying poor and 
fragmented RNA (293) 
1.5.4.2 Microarray and Next-Generation Sequencing 
When exploring high-throughput methods, it becomes clear that two methods are 
competing for the researcher's attention. Both microarray hybridisation and NGS 




produce previously. These methods have significantly more implications across 
diagnostic/clinical setting over a molecular biology lab, they give the clinical 
researcher new insight into the disease process, although this opaque view will need 
low-throughput validation, to clarify and cement these discovery platforms. 
The microarray is based on detecting complementarity between nucleic acids in the 
sample and pre-designed oligonucleotide probes. One of the original issues with 
miRNA hybridisation was finding an optimal temperature as variations were present 
across miRNA, some microarrays have dealt with this problem by using locked nucleic 
acid (LNA) technology, which has removes the temperature bias due to its higher 
melting point; however an issue that remains is cross-hybridisation between similarly 
annotated miRNA (294, 295). The microarray platform may seem outdated compared 
to NGS but has been readily and stably used across labs for two decades as NGS 
technologies have developed in parallel (296). Microarrays involve less time for 
sample preparation, a more straightforward data analysis process, and remains more 
cost-effective, particularly when it comes to large sample groups. Groups have used 
microarray data to create blood-borne miRNomes’ of human diseases, by creating 
disease profiles across multiple disease processes, and linking these back to disease-
specific genetic variants (297). 
The NGS platforms have been in constant development for the past few years 
between multiple competing companies, including Illumina, Life Technologies and 
Roche 454 (298, 299). NGS is a form of massively parallel sequencing that can 
sequence the entire genome, transcriptome, and miRNOME. The sequencing is 
performed across four steps: library preparation, cluster generation, sequencing, and 
data analysis. The NGS performance is superior to a microarray for novel miRNA 
discovery as it will the sequence the entire miRNome, unlike microarray which is 
reliant on its probe-specific design, making it impossible for microarray to discover 
novel miRNA, albeit the annotated miRNA may be novel to the disease process (300). 
1.5.4.3 Computational and Bioinformatic Approaches 
Expertise in bioinformatics and computational predictive algorithms are required to 




decipher potential miRNA-mRNA interactions, and investigate the gene enrichment 
datasets. The miRNA biomarker of interest can be explored in silico to interpret the 
miRNA gene locus, cell-specificity, and potential downstream targets (301). Findings 
in this area may assist in linking the miRNA back to the disease or injury process. 
Although many databases and tools exist to date, specific miRNA databases and 
predictive tools stand out due to their high specificity, comprehensive design, and 
regular maintenance and upgrades, including miRBase, DIANA Tools, TargetScan, and 
miRWalk (302 , 303). An outline of current tools is given below: 
• miRBase (http://www.mirbase.org/) is an annotation tool for high confidence 
miRNAs including ID, sequence, miRNA loci across species, precursor miRNA 
sequences, links to potential targets and references. It is managed by the 
University of Manchester, UK, and was updated in 2018 (239, 301). 
• DIANA Tools (http://www.microrna.gr/) provides algorithms, databases and 
software for interpreting data and it’s separated into microT-CDS and microT 
v4 (miRNA target prediction), TarBase v7.0 (Experimentally supported miRNA 
targets), and mirPath (Incorporating miRNA in pathways). It is managed by 
the University of Thessaly, Greece, and was updated in 2018 (304). 
• TargetScan (http://www.targetscan.org/) predicts miRNA targets by 
searching conserved 8mer, 7mer and 6mer sites on mRNA that match the 
miRNA seed region. It is managed by the Whitehead Institute, Massachusetts 
Institute of Technology, USA and was updated in 2018 (236). 
• miRWalk (http://mirwalk.umm.uni-heidelberg.de/) is. It is managed by the 
Medical Research Center, University of Heidelberg, Germany and was 
updated in 2018 (305). 
Gene set enrichment, over-representation, and network topology-based analysis is 
essential for investigating target gene ontology (biological process, cellular 
component, and molecular function) and KEGG pathways (knowledge of molecular 
interaction, reaction and relation). DAVID and WebGestalt are both functional gene 




throughput data to gain biological insights. Both sites are managed in the USA and 
have been updated in 2018 and 2017 respectively (306, 307). 
Careful consideration and caution are required when exploring predictive web tools 
as well-established tools and databases can be shut down or fail to be regularly 
maintained leading to downstream errors (308, 309). Another consideration is errors 
in gene names from in silico database outputs; this has been seen across 20% of 
publications within supplementary lists (310). A limitation of in silico work is that 
most predictions will need low-throughput experimental validation to confirm 
expression, this is important for both miRNA and the respective mRNA targets (264). 
1.5.4.4 Quantitative Real-Time Polymerase Chain Reaction 
qPCR is the universal low-throughput validation method for studying miRNA 
expression. Although some studies can use the rather labour intensive Northern blot 
method which can present pre-miRNA amounts and ratios, miRNA variability and 
modifications, most clinical labs prefer the use of qPCR as it’s a time-efficient 
measure of gene expression with high sensitivity and low sample input (295). There 
are five chemistries for qPCR amplicon detection: DNA-binding fluorophores, linear 
oligoprobes, 5’ nuclease oligoprobes, hairpin oligoprobes, and self-fluorescing 
amplicon; from these only two chemistries, have been carried forward into miRNA 
detection (311, 312). The DNA-binding fluorophores chemistry uses the SYBR Green 
method and the 5’ nuclease oligoprobes chemistry uses the TaqMan method. The 
SYBR Green method uses a fluorescent dye that fluoresces upon dsDNA binding and 
so the fluorescence increases after each cycle allowing a measure for amplification, 
although this method can be prone to SYBR-green binding to primer-dimers or non-
specific products. The TaqMan method uses a fluorescent reporter and quencher 
resting on adjacent nucleotides, as Taq polymerase cleaves in a 5’→ 3’ direction the 
fluorescent probes is separated from the quencher allowing fluorescence which 
measures the amount of product produced, this method does not generate 
fluorescence from primer-dimers or non-specific products(312). 
Quantification of extracted RNA is completed using a spectrophotometer as 




(ng/μl) are used across samples, this along with absolute consistency in both cDNA 
and PCR kits across the study helps ensure precision (313). Careful control measures 
can be put in place from RNA to cDNA to PCR step to ensure best practice, including 
assaying samples in triplicate to verify precision and expression stability, cDNA spike-
in to ensure consistency from cDNA to qPCR across samples, negative enzyme control 
(NEC) to assess DNA contamination, and negative template control (NTC) to evaluate 
primer-dimer contamination. All of which can help for quality control the workflow 
of the qPCR process for best results. 
Good quality qPCR results are dependent on stable and reliable normalisation 
methods. Although global, quantile and size factor specific normalisation is used for 
high-throughput miRNA profiling, the most well-recognised form of qPCR 
normalisation is relative quantification using 2-ΔΔCT, which creates values based on 
reference genes (housekeeping genes) being used as internal controls (314, 315). 
However, differences can arise for reference genes across different tissue-types and 
blood-based mediums, and so careful pre-testing or previous validation of stability is 
necessary for all reference genes in miRNA. Some common miRNA reference genes 
include miR-16, miR-223, and SN48 (213, 316-318). RNA isolation kits may consist of 
a synthetic spiked-in cel-miR-39 RNA, which can be useful for sample recovery but 
cannot be used as a type of normalisation method in qPCR steps, although some 
groups continue to do so (128). 
1.5.4.5 Exploring miRNA and miRNA Target Activity 
Cell culture modelling is required to investigate the activity of the miRNA and its 
respective mRNA target. A common way of monitoring a miRNA-mRNA interaction 
involves the use of reporters, such as dual-luciferase reporters (295). These typically 
involve two fluorescent reporters, one, which can be used as a normalisation control, 
and the other, which acts in place of a specific miRNA 3’UTR binding site. Expression 
of the specific miRNA that targets the 3’UTR binding site would cause binding at the 
aforementioned binding site preventing the reporter from fluorescing but would not 
affect the normalisation control, providing evidence of complementary binding 
(319). It is crucial to note complimentary binding in vitro, does not necessarily 




Further studies beyond proof of miRNA-mRNA interactions can be conducted with 
artificial short-interfering RNA (mimics), short-hairpin RNA (shRNA), and miRNA 
inhibitors, these can be investigated in vitro and in vivo and include overexpression, 
miRNA inhibition and the blocking of the entire pathway. The RNA interference 
(RNAi) is currently being assessed as part of the drug discovery pipeline, including for 











1.5.4 microRNA in Hypoxic-Ischaemic Encephalopathy 
miRNA function at the molecular level by affecting mRNA, with downstream effects 
on protein pathways during development and recovery following injury. A number of 
miRNAs have been previously reported in acute cellular hypoxia (table 1.3). 
Although miR-210, which is coined “the master hypoxamir”, appears as the most 
studied miRNA in HIE, the studies have focused primarily on the neonatal rat models 
and cell culture (322). miR-210 is considered of particular interest as a miR-210 mimic 
has reduced the expression of junction protein occlusion and β-catenin in HI rat pup 
brains, which shows the ability of miR-210 to disrupt blood-brain barrier integrity and 
potentially contribute to cerebral oedema associated with HIE (323). To our 
knowledge miR-374a appears to be the only miRNA to date reported to be altered in 
clinical studies. Studies of miR-210 were inconclusive, and most reports have been in 
acute tissue hypoxia post-myocardial infarction or within necrotic malignant tissue 
(213, 324). miR-374a has been consistent across both a clinical and porcine model of 
HIE; however, miR-374a studies have observed alterations in the bloodstream, but 
not in brain tissue which may implicate miR-374a as a biofluid-specific marker of HIE. 
Alterations in miR-374a are of particular interest due to its association with Wingless 
and NT-1 (Wnt)/β-catenin signalling in cancer metastasis, where miR-374a 
suppresses the negative signalling regulators Wnt inhibitors factor, phosphate and 
tensin homolog, and WNT5A (325). Wnt signalling is a major signalling system 
involved in regulating embryonic growth and development, cell differentiation, 
proliferation, migration and polarity (326). Wnt activity regulates adult neurogenesis, 
and neurogenesis is stimulated post HIE injury (327-329). Wnt/β-catenin signalling 
has been described in human neonatal tissue where high Wnt activity prevents 
degradation of beta-catenin and can inhibit pre-oligodendrocytes from 





Table 1.3. microRNA in Hypoxic-Ischaemic related brain injury. 
miRNA Associated Target(s) Model(s) References 
Let-7f NDRG Cell culture model; clinical biofluids (324, 331) 
miR-124 - Murine model (332) 
miR-132 FOXO3; Bax; Cytochrome c; 
caspase-9; Bcl-2 
Cell culture model; murine model (332, 333) 
miR-136 TIMP3 Murine model; cell culture model (334) 
miR-137 Notch1 Murine model; cell culture model (335) 
miR-17-5p TXNIP; NLRP3; caspase-1; IL-
1β 
Murine model (336) 
miR-181b/c TLR4; NF-κB; TNF-α; IL-1β; 
iNOS 
Murine model; cell culture model (337, 338) 
miR-203 MyD88 Cell culture model (339) 
miR-210 Bax; Bcl-2; Caspase-3; 
Caspase-9:GR; BDNF; TrkB 
Murine model; cell culture model (324, 340-
343) 
miR-21 Cyclin D1 Cell culture model (344) 
miR-23a/b Apaf-1 Murine model; cell culture model (345) 
miR-24 - Cell culture model (346) 
miR-27a/b Apaf-1 Murine model; cell culture model (345, 347) 
miR-30d-5p - Murine model (348) 
miR-325-3p Aanat Murine model (349) 
miR-337-3p - Murine model (350) 
miR-374a-5p - Clinical biofluids; porcine model (213, 324, 
351) 
miR-376b-5p HIF-α; VEGFA; Notch1 Murine model (352) 





To date, miR-374 has shown to be a promising HIE biomarker but needs to be 
validated in an independent cohort. It remains unclear if more cord whole blood-
based miRNA are significantly altered in HIE. Furthermore, the specific function these 
miRNA play in the cord remains unclear; it also remains unknown if predicted 
downstream mRNA targets may be altered in cord whole blood. Both validation and 
downstream exploration are critical to provide a reliable, validated, and quantifiable 
biomarker that could support both clinical decision-making and assist in early-
targeted intervention. Understanding of both miRNA and predicted downstream 





1.6 Aims of Thesis 
The specific aims of this thesis are: 
1) To identify novel UCB miRNA biomarkers and potential downstream mRNA 
targets of perinatal asphyxia, HIE and long-term outcome. 
2) To validate previously identified UCB inflammatory biomarkers and miRNA 
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Neonatal hypoxic-ischemic encephalopathy (HIE) remains a significant cause of 
neurologic disability. Identifying infants suitable for therapeutic hypothermia (TH) 
within a narrow therapeutic time is difficult. No single robust biochemical marker is 
available to clinicians. To assess the ability of a panel of candidate miRNA to evaluate 
the development and severity of encephalopathy following perinatal asphyxia (PA). 
Methodology 
This validation study included 2 cohorts. For the discovery cohort, full-term infants 
with PA were enrolled at birth to the BiHIVE1 study (2009-2011) in Cork, Ireland. 
Encephalopathy grade was defined using early electroencephalogram and Sarnat 
score (n = 68). The BiHIVE1 cohort also enrolled healthy control infants (n = 22). For 
the validation cohort, the BiHIVE2 multicenter study (2013-2015), based in Cork, 
Ireland (7500 live births per annum), and Karolinska Huddinge, Sweden (4400 live 
births per annum), recruited infants with PA along with healthy control infants to 
validate findings from BiHIVE1 using identical recruitment criteria (n = 80). The 
experimental design was formulated prior to recruitment, and analysis was 
conducted from June 2016 to March 2017. 
Results 
From 170 neonates, 160 had qPCR analysis. The BiHIVE1 cohort included 87 infants 
(21 control infants, 39 infants with PA, and 27 infants with HIE), and BiHIVE2 included 
73 infants (control [n = 22], PA [n = 26], and HIE [n = 25]). The BiHIVE1 and BiHIVE2 
had a median age of 40 weeks (interquartile range [IQR], 39-41 weeks) and 40 weeks 
(IQR, 39-41 weeks), respectively, and included 56 boys and 31 girls, and 45 boys and 
28 girls, respectively. In BiHIVE1, 12 candidate miRNAs were identified, and 7 of these 
miRNAs were chosen for validation in BiHIVE2. The BiHIVE2 cohort showed 
consistent alteration of 3 miRNAs; miR-374a-5p was decreased in infants diagnosed 
as having HIE compared with healthy control infants (median relative quantification, 





infants with PA compared with healthy control infants (median, 0.42; IQR, 0.21-0.61 
vs 0.90; IQR, 0.70-1.30; P = .004), and mir-181b-5p was decreased in infants eligible 
for TH (median, 0.27; IQR, 0.14-1.41) vs 1.18; IQR, 0.70-2.05; P = .02). 
Conclusion 
Altered miRNA expression was detected in UCB of neonates with PA and HIE. These 






Neonatal hypoxic-ischemic encephalopathy (HIE) remains a significant cause of long-
term neurologic disability and death in newborns and occurs in 1 to 6 per 1000 live 
full-term births. (354) Hypoxic-ischemic encephalopathy is a multifactorial evolving 
triphasic encephalopathy, involving both the primary injury, a latent window of 
reoxygenation, and secondary injury(355, 356). 
To date, the only proven treatment for HIE is therapeutic hypothermia (TH), which 
can improve outcome if introduced within the first 6 postnatal hours (357). However, 
accurate and timely diagnosis of HIE is difficult, and these infants are currently 
identified using biochemical and clinical measurements including Apgar scores, initial 
lactate, and base deficit, which individually have poor positive predictive values (6, 
358-360). The Sarnat grading scale of HIE with electroencephalogram grading is 
accurate when assessed at 24 hours postpartum, but this is beyond the limited 
therapeutic window(138, 361). A reliable, validated, and quantifiable biomarker 
would support clinical decision making and early targeted intervention. 
Aberrant miRNA expression has been linked to many disease states(362, 363) and 
appears stable in a cell-free state in various biologic fluids (364). Therefore, miRNAs 
offer potential as reliable and robust blood-based biomarkers in molecular 
diagnostics(249). Research on miRNA in HIE remains limited. Past studies have 
focused on cellular ex vivo work, and animal studies focused on regulation of 
apoptosis(341, 342, 347, 365). Our group has previously published what is, to our 
knowledge, the first description of miRNA profiling in a human neonatal cohort and 
reported downregulation of cord blood miR-374a-5p in infants with HIE(213). 
This study aimed to expand on our previous work in the Biomarkers in Hypoxic-
Ischemic Encephalopathy (BiHIVE1) study using a separate validation cohort and to 
explore further additional candidate miRNAs in UCB following HI injury. We wished 
to explore whether miRNAs could reliably assess the development and severity of 






2.3.1 Patient Cohorts 
Discovery Cohort: The BiHIVE Study 
Infants with a gestation greater than 36 weeks were recruited from May 2009 
through June 2011 using 1 or more of the following inclusion criteria: umbilical cord 
pH less than 7.1, 5-minute Apgar score 6 or less, and need for intubation or 
cardiopulmonary resuscitation at age 10 minutes. Recruitment procedures have 
been previously described(213). Infants with suspected or confirmed sepsis or 
coexisting congenital abnormalities were excluded from analysis. The healthy control 
population was recruited from the baseline longitudinal birth cohort(366); control 
infants were all healthy full-term infants, with uneventful deliveries, normal neonatal 
examinations, and without admission to the neonatal intensive care unit. For the 
study, infants were matched for age, sex, and gestation. 
All cases had a continuous multichannel electroencephalogram recorded, as 
previously described(66). Clinical HIE grade of encephalopathy, if any, was assigned 
at 24 hours post partum using the modified Sarnat score.9 Standardized neurologic 
assessment was performed on day 3 and at discharge. Case infants were divided into 
those with mild, moderate, or severe grade of HIE (HIE group), and those with 
biochemical or clinical signs of PA but without clinical encephalopathy (PA group). 
Validation Cohort: The BiHIVE2 Study 
A second multicenter cohort study, the BiHIVE2 validation cohort, was recruited from 
March 2013 through June 2015 at Cork University Maternity Hospital, Cork, Ireland, 
with 7500 deliveries per annum, and Karolinska University Hospital Huddinge, 
Stockholm, Sweden, with 4400 deliveries per annum. The study was designed to 
validate and expand on findings from the BiHIVE1 cohort and used identical 
recruitment criteria.19 The BiHIVE2 cohort also recruited study-specific control 
infants with uneventful deliveries, normal neonatal examination, and 5-minute 





2.3.2 Ethical Approval 
Both studies were approved by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals, and the BiHIVE2 cohort was also approved by the regional ethical 
review board in Stockholm, Sweden. Written informed consent was obtained from 
parents of all study participants. 
2.3.3 Sample Collection 
UCB of newborns in all cohorts was collected immediately following delivery of 
placenta and processed within 3 hours of delivery. Three milliliters of cord blood was 
placed directly into Tempus Blood RNA tubes (Applied Biosystems) and biobanked at 
−80°C. 
2.3.4 Detection and Quantification of miRNA 
Total RNA was isolated from the Tempus system using MagMAX for Stabilized Blood 
Tubes RNA Isolation Kit (Ambion, Life Technologies) and quantified using a NanoDrop 
8000 Spectrophotometer (ThermoScientific NanoDrop). Additionally, RNA quality 
from the BiHIVE1 study was assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc) to ensure sample quality from a random subgroup, as previously 
described(213). Isolated RNA was subsequently stored at −80°C before quantitative 
real-time polymerase chain reaction (qRT-PCR). Five nanograms per microliter of 
isolated RNA was used for reverse transcription to synthesize complementary DNA 
using Universal cDNA synthesis kit II (Exiqon), followed by an amplification step using 
the ExiLENT SYBR Green master mix (Exiqon). The qRT-PCR amplifications were 
performed in triplicate using LNA PCR Primer sets (Exiqon) on the StepOnePlus 
(Applied Biosystems). Data was analyzed according to the 2-ΔΔCT method(314). 
The panel of 12 miRNAs was chosen based on our previously published microarray 
data(213) and previous reports from the literature indicating potential alterations in 
miR-146a, miR-155, and miR-181b (367-369) (supplementary table 2.1). These 
miRNAs were analyzed using qRT-PCR in the BiHIVE1 cohort, and if the altered 
expression was confirmed, further validation was performed in the BiHIVE2 cohort. 





system (Exiqon) using SN48(370, 371) and miR-223-3p as reference genes. SN48 was 
tested for stability before qRT-PCR, and miR-223-3p had previously been found to be 
stable using these methods(213). We also included UniSp6 as a spike-in for 
complementary DNA synthesis quality control. 
2.3.5 Evaluation and Functional Classification of miRNA Gene Targets 
Possible downstream targets of the miRNAs altered across both cohorts were 
identified using the online resource miRWalk 2.0 atlas database. Four prediction 
databases were included in the retrieval (miRWalk, miRanda, miRDB, and 
TargetScan), and predicted target genes and their conserved miRNA binding sites 
were annotated. The criteria used involved a minimal seed length of 7 base pairs and 
a P value less than .05; for gene ontology, predicted targets needed to be present in 
3 or more predictive algorithms. Predicted gene targets of the miRNA were analyzed 
for fold enrichment in both gene ontology terms and Kyoto Encyclopedia of Genes 
and Genomes pathways using the DAVID 6.8 bioinformatics database 
(https://david.ncifcrf.gov/). 
2.3.6 Statistical Analysis 
Means and standard deviations and medians and interquartile ranges (IQRs) were 
used for normal and nonnormal distributions respectively. For groupwise 
comparisons, analysis of variance, Kruskal-Wallis test (n groups), t test, or Mann-
Whitney test (2 groups) were used as appropriate. Both cohorts were merged for 
predictability analysis; this is by dividing the mean relative quantification (RQ) of the 
control group in the BiHIVE discovery cohort across all groups of the discovery cohort. 
This step was repeated in the BiHIVE2 validation cohort by dividing the mean RQ of 
the control group in the validation cohort across all groups of the validation cohort. 
The predictive ability of the individual markers for HIE was assessed using positive 
and negative predictive values (NPVs) and area under the receiver operator curves. 
Correlation of data was performed using the Spearman ρ correlation coefficient. 
Binomial logistic regression was used to examine combinations of significant markers 
for associations with current eligibility for therapeutic hypothermia based on a 





statistically significant, and all P values were 2-sided. In silico analyses used an 
adjusted P value corrected for multiple testing using false discovery rate based on 
the Benjamini-Hochberg procedure(371), and an adjusted P value was considered 
significant at less than .10(108). Statistical analysis was carried out using SPSS 






2.4.1 Patient Characteristics 
In the BiHIVE1 discovery cohort, 68 infants had UCB collected at delivery, and 66 (39 
with PA and 27 with HIE) were included in the final analysis. Healthy control infants 
(n = 22) were recruited from the BASELINE cohort, and 21 were included in the final 
analysis. 
In the BiHIVE2 validation cohort, 80 infants, including healthy control infants, had 
umbilical whole blood collected at delivery, and 73 infants (22 control infants, 26 with 
PA, and 25 with HIE) were included in the final analysis. Ten samples were lost during 
extraction. The clinical characteristics of both populations are summarized in Table 
2.1. 
 
Supplementary Figure 2.1. Flowchart of recruitment, experimental procedure, statistical and in silico 





Table 2.1. Clinical demographics. 
  
BiHIVE Discovery Cohort  BiHIVE2 Validation Cohort  
Control PA HIE P-Value Control PA HIE P-Value 
n = 21 n = 39 n = 27   n = 22 n = 26 n = 25   
Gestation (wk) - 40 (39-41) 40 (39-41)  0.565 40 (39-41) 40 (39-41) 40 (39-41) 0.929 
Birthweight (g) 3420 (3200-3685) 3560 (3150-4055) 3530 (3300-4040)  0.501 3895 (3497.5-4090) 3735 (3470-4020.25) 3840 (3358.5-4149) 0.767 
Sex (M/F) 11/10 25/14 20/7  0.302 14/8 16/10 15/10 0.968 
1 min. Apgar ¥ 9 (9-9) 5 (3.25-7) 3 (1-4.25)  <0.001 9 (9-9) 6.5 (5-9) 2 (1-3) <0.001 
5 min. Apgar ¥ 10 (9.75-10) 9 (8-9) 5 (3-7)  <0.001 10 (9-10) 9 (9-10) 4 (4-6) <0.001 
Cord pH * - 7.035 (6.95-7.09) 7 (6.94-7.1)  0.379 7.265 (7.205-7.315) 7.03 (7-7.08) 6.975 (6.895-7.11) <0.001 
Initial Lactate ¥ - 5.9 (4.875-10.1) 9.95 (7.15-12.55)  0.012 - 5.6 (3.275-9.575) 11.05 (8.775-12.1) 0.006 
Initial Base Deficit ¥ - 5.7 (2.875-9.675) 11.7 (9.15-16.625)  <0.001 - 5.2 (4.55-11.35) 
14.75 (10.025-
18.275) 0.002 
Sarnat score          
Mild/Moderate/Severe  16/5/6     16/8/1  
Mode of Delivery *    0.524    0.035 
  SVD - 6 (19.5%) 6 (22%)   13 (59%) 9 (34.5%) 4 (16%)  
  Instrumental - 18 (56.5%) 15 (56%)   7 (32%) 14 (54%) 17 (68%)  
  LSCS - 7 (22%) 6 (22%)   2 (9%) 3 (11.5%) 4 (16%)  
  Unknown - 1 (0.5%) -   - - -   
Clinical Demographics in the BiHIVE and BiHIVE2 Validation Cohorts. Median (IQR) or n (%). Wk = week, g = grams, M = Male, F = Female, SVD = Spontaneous vaginal delivery, 





2.4.2 Candidate Whole Blood miRNA in the BiHIVE Discovery Cohort 
In the BiHIVE1 discovery cohort, 12 different miRNAs were analyzed. Relative 
expression levels (2-ΔΔCT) of miRNAs across 3 groups were compared between 
healthy control infants (n = 21), infants with PA (n = 39), and infants with HIE (n = 27) 
(workflow in supplementary figure 2.1). Two miRNAs were reduced in the HIE group 
compared with healthy controls; miR-199a (median RQ, 0.60; IQR, 0.39-0.79 vs 
median, 0.87; IQR, 0.56-1.40, P = .04) and miR-374a (median, 0.24; IQR, 0.13-0.40 vs 
median, 0.73; IQR, 0.22-1.46; P = .01). Three miRNAs were reduced in the PA group 
compared with healthy control individuals: miR-374a (median, 0.21; IQR, 0.07-1.19 
vs median, 0.73; IQR, 0.22-1.46; P = .04), miR-376c (median, 0.28; IQR, 0.14-0.55 vs 
median, 0.55; IQR, 0.41-1.40; P = .01), and miR-410 (median, 0.65; IQR, 0.20-0.78 vs 
median, 0.99; IQR, 0.43-1.23; P = 0.04) (Figure, 2.1A; Table 2.2). 
Supplementary Table 2.1. List of microRNA included in the BiHIVE qRT-PCR panel 
miRNA Name Accession ID Sequence Reference 
hsa-miR-18a-5p MIMAT0000072 UAAGGUGCAUCUAGUGCAGAUAG Microarray 
hsa-miR-27b-3p MIMAT0000419 UUCACAGUGGCUAAGUUCUGC Microarray 
hsa-miR-101-3p MIMAT0000099 UACAGUACUGUGAUAACUGAA Microarray 
hsa-miR-128-3p MIMAT0000424 UCACAGUGAACCGGUCUCUUU Microarray 
hsa-miR-146a-5p MIMAT0000449 CCUCUGAAAUUCAGUUCUUCAG (369)  
hsa-miR-155-5p MIMAT0000646 UUAAUGCUAAUCGUGAUAGGGGU (368)  
hsa-miR-181b-5p MIMAT0000257 AACAUUCAUUGCUGUCGGUGGGU (372)  
hsa-miR-199a-5p MIMAT0000231 CCCAGUGUUCAGACUACCUGUUC Microarray 
hsa-miR-374a-5p MIMAT0000727 UUAUAAUACAACCUGAUAAGUG Microarray 
hsa-miR-376a-3p MIMAT0000729 AUCAUAGAGGAAAAUCCACGU Microarray 
hsa-miR-376c-3p MIMAT0000720 AACAUAGAGGAAAUUCCACGU Microarray 
hsa-miR-410-3p MIMAT0002171 AAUAUAACACAGAUGGCCUGU Microarray 
The names, accession numbers and sequences of all miRNA used as targets in this study. The 
microarray is from previously published work (213). 
We next focused within the HIE group (n = 27) and looked at the differences between 
the mild (n = 16), moderate (n = 5), and severe (n = 6) grade of HIE. miR-181b was 
significantly reduced in the severe group compared with the mild group (median, 
0.08; IQR, 0.04-0.21 vs median, 0.82; IQR, 0.36-1.38; P = .01). 
To examine the ability of miRNAs to aid in clinical decision-making, we compared 
infants eligible for TH (11 with moderate or severe encephalopathy) with those 
ineligible (healthy control infants, those with PA, and those with mild HIE [n = 76]). 





199a (median, 0.49; IQR, 0.33-0.60 vs median, 0.75; IQR, 0.43-1.08, P = .049) and miR-
181b (median, 0.25; IQR, 0.16-0.32 vs median, 0.61; IQR, 0.26-1.39; P = .03). 
 
Figure 2.1. Altered relative expression levels in miRNA from the BiHIVE discovery cohort and BiHIVE2 
validation cohort across groups. A. In the BiHIVE discovery cohort there were significant differences in 
miR-199a-5p and in miR-374a-5p between the control (n = 21) and hypoxic-ischemic encephalopathy 
(HIE) (n = 27) groups and differences in miR-374a-5p, miR-376c-3p, and miR-410 between the control 
and perinatal asphyxia (n = 39) groups. B. In the BiHIVE2 validation cohort there were significant 
differences in miR-374a-5p and miR-410 across the control (n = 22) vs HIE (n = 25) groups. In miR-
181b-5p, miR-376a-3p and miR-376c-3p there were significant differences across the control vs PA (n 
= 26). Finally, in miR-181b-5p, miR-199a-5p and miR-376a-3p there were significant differences across 
the PA vs HIE groups. Data in boxplots represent median and interquartile range (IQR). * Significant at 
P < 0.05. 
2.4.3 Validation of Candidate Whole Blood miRNA in BiHIVE2 Cohort 
From the 12 candidate miRNAs, 5 miRNAs showed consistent significance (miR-374a, 
miR-376c, miR-410, miR-181b, and miR-199a), and 2 additional miRNA were 
included: miR-376a, with a strong trend in differentiating PA vs HIE (median, 0.37; 





suggested role in immune response and microglial activation (368). The 5 miRNAs 
with no significant and consistent changes were not tested further in BiHIVE2. 
Of the 7 candidate miRNAs tested, 3 miRNAs showed consistent altered expression 
levels in the BiHIVE2 cohort. miR-374a was significantly reduced in the HIE group vs 
control group (median, 0.38; IQR, 0.17-0.77 vs median, 0.95; IQR, 0.68-1.19; 
P = .009), and miR-376c was significantly reduced in the PA group compared with the 
control group (median, 0.42; IQR, 0.21-0.61 vs median, 0.90; IQR, 0.70-1.30; P = .004) 
(Figure, 2.1B; Table 2.2). There was no difference between grades of HIE in the 
validation cohort. 
As in our discovery cohort, we separated infants in the validation cohort into 2 
groups, infants eligible for TH (n = 9) and infants ineligible for TH (n = 64), and found 
miR-181b to be significantly reduced in the group eligible for TH compared with 
infants not eligible (median, 0.27; IQR, 0.14-1.41 vs median, 1.18; IQR, 0.70-2.05; 





Data represents median relative quantification (RQ) and interquartile range (IQR). * Significantly altered, P < 0.05 (blue). ¥ Significantly altered, P < 0.05, in both studies 
(green).
Table 2.2. Altered miRNA expression in the BiHIVE discovery cohort and BiHIVE2 validation cohort. 
BiHIVE miRNA 181b 199a 374a 376a 376c 410 
Control vs Hypoxic 
Ischemic Encephalopathy 
0.76 (0.22-1.36) vs 
0.34 (0.21-0.88) 
* 0.87 (0.56-1.40) vs 
0.60 (0.39-0.79) 
¥ 0.73 (0.22-1.46) vs 
0.24 (0.13-0.40) 
0.72 (0.30-1.32) vs 
0.78 (0.44-3.06) 
0.55 (0.41-1.40) vs 
0.59 (0.15-1.22) 
0.99 (0.43-1.23) vs 
0.75 (0.17-1.10) 
Control vs Perinatal 
Asphyxia 
0.76 (0.22-1.36) vs 
0.58 (0.27-2.20) 
0.87 (0.56-1.40) vs 
0.61 (0.29-1.03) 
* 0.73 (0.22-1.46) vs 
0.21 (0.07-1.19) 
0.72 (0.30-1.32) vs 
0.37 (0.15-0.78) 
¥ 0.55 (0.41-1.40) vs 
0.28 (0.14-0.55) 
* 0.99 (0.43-1.23) vs 
0.65 (0.20-0.78) 
Perinatal Asphyxia vs 
Hypoxic Ischemic 
Encephalopathy 
0.58 (0.27-2.20) vs 
0.34 (0.21-0.88) 
0.61 (0.29-1.03) vs 
0.60 (0.39-0.79) 
0.21 (0.07-1.19) vs 
0.24 (0.13-0.40) 
0.37 (0.15-0.78) vs 
0.78 (0.44-3.06) 
0.28 (0.14-0.55) vs 
0.59 (0.15-1.22) 
0.65 (0.20-0.78) vs 
0.75 (0.17-1.10) 
Ineligible for cooling vs 
eligible for cooling 
¥ 0.61 (0.26-1.39) 
vs 0.25 (0.16-0.32) 
* 0.75 (0.43-1.08) vs 
0.49 (0.33-0.60) 
0.24 (0.08-1.09) vs 
0.37 (0.24-0.53) 
0.59 (0.25-1.20) vs 
0.61 (0.39-2.35) 
0.49 (0.27-1.02) vs 
0.46 (0.14-1.20) 
0.75 (0.36-1.08) vs 
0.60 (0.15-0.85) 
BiHIVE2 miRNA Validation 181b 199a 374a 376a 376c 410 
Control vs Hypoxic 
Ischemic Encephalopathy 
0.98 (0.82-1.30) vs 
0.96 (0.25-2.12) 
0.96 (0.57-1.26) vs 
0.90 (0.70-1.53) 
¥ 0.95 (0.68-1.19) vs 
0.38 (0.17-0.77) 
0.88 (0.51-1.29) vs 
0.56 (0.25-1.03) 
0.90 (0.70-1.30) vs 
0.54 (0.27-1.23) 
* 0.86 (0.60-1.37) vs 
0.57 (0.37-0.95) 
Control vs Perinatal 
Asphyxia 
* 0.98 (0.82-1.30) 
vs 1.85 (0.85-2.77) 
0.96 (0.57-1.26) vs 
0.63 (0.39-0.92) 
0.95 (0.68-1.19) vs 
0.55 (0.28-1.19) 
* 0.88 (0.51-1.29) vs 
0.27 (0.17-0.72) 
¥ 0.90 (0.70-1.30) vs 
0.42 (0.21-0.61) 
0.86 (0.60-1.37) vs 
0.38 (0.22-1.06) 
Perinatal Asphyxia vs 
Hypoxic Ischemic 
Encephalopathy 
* 1.85 (0.85-2.77) 
vs 0.96 (0.25-2.12) 
* 0.63 (0.39-0.92) vs 
0.90 (0.70-1.53) 
0.55 (0.28-1.19) vs 
0.38 (0.17-0.77) 
* 0.27 (0.17-0.72) vs 
0.56 (0.25-1.03) 
0.42 (0.21-0.61) vs 
0.54 (0.27-1.23) 
0.38 (0.22-1.06) vs 
0.57 (0.37-0.95) 
Ineligible for cooling vs 
eligible for cooling 
¥ 1.18 (0.70-2.05) 
vs 0.27 (0.14-1.41) 
0.73 (0.51-1.20) vs 
0.95 (0.79-2.05) 
0.70 (0.28-1.17) vs 
0.39 (0.22-0.70) 
0.53 (0.24-1.15) vs 
0.37 (0.24-0.70) 
0.53 (0.24-1.04) vs 
0.69 (0.35-1.27) 


































































































miR-155  1.00 -0.05 0.30† 0.23* 0.45† 0.57† 0.41† 0.08 -0.22 -0.14 -0.09 -0.05 -0.27* 
miR-181b -0.05 1.00 0.04 0.32† 0.04 0.02 0.06 -0.08 -0.17 -0.36† 0.14 0.12 0.33† 
miR-199a 0.30† 0.04 1.00 0.10 0.26* 0.31† 0.22* -0.03 0.03 -0.07 0.01 -0.04 -0.05 
miR-374a 0.23* 0.32† 0.10 1.00 0.17 0.19 0.16 0.09 -0.19 -0.12 0.18* 0.14 0.08 
miR-376a 0.45† 0.04 0.26* 0.17 1.00 0.87† 0.82† -0.02 -0.08 0.15 -0.03 -0.01 -0.27* 
miR-376c 0.57† 0.02 0.31† 0.19 0.87† 1.00 0.83† 0.08 -0.10 0.00 0.05 0.00 -0.24 
miR-410 0.41† 0.06 0.22* 0.16 0.82† 0.83† 1.00 0.18 -0.04 -0.01 0.14 0.15 -0.18 
Cord pH 0.08 -0.08 -0.03 0.09 -0.02 0.08 0.18 1.00 -0.39† -0.15 0.30† 0.26† 0.12 
Initial Lactate -0.22 -0.17 0.03 -0.19 -0.08 -0.10 -0.04 -0.39† 1.00 0.57† -0.19 -0.15 -0.38* 
Initial Base Deficit -0.14 -0.36† -0.07 -0.12 0.15 0.00 -0.01 -0.15 0.57† 1.00 -0.29* -0.53† -0.50† 
1 min. Apgar -0.09 0.14 0.01 0.18* -0.03 0.05 0.14 0.30† -0.19 -0.29* 1.00 0.83† 0.67† 
5 min. Apgar -0.05 0.12 -0.04 0.14 -0.01 0.00 0.15 0.26† -0.15 -0.53† 0.83† 1.00 0.83† 
10 min. Apgar -0.27* 0.33† -0.05 0.08 -0.27* -0.24 -0.18 0.12 -0.38* -0.50† 0.67† 0.83† 1.00 
Spearman’s Rho correlation with correlation coefficients describing associations across miRNAs and current markers. * Correlation is significant at P < 0.05 (blue). † Correlation 





2.4.4 Ability to Predict Eligibility for Therapeutic Hypothermia in the BiHIVE and 
BiHIVE2 Cohorts 
We merged both cohorts to examine the ability of miR-181b expression to detect 
moderate/severe HIE. We compared it with current early biochemical and clinical 
markers, using the standard cutoffs used in previous trials of TH (374). Associations 
across miRNA and current markers can be seen in Table 2.3. 
miR-181b had an area under the curve of 0.752 (95% CI, 0.610-0.893) for the 
prediction of moderate-severe HIE. miR-181b performed similar to current 
biochemical markers and had the highest NPV of 99% (Table 2.4). Clinical Apgar 
scores performed better than biochemical markers and miR-181b (Table 2.4). Logistic 
regression was performed to assess the ability of a combination of miR-181b and 
Apgar at 5 minutes to predict moderate-severe HIE. The model was statistically 
significant at χ2 = 42.576; P < .001. The model explained 60% (Nagelkerke R2) of the 
variance in the eligibility for TH and correctly classified 93% of cases. However, the 






Table 2.4. Biochemical and clinical markers of infants’ eligible for therapeutic hypothermia. 
  PPV (%) NPV (%) AUC (CI) P-Value 
Biochemical markers     
  pH * 48 85 0.758 (0.638-0.879) 0.001 
  Lactate * 33 91 0.759 (0.617-0.902) 0.001 
  Base Deficit † 69 86 0.833 (0.729-0.936) <0.001 
  miR-181b * 25 99 0.752 (0.610-0.893) 0.002 
Clinical markers     
  Apgar at 1min. † 55 97 0.867 (0.790-0.944) <0.001 
  Apgar at 5min. † 90 92 0.918 (0.854-0.981) <0.001 
  Apgar at 10min. † 31 93 0.926 (0.847-1.000) <0.001 
Combined marker     
  miR-181b + Apgar at 5min. † 83 95 0.918 (0.826-1.000) <0.001 
Biochemical and clinical markers of infants’ eligible for therapeutic hypothermia at birth, across both 
cohorts. PPV = positive predictive value. NPV = negative predictive value. AUC = area under the curve. 
Min. = minute. The optimum cut-off value for miR-181b is RQ = 0.492, with a sensitivity = 79% and 
specificity = 60%. Standard cut-off values for hypothermia were used for Apgar scores (≤ 5), pH (≤ 7.0) 
and base deficit (≥ 16 mmol/L), based on the Toby criteria (375), and lactate (≥ 7.0). * P < 0.05. † P < 
0.001. 
2.4.5 Targets and Roles of miRNA 
A list of potential miRNA-gene targets were generated for each of the 3 miRNAs 
significantly altered across both cohorts: miR-376c, miR-374a, and miR-181b. For 
enrichment of biologic processes, there was an overlap between miR-376c and miR-
181b targets for regulation of RNA metabolic process and regulation of RNA 
biosynthesis processes (Supplementary figure 2.2). For enrichment of the cellular 
component, there was an overlap in miR-374a and miR-376c for postsynaptic 
specialization (Supplementary figure 2.2). Finally, for the enrichment of molecular 
function, there was an overlap across all 3 miRNAs for regulatory region DNA binding 
and transcriptional activator activity. For miR-181b and miR-374a, there was an 
overlap for double-stranded DNA binding, and in miR-374a and miR-376c there was 






Supplementary Figure 2.2. Functional Enrichment Analysis of GO and KEGG. A. Biological Process. B. Cellular Function. C. Molecular Function. D. KEGG. Data graphs represent fold enrichment 
from list of miRNA target genes. Adjusted P-value corrected for multiple testing using false discovery rate (FDR) based on Benjamini-Hochberg procedure was considered significant. † = 






We have validated 3 miRNAs in neonatal PA and HIE by using 2 well-defined, 
independent cohorts. From the 12 candidate miRNAs, 5 miRNAs were differentially 
expressed in cord blood in the BiHIVE1 discovery cohort. Following this, expression 
patterns of 3 of 5 miRNAs were validated as consistently altered in the BiHIVE2 
multicenter validation cohort. The miRNA biomarkers assessed have shown utility in 
distinguishing perinatal asphyxia and HIE from healthy control infants and may help 
identify newborns suitable for TH. In both the BiHIVE1 and BiHIVE2 cohorts, miR-
374a, previously identified (213) and validated in this study, was found to be 
expressed at lower levels in the UCB of HIE infants compared with the healthy control 
infants. We also found a consistent downregulation of miR-376c in perinatal asphyxia 
compared with healthy controls and previously reported downregulation of miR-
181b in infants with moderate and severe HIE compared with healthy control infants 
(373). 
Research in miRNA is still quite novel, and most studies of miR-374a and miR-376c 
have been focused on cancer research. MiR-374a was first described in colon cancer 
(376) and miR-376c in ovarian cancer (377) These studies linked them to 
dysregulation of the Wnt/β-catenin pathway (325, 378) by targeting associated genes 
in the pathway via functional assays, including WIF1, PTEN, WNT5A, and LRH-1, 
respectively. Other pathways explored in miR-374a include PI3K/AKT via CCND1 (379) 
and for miR-376c include TGF-β signaling via ALK7 (380). Our miR-374a in silico 
analysis found signaling pathways regulating pluripotency of stem cells as a predicted 
Kyoto Encyclopedia of Genes and Genomes pathway, which encompasses a number 
of pathways including TGFβ/Smad, PI3K-Akt, and the Wnt/β-catenin signaling 
pathway. The Wnt/β-catenin signaling described in both miR-374a and miR-376c has 
also been described in a HIE cell modeling, where high Wnt activity prevents 
degradation of β-catenin and can inhibit preoligodendrocytes from differentiating 
into mature oligodendrocytes (330). ALK7, a functional target of miR-376c, has also 
been shown to impair oligodendrocyte differentiation and myelination, where ALK7 





Few studies to date have examined miR-374a in neonatal HIE. A piglet model 
reported temporal changes in expression after injury (351) and a 2017 clinical HIE 
study confirmed downregulation in UCB in neonatal HIE (324). 
This study also reported the downregulation of miR-181b in infants with moderate 
and severe HIE and compared the predictive ability of miR-181b with biochemical 
and clinical markers in HIE (Table 2.4). The strong NPV of 99% from miR-181b could 
make this miRNA a useful tool for the clinical setting because it is quantifiable and 
not subjective. The Apgar score is reliant on subjective observation and can differ in 
interobserver variability, and past studies have called for more objective and precise 
measures (381). Additionally, instrumental deliveries were more prevalent in the PA 
and HIE groups but were not associated with our validated miRNAs. 
While miR-199a, miR-376a, and miR-410 were not validated as significantly altered 
in both cohorts, it is essential to recognize the distribution of Sarnat grades across 
BiHIVE2 (Table 2.1). Although recruitment went on for a similar period across 2 
different centers, the number of severe-grade HIE infants recruited to the BiHIVE2 
validation cohort was significantly lower. Thus, validation with an equal distribution 
of grades of HIE may highlight further miRNAs altered in more severe grades of HIE 
in future studies. 
Our study has focused on whole blood instead of either serum or plasma; this 
approach has given a higher yield of miRNA and allowed us to explore both cellular 
and extracellular miRNA expressed in the blood. This may have masked altered 
expression seen in extracellular miRNA owing to abundant levels of cellular miRNA in 
whole blood (274). Previous studies on circulating miRNA have proposed that cellular 
damage caused by injury may release cellular miRNA into the serum or plasma. This 
may be comparable to how cellular enzymes are released after apoptosis and 
necrosis or possibly through a cell-specific transport that releases specific miRNAs 
(382). We do not know how these decreased circulating expression levels might 
relate to altered expression within tissues, particularly within the brain. Studies in 
peripheral tissues would help better understand the mechanism of this altered 





these miRNA to assess whether they are innocent bystanders or play an active role 
in the pathophysiology of hypoxic injury. 
The strength of our study lies in the fact that we have studied the miRNA in 2 
completely separate cohorts, recruited using identical and strict recruitment criteria. 
The BiHIVE2 validation cohort was recruited across 2 different countries, indicating 
that our findings may be applicable across distinct geographical areas. The altered 
expression of UCB miRNAs immediately after birth implies that changes in miRNA 
expression may occur during injury. Additional research is required to demonstrate 
whether these changes persist during the subsequent progression of HI injury. 
In conclusion, we have validated the decreased expression of 2 miRNAs, miR-374a 
and miR-376c, in whole blood from the umbilical cord of newborns with PA and HIE 
in 2 independent cohorts. We have also expanded on our previous research in miR-
181b; its strong NPV of may bring this miRNA forward as a quantifiable non-invasive 








Alterations in Umbilical Cord Blood messenger RNA 
Expression in Neonatal Hypoxic-Ischaemic 
Encephalopathy and Long-Term Outcome 
 
Marc Paul O’Sullivan, BSc1,2,3, Sophie Casey, BSc1,2, Mikael Finder, MD4, Deirdre 
Twomey, PhD1,2, Caroline Ahearne, MD, PhD1,2, Gerard Clarke, PhD1,5,6, Boubou 
Hallberg, MD, PhD4. Geraldine B. Boylan, PhD1,2, Deirdre M. Murray, MD, PhD1,2,3 
 
1The Irish Centre for Fetal and Neonatal Translational Research (INFANT) 
2Department of Paediatrics and Child Health, University College Cork, Cork, Ireland 
3National Children’s Research Centre, Crumlin, Dublin 12, Ireland 
4Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 
and Karolinska University Hospital, Stockholm, Sweden 
5Department of Psychiatry and Neurobehavioural Science, University College Cork, 
Ireland 












Hypoxic-ischaemic encephalopathy (HIE) remains an important cause of neonatal 
death and long-term neurological disability. It remains challenging to classify infants 
eligible for therapeutic hypothermia (TH) within the short postnatal therapeutic time 
window of 6 hours. No objective and robust biological marker is available in the 
clinical setting. The purpose of this study was to explore two predicted downstream 
mRNA targets, nuclear factor of activated T-cells 5 (Nfat5) and Frizzled-4 (Fzd4), of 
the previously validated microRNAs, miR-181b, miR-374a, and miR-376c, in whole 
blood across our two independent BiHiVE cohorts, and to assess their ability to 
predict grade of HIE and neurodevelopmental outcome. 
Methodology 
This study included two cohorts. The discovery cohort recruited full-term infants with 
PA at birth to the Biomarkers in Hypoxic-Ischemic Encephalopathy (BiHiVE1) study in 
Cork, Ireland (2009-2011). Encephalopathy grade was defined using early 
electroencephalogram and Sarnat score (n = 68). Healthy control infants were 
recruited from the BASELINE birth cohort (2008-2016) (n = 22). The validation cohort 
recruited full-term infants in Cork, Ireland, and Karolinska Huddinge, Sweden to the 
BiHiVE2 multi-centre study (2013-2015), the validation study recruited infants with 
PA along with healthy control infants to validate findings from BiHiVE1 using identical 
recruitment criteria (n = 80). UCB was processed and biobanked at delivery. Infants 
were assigned a modified Sarnat score at 24 hours. Infants were followed-up at 18-
36 months of age. Candidate mNFAT5 and mFZD4 were measured using quantitative 
real-time polymerase chain reaction. 
Results 
From 170 neonates, 126 were included in the analyses. The BiHiVE1 cohort included 
55 infants (control infants [n = 16], infants with PA [n = 19], and infants with HIE [n = 
20]), and BiHiVE2 included 71 infants (control [n = 22], PA [n = 25], and HIE [n = 24]). 





weeks] and included 82 males and 44 females. In grade of HIE severity, the level of 
mFZD4 was increased in severe HIE (median relative quantification (RQ) = 2.98 (IQR 
= 2.23-3.68)) vs mild HIE (0.88 (0.46-1.37)), P = 0.004, and in severe HIE (2.98 (2.23-
3.68)) vs moderate HIE (1.05 (0.81-1.20)), P = 0.003. In eligibility for therapeutic 
hypothermia, the level of mFZD4 was increased in infants eligible for TH (1.20 (0.93-
2.37)) vs infants’ ineligible for TH (0.81 (0.46-1.53)), P = 0.017. Neurodevelopmental 
outcome was available in 56 infants. Levels of mNFAT5 were increased in severely 
abnormal (1.26 (1.17-1.39)) vs normal outcome infants (0.97 (0.83-1.24)), P = 0.036, 
and in severely abnormal (1.26 (1.17-1.39)) vs mildly abnormal outcomes infants 
(0.96 (0.80-1.06)), P = 0.013. Levels of mFZD4 were increased in severely abnormal 
(2.51 (1.60-3.56)) vs normal outcome infants (0.74 (0.48-1.49)), P = 0.004, and in 
severely abnormal (2.51 (1.60-3.56)) vs mildly abnormal outcome infants (0.97 (0.75-
1.34)), P = 0.026. 
Conclusions 
Increased mFZD4 expression was observed in umbilical cord whole blood of neonates 
with severe HIE; both mNFAT5 and mFZD4 expression was increased in infants with 
severely abnormal long-term outcome. These mRNA could aid current measures as 






HIE is the most prevalent form of brain injury in the newborn and affects 1.5 per 1000 
live births in the developed world (36). Rates are significantly higher in the 
developing world, with significant risk of long-term disability (383). Currently, the 
only treatment for the moderate/severe grade of HIE is therapeutic hypothermia, 
which must be implemented within the first 6-hours of life (384, 385).  Current clinical 
and biochemical markers can be inconclusive in forming a definitive diagnosis and 
seem to be poor markers for long-term neurodevelopmental outcome (153). Novel 
biomarkers continue to be explored in pilot studies, but no clear molecular marker 
has been developed as of yet to compete with current markers. 
Gene transcripts have been used for diagnosis and prognosis across various 
conditions, and the mRNA explored could also give insight into the underlying 
biological mechanism (386, 387); miRNA are small non-coding RNA nucleotides 
involved in the post-transcriptional modification of mRNA. Both may be dysregulated 
in the tissue and blood in many disorders of cell growth and differentiation (249, 362, 
364). Cellular miRNA and mRNA are present in erythrocytes, leukocytes and platelets; 
and extracellular miRNA and mRNA are present in exosomes, microvesicles, and 
bound to proteins (278, 388, 389). Our group has previously reported  a panel of 
whole blood miRNA (miR-374a, miR-376c and miR-181b), with the ability to 
differentiate HIE, PA, and infants eligible for therapeutic hypothermia (390). This 
study aimed to expand on our previous work using predicted downstream mRNA 
targets of previously validated miRNA in the UCB following HIE. 
The downstream mRNA targets focused on two mRNA associated with the Wnt 
pathway both mFZD4 and mNFAT5. The canonical and non-canonical Wnt signalling 
pathways are known to affect gene transcription, cytoskeletal regulation and calcium 
regulation (391). Wnt signalling has been studied across both cancer and embryonic 
development, with a recent comparative study highlighting pathological levels of 
Wnt in oligodendrocyte progenitor cells of neonatal HIE tissue (330). Fzd4 acts as a 
cell surface receptor for the Wnt ligand; and Nfat5 regulates cell adhesion, migration 





Wnt signalling via inhibition of β-catenin acetylation (392-395). The study explored if 






3.3.1 Patient Populations 
The BiHiVE1 Discovery Cohort 
Infants with a gestation > 36 weeks were recruited from May 2009 to June 2011 using 
one or more of the following inclusion criteria: cord pH < 7.1, 5-minute Apgar score 
≤ 6, need for intubation or cardiopulmonary resuscitation at 10 minutes of age. 
Recruitment and data collection procedures have been previously described (213). 
Infants with suspected or confirmed sepsis, or co-existing congenital abnormalities 
were excluded from analysis. The healthy control population was recruited from the 
BASELINE longitudinal birth cohort (396); controls were all healthy full-term infants, 
with uneventful deliveries, normal neonatal examinations and without admission to 
the neonatal intensive care unit. All case infants had a continuous EEG recorded, 
which commenced shortly after delivery, as previously described (66). Clinical HIE 
grade of encephalopathy, if any, was assigned at 24 hours postpartum using the 
modified Sarnat score (77). Standardised neurologic assessment was additionally 
performed on day 3 and at discharge. Case infants were divided into those with a 
mild, moderate, or severe grade of HIE (HIE group), and those with biochemical or 
clinical signs of perinatal asphyxia, but without clinical encephalopathy (PA group). 
The BiHiVE2 Validation Cohort 
The second multi-centre study, the validation cohort was recruited from March 2013 
to June 2015 at Cork University Maternity Hospital, with 7,500 deliveries per annum, 
and Karolinska University Hospital Huddinge, with 4,400 deliveries per annum. The 
study was designed to validate the findings of the BiHiVE1 discovery cohort and used 
identical recruitment criteria to the BiHiVE1 cohort (213). The BiHiVE2 cohort, unlike 
BiHiVE1, recruited additional control infants; these were infants with uneventful 
deliveries, normal neonatal examination and a 5-minute Apgar scores > 8. Infants 
were matched for gestational age, sex, and birthweight. The clinicaltrials.gov 
identifier for the BiHiVE2 study is NCT02019147. The Clinical Research Ethics 





Ethical Review Board in Stockholm also approved the multi-centre validation cohort. 
Written informed consent was obtained from parents of all study participants. 
3.3.2 Sample Collection  
UCB was collected following the delivery of the placenta and processed within 3 
hours of birth. 3 mL of cord blood was placed directly into Tempus Blood RNA tubes 
(Applied Biosystems, USA) and biobanked at -80ᵒC in both Cork, Ireland, and 
Karolinska, Sweden. 
3.3.3 Prediction of mRNA Targets 
A list of previously validated miRNAs, miR-181b, miR-374a, and miR-376c  (390) were 
entered into miRecords  (http://c1.accurascience.com/miRecords/) (397) which 
generated a list of predicted downstream target genes in Homo Sapiens. Search 
criteria were set to compile results from at least 3 target prediction programs 
including miRanda, miRTarget2, picTar, PITA, RNAhybrid and Targetscan. The 
generated list of target genes were subsequently compared with the Wnt signalling 
pathway using the KEGG pathway targets generated from WebGestalt, the Web-
based Gene Set Analysis Toolkit (http://www.webgestalt.org/webgestalt_2013/) 
(330, 398).  
3.3.4 Detection and Quantification of miRNA and mRNA Expression 
Total RNA was isolated from the Tempus system using the MagMAX for Stabilized 
Blood Tubes RNA Isolation Kit (Ambion, Life Technologies, USA) and quantified using 
a NanoDrop 8000 Spectrophotometer (ThermoScientific NanoDrop, USA). RNA 
quality from the BiHiVE1 study was assessed using an Agilent 2100 Bioanalyzer 
(Agilent Technologies Inc, Agilent Laboratories, California) to ensure sample quality 
from a random subgroup of the samples, as previously described (390). Isolated RNA 
were stored at -80ᵒC before quantitative real-time PCR (qPCR, polymerase chain 
reaction). 5 ng/μl of isolated RNA was used for reverse transcription to synthesise 
cDNA (complementary DNA) using Universal cDNA synthesis kit II (Exiqon, Denmark, 
acquired by Qiagen, Netherlands). The expression levels of mNFAT5 and mFZD4 were 





Technologies, Paisley, UK); 18s was used as a reference gene, see table 3.1 (399). 
Samples were incubated at 95°C for 10 min, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute on the StepOnePlus™ Real-Time PCR System (Applied 
Biosystems, Life Technologies, Paisley, UK). All samples were run in triplicate, cycle 
threshold (CT) values were recorded, and expression levels were calculated relative 
to controls using the 2-ΔΔCT method (400). Both cohorts were merged by dividing the 
average relative quantification (RQ) of the control group in the BiHiVE discovery 
cohort across all groups of the discovery cohort. This step was repeated in the 
BiHiVE2 validation cohort by dividing the average RQ of the control group in the 
validation cohort across all groups of the validation cohort. 
Table 3.1. TaqMan® Gene Expression Assays. 





3.3.5 Neurodevelopmental Assessment 
The neurodevelopmental assessment was carried out by a trained clinician or 
psychologist when the child was aged between 18 and 36 months of age and 
consisted of the BSID-III (401). The BSID-III is an individually administered, gold-
standard neurodevelopmental assessment designed to measure the developmental 
functioning of both infants and toddlers (1 to 42 months) and includes Cognitive, 
Language (Receptive and Expressive), Motor (Fine and Gross), Social-Emotional, and 
Adaptive Behaviour Scales. The child’s outcome as measured by the BSID-III is 
determined using the composite scores of the administered subscales. Each 
composite score has a standardised mean of 100 and a standard deviation (SD) of 15 
such that a value below 85 is conventionally used to indicate neurodevelopmental 
delay (402). For this study, the outcome was designated as normal if the child scored 
> 85 across all 3 BSID-III subscales. Children were excluded if they were tested in a 
language that was not their first language. The infant was designated mildly 





outcome if 2-3 subscales scored ≤ 70 or the infant suffered CP or death, as previously 
described (189). 
3.3.6 Statistical Analyses 
Data were analysed using the statistical software package IBM SPSS version 24.0 
(USA) and GraphPad Prism version 8. Descriptive analysis was carried out using mean 
and standard deviation (SD), and median and interquartile ranges (IQRs) for 
parametric and non-parametric data respectively for continuous variables and 
percentages for categorical variables. For group-wise comparisons, ANOVA, Kruskal-
Wallis test (n groups), Student’s t-test or Mann-Whitney test (2-groups) were used 
as appropriate for continuous variables. Chi-square tests were performed to assess 
categorical demographics. Correlation of data was performed using Pearson’s 
correlation coefficient. The predictive ability of the individual markers for the 
severely abnormal outcome was assessed using Positive and Negative Predictive 







3.4.1 Patient Populations 
One-hundred and twenty-six infants (mean (SD) gestational age in weeks = 39.8 (1.2); 
82 [65%] male) from both the BIHiVE1 and BiHiVE2 cohort were included in the 





Table 3.2. Patient populations. 
 BiHIVE1 Discovery Cohort  BiHIVE2 Validation Cohort  
 Control 
n = 16 
PA 
n = 19 
HIE 
n = 20  
P-Value 
Control 
n = 22 
PA 
n = 25 
HIE 
n = 24  
P-Value 








Sex – M/F 9/7 12/7 16/4 0.286 14/8 16/9 15/9 0.994 
1 min. Apgar a N/A 6 (4-8) 3 (1-4) <0.001 9 (9-9) 6 (5-8) 1 (2-4) <0.001 
5 min. Apgar a 10 (9.5-10) 9 (7-10) 5 (3-7) <0.001 10 (9-10) 9 (9-9) 4 (4-6) <0.001 














  10/5/5    15/8/1  
Mode of Delivery, No. (%)    0.493    0.054 
SVD N/A 2 (10) 5 (25)  13 (59) 8 (32) 4 (17)  
Instrumental N/A 14 (74) 12 (60)  7 (32) 14 (56) 16 (67)  
LSCS N/A 3 (16) 3 (15)  2 (9) 3 (67) 4 (17)  
Population Demographics a-cross both cohorts. Mean (SD), Median (IQR) or n (%). Wk = week, g = grams, M = Male, SVD = Spontaneous 





3.4.2 mRNA Expression Across Groups and HIE Grade 
Two genes were predicted in the Wnt signalling pathway as downstream targets of 
all three of the previously validated miRNAs (390). Both mNFAT5 and mFZD4 
expression were subsequently analysed using qPCR. The final groups consisted of 124 
infants; including healthy controls, n = 37, infants with PA (without encephalopathy), 
n = 43, and infants with HIE, n = 44. The mRNA expression analysis showed no altered 
expression across the healthy control vs PA vs HIE groups. 
The mRNA expression analysis across grades within the HIE group included 44 infants. 
The HIE group included mild HIE grade, n = 25, moderate HIE grade, n = 13, and severe 
HIE grade infants, n = 6. Altered levels of mFZD4 were observed across the grades of 
HIE, P = 0.008; increased levels of mFZD4 were observed in severe HIE (median 
relative quantification (RQ) = 2.98 (IQR = 2.23-3.68)) vs mild HIE (0.88 (0.46-1.37)), P 
= 0.004, and in severe HIE (2.98 (2.23-3.68)) vs moderate HIE (1.05 (0.81-1.20)), P = 
0.003. No differences were determined between mild and moderate HIE infants 
(figure 3.1A). No altered levels of mNFAT5 were observed across grades, P = 0.568. 
The mRNA expression analysis of ability to detect therapeutic eligibility (TH) grouped 
the total population into infant’s ineligible for TH (healthy controls, PA, and mild HIE), 
n = 105, and infants eligible for TH (moderate HIE and severe HIE), n = 19. Increased 
levels of mFZD4 were observed in infants eligible for TH (1.20 (0.93-2.37)) vs infants’ 
ineligible for TH (0.81 (0.46-1.53)), P = 0.017 (figure 3.1B). No altered levels of 






























































Figure 3.1. Relative quantification levels in messenger RNA from the BiHiVE studies. A. Across population groups. The hypoxic ischaemic encephalopathy (HIE) group included 
infants with mild HIE grade, n = 25, moderate HIE grade, n = 13, and severe HIE grade, n = 6. Increased RQ levels of mFZD4 were observed in infants with severe HIE grade vs 
mild HIE grade, and  in severe grade vs mild grade. B. Assessing eligibility for TH. The groups included infants ineligible for TH (healthy controls, PA, and mild HIE), n = 105, 
and infants eligible for TH (moderate HIE and severe HIE), n = 19. Increased RQ levels of mFZD4 were observed in infants eligible for TH vs infants ineligible for TH. *P < 0.05. 





3.4.3 mRNA Expression in Neurodevelopmental Outcome 
Neurodevelopmental outcome was available in sixty-three infants from both the 
BIHiVE1 and BiHiVE2 cohort, from this group; seven infants were excluded as they 
were tested in a language that was not their first language. The final mRNA 
expression analysis of the neurodevelopmental outcome group included 56 infants 
including a normal outcome, n = 38, a mildly abnormal outcome, n = 11, and a 
severely abnormal outcome, n = 7. Altered levels of mNFAT5 were observed across 
the outcome groups, P = 0.051; increased levels of mNFAT5 were observed in 
severely abnormal (1.26 (1.17-1.39)) vs normal outcome infants (0.97 (0.83-1.24)), P 
= 0.036, and in severely abnormal (1.26 (1.17-1.39)) vs mildly abnormal outcomes 
infants (0.96 (0.80-1.06)), P = 0.012. Altered levels of mFZD4 were observed across 
the outcome groups, P = 0.012; Increased levels of mFZD4 were observed in severely 
abnormal (2.51 (1.60-3.56)) vs normal outcome infants (0.74 (0.48-1.49)), P = 0.004, 
and in severely abnormal 0.74 (2.51 (1.60-3.56)) vs mildly abnormal outcome infants 
0.97 (0.75-1.34)), P = 0.026 (figure 3.2). No differences were determined between 

































Figure 3.2. Relative quantification levels in messenger RNA from the BiHiVE studies assessing 
neurodevelopmental outcome. The analysis included infants with a normal outcome, n = 38, infants 
with a mildly abnormal outcome, n = 11, and infants with a severely abnormal outcome, n = 7. 
Increased RQ levels of mNFAT5 and mFZD4 were observed in the severely abnormal outcome group 
vs normal and moderately abnormal outcome. *P < 0.05. Bar graphs represent fold change of RQ 





3.4.4 Ability to Assess Eligibility for TH and Neurodevelopmental Outcome 
In our final analysis we compared mNFAT5 and mFZD4 with current early biochemical 
and clinical markers, using the standard cut-offs used in previous trials of TH (374), 
these were determined for both eligibility for TH and neurodevelopmental outcome 
independently.  Infants with normal/mildly abnormal outcome, n = 49, were grouped 
against infants with severely abnormal outcome, n = 7. Associations between 
mNFAT5 and mFZD4 and current standard of care markers can be seen in Table 3.3. 
Both mNFAT5 and mFZD4 had a high NPV compared to current markers in assessing 
eligibility for therapeutic hypothermia. In predicting severely abnormal 
neurodevelopmental outcome mFZD4 had a higher AUC and PPV than all current 







Table 3.3. Comparison of biochemical and clinical markers. 
Marker PPV (%) NPV (%) AUC (95% CI) P-Value 
Eligibility for therapeutic hypothermia    
Biochemical markers     
   Cord pH 24 88 0.613 (0.445-0.781) 0.156 
   Lactate * 39 43 0.778 (0.640-0.915) 0.001 
   Base deficit * 67 82 0.792 (0.669-0.914) <0.001 
   mNFAT5 22 90 0.622 (0.495-0.748) 0.093 
   mFZD4 * 26 93 0.673 (0.542-0.805) 0.017 
Clinical markers     
   Apgar at 1 min. * 31 98 0.869 (0.792-0.946) <0.001 
   Apgar at 5 min. * 58 96 0.912 (0.846-0.978) <0.001 
Severely abnormal neurodevelopmental outcome 
Biochemical markers  
   Cord pH 6 92 0.309 (0.060-0.558) 0.274 
   Lactate 22 100 0.656 (0.372-0.940) 0.278 
   Base deficit 44 91 0.727 (0.470-0.983) 0.089 
   mNFAT5 * 29 95 0.776 (0.651-0.900) 0.019 
   mFZD4 * 50 96 0.843 (0.692-0.993) 0.004 
Clinical markers  
    Apgar at 1 min. * 20 96 0.800 (0.550-1.000) 0.011 
    Apgar at 5 min. * 29 95 0.780 (0.563-0.997) 0.017 
The optimum cut-off value in mNFAT5 and mFZD4 in eligibility for TH was an RQ = 1.0674 and 1.0038; 
and in neurodevelopmental outcome was an RQ = 1.2279 and 1.9896 respectively. Standard cut-off 
values for PPV and NPV were based on the TOBY criteria (374) for Apgar scores ≤  5, pH ≤ 7.0 and base 
deficit ≥ 16 mmol/L; and lactate ≥ 7.0. * P < 0.05. AUC = area under the curve; CI = confidence interval; 






This is the first clinical study to use two independent cohorts to measure mRNA 
targets of previously validated miRNA in the whole blood of infants with HIE. The 
study identified increases in mFZD4 in the severe grade of HIE, increases in mFZD4 in 
infants eligible for TH; and mNFAT5 and mFZD4 were both increased in infants that 
went on to have a severely abnormal outcome. These mRNAs show the potential to 
use cord blood as a potential biomarker to distinguish infants that will develop a 
severely abnormal neurodevelopmental outcome from the normal and mildly 
abnormal follow-up population. 
Molecular diagnostics is becoming an increasingly important clinical tool; and now 
molecular material in circulating biofluids can be measured for both diagnostic and 
prognostic purposes (286, 403, 404). Whole blood contains mRNA from various sites 
of origin including leukocytes, erythrocytes, platelets, microvesicles and exosomes 
and potential apoptotic budding. mRNA in vesicles is believed to be primarily short 
fragments of mRNA (288, 405). Previous reports have shown that circulating 
exosomal mRNA can be translated into proteins in target mast cells and can alter 
protein production in these cells (278, 288). 
Pathological states of Wnt have been previously identified in neonatal brain injury, 
and this high Wnt activity has been proposed as an explanation for failed myelination 
in white matter lesions at birth; the two mRNA in this study are both associated with 
the Wnt pathway, mNFAT5 and mFZD4, and were chosen as they were predicted 
downstream targets of the previously validated miRNAs, miR-181b, miR-374a and 
miR-376c, and all three miRNAs were downregulated in HIE (330, 390). Wnt signalling 
plays an essential role in embryonic development, including neural development, 
axon guidance and synaptogenesis; and controls self-renewal across multiple adult 
tissues (326, 406, 407). In relation to the central nervous system, its role has been 
described in inflammation, axon regeneration, myelination, prevention of neural 
death, astrocyte generation, glial cell proliferation and blood-brain barrier integrity 
(408-410). Wnt signalling operates via the canonical Wnt/β-catenin pathway and the 





Wnt signalling has previously been described in neonatal white matter injury where 
oligodendrocyte progenitor cells in lesions exhibited high levels of Wnt activity (330). 
Hippocampal neuronal models of oxygen-glucose deprivation/reoxygenation-
induced injury can suppress the Wnt/β-catenin pathway which can be reactivated by 
exposing the neurons to mild hypothermia (413). 
The mFZD4 codes for the Fzd4 receptor, a member of the frizzled/smoothened 
superfamily of cell-surface proteins that function as receptors for the Wnt ligands; 
and can activate both canonical and non-canonical Wnt pathways (414). The Fzd4 
mRNA is 7.7 kb in size and is detectable across most normal human tissues with larger 
quantities in fetal kidneys, and adult hearts, skeletal muscles, and ovaries (415). High 
expression of Fzd4 is seen during early hematopoiesis and may suggest a role in 
hematopoietic regulation. Mice Fzd4 knockout models develop cerebellar and 
auditory dysfunction (416, 417). The study was unable to identify the source of whole 
blood mFZD4 and with this it is unclear if the increased expression is directly or 
indirectly linked to the brain or another source, one proposed explanation is that 
FZD4 has previously been implicated in angiogenesis during retinal vasculature 
formation in the brain; and loss of FZD4 can reduce endothelial proliferation and lead 
to leakiness of the blood-retinal barrier and the blood-brain barrier, which may 
permit the release of mFZD4 into the peripheral circulation (418-420). 
NFAT5 was the first discovered of the NFAT family; this family of proteins are 
expressed almost ubiquitously across every tissue, including the placenta, and are 
known as transcriptional regulators in cytokine and immune cell expression (421-
423).  NFAT5 is widely expressed in the kidneys and is an essential regulator of 
osmotic stress; both the fetal and adult brain have a high expression of NFAT5, with 
10-fold higher levels in fetal brains, with highest expression in the cerebellum (424-
426). Recent studies have reported that NFAT5 is positively regulated by hypoxia; 
renal ischaemic studies have proposed that NFAT5 functions as a molecular switch 
towards cell survival following ischaemic injury (427-429). NFAT5 has also been 






For this study, we have conducted a subgroup analysis of infants with long-term 
outcome and have observed significant alterations for infants at risk of severely 
abnormal outcome with both mNFAT5 and mFZD4 performing better than current 
clinical markers at birth. These infants had an extremely poor outcome despite 
hypothermia. This could be used in clinical practise by collecting cord blood in 
Tempus tubes for infants who meet the criteria for perinatal asphyxia (see 
recruitment criteria in methodology) at birth, the samples could then have the whole 
blood RNA isolated and a qPCR performed during the first day of life, the results of 
the analysis could then be useful to guide treatment decisions during the subsequent 
postnatal days and identify those newborns who should be offered more 
experimental adjunct therapies to optimise developmental outcomes.  
Limitations to this study include the use of whole blood instead of serum or plasma, 
making it more difficult to distinguish if the differences we are detecting are cellular 
blood-based mRNA or extracellular mRNA. If the alterations are extracellular-based 
mRNA this could imply a form of active transport, apoptosis, or removal of excess 
cellular mRNA (430-432). Although this study analyses mRNA targets of previously 
validated miRNA biomarkers, the alterations we have observed must only be 
considered as mRNA biofluid alterations and cannot be construed as a cause and 
effect miRNA-mRNA interaction. However, this study does promote further 
investigation into the potential role of the putative miRNA-mRNA interactions and 
how they may affect the related pathways, such as Wnt, in the HIE process. This study 
also highlights a theme that is not new to HIE biomarker studies, where it remains 
easier to establish differences between infants with a severe grade of HIE against 
other groups. It remains difficult to determine differences between the moderate 
grade of HIE and other groups. 
The strengths of our study include using two individual cohorts we were able to 
increase the sample size in a population that remains difficult to recruit in the 
developed world, with both studies requiring strict identical recruitment criteria 
across all centres. The BiHiVE2 cohort was a multi-centre study recruited across two 
countries, and both cohorts included EEG monitoring interpreted by trained 





psychologists. Finally, the umbilical cord was used for sample collection to gain 
insight into the neonate’s condition at birth, this was the optimal choice, as it remains 
non-invasive to both the mother and infant and contains a large blood volume, which 
can be difficult to acquire from the infant during the early postnatal period. Blood 
was collected using the TempusTM blood RNA system, a reliable method for 
maintaining high quality and quantity of mRNA and required a minimum of 3mL of 
whole blood (433). 
In conclusion, we have observed increased umbilical cord whole blood mRNA 
expression in infants with severe HIE (mFZD4), in infants eligible for TH (mFZD4) and 
in infants with severely abnormal long-term outcome (mNFAT5 and mFZD4). These 
mRNA combined with current diagnostic tools may have potential as early objective 
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The role of inflammation is an important factor in the progression of hypoxic-
ischaemic encephalopathy. We have previously shown that (interleukin-16) IL-16 is 
increased in infants with moderate and severe HIE and relates to poor 
neurodevelopmental outcomes. We aimed to validate IL-16 as a cord blood-based 
biomarker of HIE and to examine its relationship with long-term outcomes. 
Methodology 
The study sample consisted of 105 full-term infants who experienced perinatal 
asphyxia (with and without an encephalopathy) along with healthy, gestational age-
matched newborn controls. Umbilical cord serum was processed and biobanked at 
delivery. Infants were assigned a modified Sarnat score at 24 hours. Analysis of IL-16 
cytokine cord blood levels was performed using the sandwich-based ELISA technique. 
Results 
Cord blood-based IL-16 was increased in infants with perinatal asphyxia and HIE 
relative to controls, P = 0.025. IL-16 was also increased in the HIE group relative to 
controls, P = 0.042. There was no significant difference in IL-16 across grades of HIE 
or in those with abnormal outcomes at 2-years of age. 
Conclusion 
This study validates findings that cord blood-based IL-16 levels are increased in 






Hypoxic-Ischaemic Encephalopathy (HIE) is an important cause of brain injury in the 
newborn, with an evolving inflammatory response (18, 434). Early classification of 
HIE remains difficult, as the extent of injury increases over the first few hours of life, 
along with the potential for long-term neurological disability (435, 436). Therapeutic 
hypothermia (TH) can attenuate oxygen and metabolic demand, reduce 
inflammation, and may supress the evolution of apoptotic and necrotic cell death 
(437-439). To achieve these benefits TH must be initiated within the first 6 hours of 
life. Within this narrow time window, we must correctly identify those infants that 
would benefit the most from intervention(32, 73, 440). A robust and reliable early 
biochemical marker would greatly aid in clinical decision-making. 
Currently, acid-base balance, along with clinical examination, are relied upon to guide 
treatment, but individually, these can have low predictive values (8, 441) (442). The 
exact extent of injury may not be apparent without using electroencephalogram 
(EEG) or magnetic resonance imaging (MRI). However, both methods require 
specialised equipment and expertise and are often unavailable within the 6-hour 
therapeutic window(22, 29). 
The potential of biomarkers has been explored in a variety of biological 
measurements both invasive and non-invasive including serum, plasma, whole 
blood, cerebrospinal fluid, saliva, and urine (153, 443, 444). Many biomarkers have 
been considered a success in early screening, but no one HIE biomarker has been 
validated in a second cohort (153). Interleukin 16 (IL-16) is a pro-inflammatory 
cytokine stored and released from CD8+ cytotoxic T-cells, and upon release can 
generate an inflammatory response by using its chemotactic properties for attracting 
cells with the CD4+ surface molecule such as CD4+ helper T-cells (445). Before 
activation, this cytokine can exist within a neuronal precursor, NIL-16, found in 
neurons in both the cerebellum and hippocampus, or a non-neuronal precursor, pro-
IL-16. Both precursors are cleaved by the apoptosis-related caspase-3 to produce 
mature IL-16 (446, 447). We have previously shown that IL-16 was a measurable 





years of age (66, 189). We aimed to validate raised cord blood IL-16 as a marker for 






4.3.1 BiHIVE2 Study 
This multi-centre cohort study (clinicaltrials.gov ID: NCT02019147) recruited cases of 
perinatal asphyxia and healthy controls from Cork University Maternity Hospital and 
Karolinska University Hospital from 2013 to 2015. The study was designed to validate 
findings from the original Biomarkers in Hypoxic-Ischaemic Encephalopathy (BiHIVE) 
study (a biomarker discovery cohort), identical inclusion and exclusion criteria were 
applied in the two studies (66). All cases  recruited to the study were inborn and 
recruited if they had: gestational age of greater than or equal to 36 weeks and one 
or more of the following: cord pH less than 7.1, 5-minute Apgar score ≤6 or had been 
intubated or resuscitated at birth. All cases were observed for the duration of the 
perinatal period to detect the development of HIE and infants that did not go on to 
develop HIE were grouped as perinatal asphyxia at discharge. Multi-channel EEG at 
24 hours was used to corroborate the clinical Sarnat grade of HIE. Healthy controls 
were recruited concurrently. Controls were full-term infants with uneventful 
deliveries, normal Apgar scores, and normal neonatal examinations and without 
admission to the neonatal intensive care unit. All HIE cases had continuous multi-
channel EEG applied, and recordings were started as soon as possible after birth and 
graded as previously described (29). Clinical HIE grade was assigned at 24 h 
postpartum using a modified Sarnat score (448). Infants in this cohort went on to be 
cooled according to the entry criteria and guidelines set by the UK Total Body 
Hypothermia for Neonatal Encephalopathy (TOBY) cooling registry (from the UK 
TOBY Cooling Register Clinician's Handbook, section 2.1, 
http://www.npeu.ox.ac.uk/toby). The Clinical Ethics Committee of the Cork Teaching 
Hospitals and the Stockholm Ethical Review Board approved these studies in 
respective countries. Written informed consent was obtained from the parents. 
4.3.2 Sample Collection 
UCB was drawn and biobanked in all infants. The sampling, processing, and storage 
of samples was conducted with reference to strict standard operating procedures. 





30 minutes to clot. Following this, the serum was centrifuged at 2,400 ×g for 10 
minutes at 4°C. It was then pipetted into a sterile second spin tube and centrifuged 
at 3,000 xg for a further 10 minutes at 4°C, and aliquoted into 250 μl microtubes 
before storage at −80°C. 
4.3.3 Serum Cytokine Quantification 
IL-16 serum levels were measured with a sandwich ELISA using the DuoSet ELISA 
development kit (R&D Systems, Minneapolis, MN, USA). The kit used a mouse anti-
human IL-16 capture antibody, biotinylated goat anti-human IL-16 detection 
antibody and recombinant human IL-16 standard. Samples were diluted 1:1 and run 
in duplicates. The range of cytokine detection was from 15.6-1,000 pg/mL and a CV 
cut off < 20% was used. 
4.3.4 Assessment of Outcomes 
The neurodevelopmental assessment was carried out when the child was aged 
between 18 and 36 months of age. The assessment consisted of the BSID-III in 
addition to three parental report questionnaires: a developmental screening 
questionnaire, the Child Behaviour Checklist for children 1½ -5 years and the Social-
Emotional and Adaptive Behaviour Scale of the BSID-III (449). For the present study, 
only the BSID-III will be described. The BSID-III is an individually administered, gold-
standard neurodevelopmental assessment designed to measure the developmental 
functioning of infants and toddlers (1 to 42 months). It includes Cognitive, Language 
(Receptive and Expressive), Motor (Fine and Gross), Social-Emotional, and Adaptive 
Behaviour Scales.  The child’s outcome as measured by the BSID-III is determined 
using the composite scores of the administered subscales. Each composite score has 
a standardised mean of 100 and a standard deviation (SD) of 15 such that a value 
below 85 is conventionally used to indicate neurodevelopmental delay (450). In this 
study, to adjust for the differences between Irish and Swedish populations, a 
population-based Z-score was created in place of the standardised mean and 
standard deviation. Both countries had a mean calculated. The two-year outcome 
was considered normal if it did not fall one standard deviation below the calculated 
control group mean in all three composite categories (cognitive, language and 





the calculated control group mean in one or more of the three composite categories 
and severely abnormal if it fell two standard deviations below the mean, the child 
suffered from severe autism or if the infant was diagnosed with CP or suffered 
neonatal death. 
4.3.5 Statistical Analysis 
Statistical analysis was carried out using IBM SPSS Statistics 22 (USA). For group-wise 
comparisons, ANOVA or the Kruskal-Wallis test (n groups), or Student’s t-test or 
Mann-Whitney test (2-groups) were used as appropriate. The predictive ability of the 
individual markers for HIE was assessed using positive and negative predictive values 
(PPVs and NPVs), sensitivity and specificity, and area under the receiver operator 
curves (AUROC). IL-16 was compared with the current standard markers for HIE 
including pH, lactate, base deficit and 1, 5, and 10-minute Apgar. The threshold for 






4.4.1 Patient Characteristics 
A total of 113 infants recruited to the BiHIVE2 study were included in the analyses 
for the present study. The sample consisted of 27 neonates who experienced 
perinatal asphyxia without HIE, 26 who experienced HIE (15 mild, 10 moderate and 
1 severe) and 60 healthy, sex and age-matched controls. In the HIE infants, 8 
moderate and 1 severe, went on to receive TH according to TOBY criteria and 
guidelines. Eight infants were excluded from the analyses, as their IL-16 levels were 
undetectable. The clinical characteristics of the study sample are summarised in 
Table 4.1. 
4.4.2 Validation Results 
There was a significant increase in IL-16 in infants with perinatal asphyxia, including 
those that went on to develop HIE, median (interquartile range (IQR)) = 298.61 
(204.26-374.25) pg/mL, relative to the healthy sex and age-matched control group, 
median (IQR) = 204.89 (128.82-338.9) pg/mL, P = 0.024 (figure 4.1A). IL-16 was 
further increased in the HIE group, median (IQR) = 324.12 (185.03-391.31) pg/mL 
relative to the control group, median (IQR) = 204.89 (128.82-338.9) pg/mL, P = 0.041 
(figure 4.1B). No significant differences in IL-16 were observed in infants considered 
eligible for TH (moderate/severe HIE, n = 11) when compared with infants not eligible 
for TH (control/PA/mild HIE, n = 94), P = 0.198. There was no significant difference in 
IL-16 between infants with normal and abnormal outcome at two years of age, P = 





Table 4.1. Characteristics of study sample as a function of clinical and non-clinical groups. 
BIHIVE2 Study Control PA HIE P-Value 
n = 113 n = 60 n = 27 n = 26   
Gestation (wk) 40 (39-41) 40 (39-41) 40 (39-41) 0.782 
Sex (M/F) 34/26 16/11 14/12 0.925 
Birth Weight (g) 3737.5 (549.1) 3610.0 (510.8) 3680.0 (495.6) 0.098 
Admitted to NNU (Y/N)† 3/57 8/19 26/0 <0.001 
Mode of Delivery†    <0.001 
 SVD 47 (78.3%) 12 (44.4%) 5 (19.2%)   
  Instrumental 8 (13.3) 11 (40.7%) 18 (69.2%)   
  LSCS 5 (8.3%) 4 (14.4%) 3 (11.5%)   
1min Apgar† 9 (9-9) 7 (5-8) 3 (1-4) <0.001 
5min Apgar† 10 (10-10) 9 (8-10) 5 (4-6) <0.001 
10min Apgar† 10 (10-10) 10 (10-10) 7 (6-8) <0.001 
First Cord pH* 7.4 (7.3-7.4) 7.2 (7.2-7.3) 7.0 (6.9-7.1) 0.001 
First Base Deficit (-) * 6.1 (3.6-8.5) 5.0 (4.6-9.0) 14.7 (12.5-17.3) 0.003 
First Lactate* 4.8 (2.7-6.8) 4.4 (3.6-7.9) 11.0 (9.6-12.1) 0.004 
Mean (Standard Deviation) [one-way analysis of variance to compare groups], Median 
(Interquartile Range) or n (%) [Kruskal-Wallis H test used to compare groups]. M = Male, F 
= Female, NNU = Neonatal Unit, SVD = Spontaneous vaginal delivery, LSCS = Lower segment 






Figure 4.1. IL-16 assay levels in umbilical cord blood serum. Represented by box plots across A. Two 
groups where there was an increase in IL-16 in the cases (PA and HIE) compared to the controls, P = 
0.025. B. There was a significant increase in IL-16 in the HIE group compared to the control group, P = 
0.041. 
4.4.3 Predictability Compared with Current Markers for Cooling Eligibility 
Assessors of predictability were used to compare the current biochemical (pH, 
lactate, base deficit) and clinical markers (Apgar) for identifying infants eligible for TH 
with our candidate marker IL-16 (table 4.2). IL-16 had a high negative predictive value 
(NPV) of 95% but had a low positive predictive value (PPV) of 16% compared to the 
current clinical and biochemical markers using a cut-off of > 256 pg/mL. The values 
for current markers were set using standard cut-off values used to determine 





Table 4.2. Current standard parameters and IL-16, to predict moderate-severe Sarnat score at 24hr for 
infants with HIE. 
PPV = positive predictive value, NPV = negative predictive value, AUC = area under the curve, CI = 
Confidence Internal. For calculating PPV and NPV standard cut off values for cooling eligibility were 
used for pH (≤7.0), lactate (>7), base deficit (≥16 mmol/L) and Apgar 1,5 and 10-minute (≤5). The 
optimum cut off values for IL-16 was calculated to be >256 pg/mL with 73% sensitivity and 55% 









(%) AUC (CI) P-Value 
Biochemical Markers 
      
pH* 47 82 64 77 0.740 (0.579-0.90) 0.023 
Lactate* 40 89 91 34.8 0.763 (0.592-0.933) 0.014 
Base Deficit* 67 84 60 92 0.844 (0.704-0.984) 0.002 
Clinical Markers 
      
1min. Apgar† 29 99 73 85 0.864 (0.782-0.946) <0.001 
5min. Apgar† 47 96 55 93 0.906 (0.840-0.973) <0.001 
10min. Apgar† 80 93 18 100 0.920 (0.812-1.0) <0.001 
Candidate Marker 
      






This validation study echoes the findings of our initial study (189) where we 
demonstrated that the levels of IL-16 in cord blood were raised in infants with HIE. 
These results suggest that an early inflammatory response occurs in perinatal 
asphyxia but that it is more pronounced in infants that go on to develop HIE.  
The immune response of the body is an active process that continues to change 
during early development. This response can cause massive disruptions following 
perinatal injury (54). Cytokines are produced by immune cells, including microglia 
and astrocytes, which act as regulators of inflammatory interactions, while also 
changing with length and severity of injury (434, 451). The role of cytokines can be 
either pro-inflammatory or anti-inflammatory. In the context of ischaemic insults in 
both adult and newborns, the exact role of the inflammatory response remains 
controversial (434). 
Changing cytokine levels have been described in HIE, and several studies have 
focused on the pro-inflammatory cytokines IL-1β, IL-6 and tumour necrosis factor 
(TNF-α) as potential markers for this condition (184, 208, 210, 452). Results of these 
studies have varied around viable markers in cerebrospinal fluid and cord blood, but 
to our knowledge none of these possible biomarkers have been validated in an 
independent cohort (184, 208, 452). 
This study explores the pro-inflammatory cytokine, IL-16, that may act as a viable 
biomarker for HIE. A series of biomarker studies have demonstrated an increase in 
IL-16 levels in stroke, ischaemic cerebrovascular dementia and HIE (66, 453, 454). 
Mature IL-16 is produced following caspase-3 cleavage from either its precursor 
proteins pro-IL-16 or NIL-16 (446, 447). IL-16 is recognised as a mediator of CD4+ T-
cells, to promote the production of the TNF-α, IL-1β and IL-6, and may act as a 
regulator of apoptosis (455, 456). 
Regarding the clinical utility of serum IL-16 levels for predicting eligibility for TH, it 
did not give better prediction than existing clinical and biochemical markers (table 





67% for the base deficit, and it had an NPV of 84%. The most substantial clinical 
marker was Apgar at 10 minutes with the highest PPV of 80% and NPV of 93%.  Apgar 
at 10 min < 5 is a frequent but not absolute marker for a Moderate/Severe HIE grade 
(5), and as seen in this study, it can have low sensitivity = 18% (table 4.2). 
Although this study aimed to mirror the original study as much as possible, there 
were some critical differences between the two (66). For example, the present study 
only included one infant with severe HIE whereas the original study, included seven 
infants with severe HIE. It is likely that this reduction in severe HIE cases is driven by 
improvements in the obstetric care provided at the two recruiting hospitals. 
R&D human IL-16 DuoSet ELISA development kit was used to measure the IL-16 
cytokine in this study, and the previous study was performed with multiplex assays 
using Luminex technology (Rules Based Medicine, Austin, TX; acquired by Myriad 
Genetics, Utah, USA). Use of different assays for measuring cytokines have been 
known to correlate well, but it is unclear if identical antibody pairs, diluents and 
blockers were used and these may be needed to produce similar quantitation values, 
therefore, this must be highlighted for future studies (457). 
In the present study, umbilical cord serum was used due to a limited number of 
plasma samples. Changing between serum and plasma have been suggested to affect 
cytokine measurements (458, 459), including measurements of IL-16, which is shown 
to yield lower levels in serum compared to plasma (460). This lower yield is consistent 
in our study where the median of both control and HIE group were lower compared 
to the original study. However, the trend towards increased IL-16 levels in HIE 
remains. 
Our group previously described alterations in IL-16 with a level above 514 pg/mL 
using the Luminex assay, which predicted severe disability or death at three years. 
However, we did not observe similar outcomes in this study (189). Here, only three 
infants had the severely abnormal outcome (including autism), and these were 
spread across control, PA and moderate HIE groups. There were no incidents of CP 





This study was performed with a large cohort of 113 infants recruited independently 
from the original study. We continued to see an increase in cord blood-based IL-16 
levels in asphyxiated and HIE infants compared to healthy controls. Changes in the 
ELISA kit, the medium (serum vs plasma), and the number of infants with a severe 
grade of HIE, prevented us from comparing our absolute ranges of IL-16 with those 
observed in the original study. 
IL-16 is raised in the UCB of infants with perinatal asphyxia and HIE. Although this 
suggests that asphyxia produces an early inflammatory response, IL-16 alone is not 
more predictive than current markers, and so, the search for a reliable and robust 
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The Activin A protein and its receptor mACVR2B have both been considered viable 
biomarkers for the diagnosis of hypoxic-ischaemic encephalopathy; mACVR2B is 
considered a downstream target of the previously validated miR-374a (chapter 3). 
The aim of this study was to assess levels of serum Activin A and whole blood 
mACVR2B as early biomarkers of perinatal asphyxia, severity of hypoxic-ischaemic 
encephalopathy, and long-term neurodevelopmental outcome. 
Methodology 
One-hundred and twenty-six infants were included in these analyses of the BiHIVE2 
validation cohort selected from the total population of the BiHIVE2 cohort, a multi-
centre independent study, recruited in both Cork University Hospital, and Karolinska 
Huddinge, Sweden from 2013-2015. Serum Activin A was measured using ELISA, and 
whole blood mACVR2B was measured using quantitative real-time polymerase chain 
reaction. 
Results 
From 126 infants included in the analyses, the serum Activin A analysis included 101 
infants (controls = 50, PA = 28, HIE = 23). No differences were observed across the 
groups, P = 0.693. The HIE group included 23 infants (mild = 14, moderate = 9), and 
no differences were observed across the grades of HIE, P = 0.115. The whole blood 
mACVR2B analyses included 67 infants (controls = 22, PA = 23, and HIE = 22), and no 
differences were observed across the groups, P = 0.746. The HIE group included 22 
infants (mild = 15, moderate = 7) and no differences were observed across the grades 
of HIE, P = 0.468. No differences were observed in infants followed up to 18-36 










Umbilical cord serum Activin A and whole blood mACVR2B are not effective 
biomarkers of infants with moderate HIE; they are unable to distinguish across the 






Novel biomarkers in neonatal hypoxic-ischaemic encephalopathy (HIE) are critical to 
improving efficiency in early diagnosis. Currently, a combination of biochemical and 
clinical measurements are used to identify the presence of the encephalopathy and 
the grade of injury, but these measurements are inadequate (6, 8, 441, 442). Early 
identification is critical as therapeutic hypothermia within the first 6 hours of life can 
improve long-term outcome in the moderate and severe HIE infants. Both early 
electroencephalogram (EEG) and magnetic resonance imaging (MRI) have been 
proven as accurate measures for early diagnosis, but both require specialist training 
for interpretation (22, 29). Multiple biomarkers have been explored across pilot 
studies, but unfortunately, large-scale independent study validation is scarce across 
the field (135). Our group has previously found alterations in umbilical cord whole 
blood levels of mACVR2B, an activin receptor, along with altered trends in umbilical 
cord serum levels of activin A specific to severe HIE(462). The mACVR2B receptor has 
been identified as a predicted target of miR-374a, this miRNA is decreased in cord 
whole blood of infants with HIE (390, 462). 
Activins are circulating proteins that origin from various tissue sources and are 
involved in regulating stimulation and secretion of the follicle stimulating hormone 
(463). Activin A is the most biologically active form of activin, and is a dimeric growth 
factor containing two βA subunits, and its biological activity is mediated via two type 
1 receptors, ACVR1A and ACVR1B, and two type 2 receptors, ACVR2A and ACVR2B 
(464, 465). Activin receptors and the  activin subunit mRNA are highly expressed in 
neuronal cells (466, 467). The receptors are part of the TGF-β receptor family and 
control ligands that signal through the TGF-β pathway (468). The activin receptors 
are involved in growth, differentiation, regulation and apoptosis (469). 
Specific roles in activin signalling include muscle growth, reproduction and early 
development, with overactivation related to cancer (470-472). Activin has previously 
displayed neuroprotective properties, and its levels have varied across the brain  
(473). Activin mRNA expression has been noted in a wide variety of tissues including 





of particular interest in HIE as it has been shown to enhance oligodendrocyte 
differentiation (475), and its receptor ACVR2B appeared to be downregulated during 
oligodendrocyte remyelination and increased specifically in the non-repairing lesions 
(476). The pattern of distribution of activin mRNA has been observed around 
microvessels in the days following HIE in the rat brain (477). Activin A has been 
studied in clinical HIE and found to be correlated with both magnetic resonance 
imaging diffusion co-efficient value and severity of HIE grade, and changes in activin 
A have been observed across the first days of life (194, 195, 478, 479).  
This study aimed to assess if alterations in mild or moderate HIE could be detected 
both cord whole blood mACVR2B and serum cord blood levels of activin A in an 
independent multi-centre cohort study recruited across two countries. Further to 
this, we wanted to assess if alterations in these cord blood biomarkers was 







5.3.1 Patient Population 
The BiHIVE2 multi-centre cohort was recruited from March 2013 to June 2015 at Cork 
University Maternity Hospital, with 7,500 deliveries per annum, and Karolinska 
University Hospital Huddinge, with 4,400 deliveries per annum. The study was 
designed to validate and expand on findings from the original BiHIVE (Biomarkers in 
Hypoxic-Ischaemic Encephalopathy) study and used identical recruitment criteria to 
the BiHIVE1 cohort (213). All cases recruited to this study were inborn and fulfilled 
the following inclusion criteria: gestational age ≥36 weeks and one or more of the 
following: cord pH <7.1, 5 min. Apgar score ≤6, and intubation or resuscitation at 
birth. All cases were observed for the duration of the perinatal period to detect the 
development of HIE, and infants who did not go on to develop HIE were grouped as 
PA at discharge. All HIE cases had continuous multi-channel EEG applied, and 
recordings were started as soon as possible after birth and graded as previously 
described (66). A clinical HIE grade was assigned at 24 h postpartum using a modified 
Sarnat score (77). Full-term healthy control infants were concurrently recruited with 
uneventful deliveries, both normal Apgar scores and neonatal examinations, and 
without admission to the neonatal intensive care unit. Infants were matched for 
gestational age, sex, and birthweight. The clinicaltrials.gov identifier for the BiHIVE2 
study is NCT02019147. The Clinical Research Ethics Committee of the Cork Teaching 
Hospitals and the Regional Ethical Review Board in Stockholm approved the BiHIVE2 
multi-centre validation cohort. Written informed consent was obtained from parents 
of all study participants. 
5.3.2 Sample Collection  
UCB was collected immediately following the delivery of the placenta and processed 
within 3 hours. The 3 mL cord blood used for gene expression analyses was placed 
directly into Tempus Blood RNA tubes (Applied Biosystems, USA) and biobanked at -
80ᵒC. The cord blood serum was placed in a serum vacutainer and allowed 30 
minutes to clot. Following this, the serum was centrifuged at 2,400 x g for 10 min at 





for a further 10 min at 4 °C and aliquoted into 250-μL microtubes before storage at 
−80 °C 
5.3.3 Serum Activin A Quantification 
Activin A serum levels were measured with a sandwich ELISA using the DuoSet ELISA 
development kit (R&D Systems, Minneapolis, MN, USA). The kit used a mouse anti-
human activin A capture antibody, biotinylated mouse anti-human activin A 
detection antibody and recombinant human activin A standard. Samples were 
diluted 1:1 and run in duplicates. The range of cytokine detection was from 125-8,000 
pg/mL, and a coefficient of variation (CV) cut off < 20% was used between duplicates. 
5.3.4 Detection and Quantification of messenger RNA Expression 
Total RNA was isolated from the Tempus system using the MagMAX for Stabilized 
Blood Tubes RNA Isolation Kit (Ambion, Life Technologies, USA) and quantified using 
a NanoDrop 8000 Spectrophotometer (ThermoScientific NanoDrop, USA). Isolated 
RNA was stored at -80ᵒC before quantitative real-time PCR (qRT-PCR, polymerase 
chain reaction). Five ng/μl of isolated RNA was used for reverse transcription to 
synthesise cDNA (complementary DNA) and the mACVR2B expression was analysed 
using ExiLERATE LNATM qPCR (Exiqon, Denmark, acquired by Qiagen, Netherlands), 
with SN48 as a reference gene (370). All samples were run in triplicate, cycle 
threshold (CT) values were recorded, and expression levels were calculated relative 
to controls using the 2-ΔΔCT method (400). 
5.3.5 Neurodevelopmental Assessment 
The neurodevelopmental assessment was performed by a trained clinician or 
psychologist when the child was aged between 18 and 36 months of age and 
consisted of the BSID-III (401). The BSID-III is an individually administered, gold-
standard neurodevelopmental assessment designed to measure the developmental 
functioning of both infants and toddlers (1 to 42 months) and includes Cognitive, 
Language (Receptive and Expressive), Motor (Fine and Gross), Social-Emotional, and 
Adaptive Behaviour Scales. The child’s outcome as measured by the BSID-III is 
determined using the composite scores of the administered subscales. Each 





such that a value below 85 is conventionally used to indicate neurodevelopmental 
delay (402). In this study, to adjust for the differences between Irish and Swedish 
populations, a population-based Z-score was created in place of the standardised 
mean and standard deviation (480). The two-year outcome was considered normal 
if it did not fall one SD below the calculated control group mean in all three composite 
categories (cognitive, language and motor). The outcome was considered abnormal 
if it fell one SD below the calculated control group mean in one or more of the three 
composite categories and severely abnormal if it fell two standard deviations below 
the mean in one or more group, or if the child had severe autism, CP or neonatal 
death. 
5.3.6 Statistical Analyses 
Descriptive analyses were conducted using mean and standard deviation (SD), and 
median and interquartile ranges (IQRs) for parametric and non-parametric data 
respectively, and continuous variables and percentages were used for categorical 
variables. For group-wise comparisons, ANOVA, Kruskal-Wallis test (n groups), 
Student’s t-test or Mann-Whitney test (2-groups) were used as appropriate for 
continuous variables. Chi-square tests were performed to assess categorical 
demographics. Data were analysed using the statistical software package IBM SPSS 






5.4.1 Patient Population 
One-hundred and twenty-six infants were included in these analyses of the BiHIVE2 
validation cohort. The patient population is summarised in Table 5.1. 
Table 5.1. BiHIVE2 cohort patient population. 
 
Control 
n = 57 
PA 
n = 35 
HIE 
n = 31 
P-Value 
Gestation (wk) 40 (39-41) 40 (39-41) 40 (39-41) 0.680 
Birthweight (g) 3789 (599) 3712 (500) 3641 (484) 0.471 
Sex - M (%) 33 (58%) 20 (57%) 18 (58%) 0.997 
1 min. Apgar* 9 (9-9) 7 (5-9) 3 (1-4) <0.001 
5 min. Apgar* 10 (10-10) 9 (9-10) 4 (4-6) <0.001 
Initial Lactate* 2.7 (2.6-4.75) 4.4 (2.9-6.8) 10.95 (9.6-12) <0.001 

























Clinical Demographics in the BiHIVE2 Validation Cohorts. Mean (SD), Median (IQR) or n 
(%). Wk = week, g = grams, M = Male, SVD = Spontaneous vaginal delivery, LSCS = Lower 
segment caesarean section. * = P < 0.05. 
5.4.2 Activin A and mACVR2B Across Groups and HIE Grades 
The serum activin A analysis included one-hundred and one infants, including 
controls, n = 50, PA, n = 28, and HIE, n = 23 (14 mild and 9 moderate), nineteen serum 
samples were excluded due to haemolysis, fibrin clots, and high CV levels. On analysis 
of ELISA results, there was no statistically significant difference observed between 
controls (median pg/ml = 614.88 (interquartile range (IQR) = 409.63-1217.54)), n = 
50, and cases (847.81 (378.89-1402.68)), n = 51, P = 0.392; or across the patient 
groups, controls (614.88 (409.63-1217.54)), PA (1016.05 (329.58-1796.91)), and HIE 





observed across grades of HIE, mild (739.46 (321.08-1141.89)) and moderate 





































Figure 5.1. Activin A in serum. Analysis across A. Patient groups, no significant difference across groups, 
P = 0.693. B. Grades of HIE, no significant difference across grades of HIE, P = 0.115. Boxplots represent 
median, IQR and min-max. 
The mACVR2B expression analysis were carried out on a subgroup of the population 
due to limited cord whole blood samples and included sixty-seven infants, including 
controls, n = 22, PA, n = 23, and HIE, n = 22 (15 mild and 7 moderate). In the gene 
expression analysis there was no significant difference observed between controls 
(median relative quantification (RQ) = 0.92 (IQR = 0.61-1.15)), n = 22, and cases (0.85 
(0.58-1.18)), n = 46, P = 0.689, or across the patient groups, controls (0.92 (0.61-
1.15)), PA (0.79 (0.56-1.11)) and HIE (0.89 (0.58-1.31)), P = 0.746 (figure 5.2A). There 
were also no differences observed across grades of HIE, mild (mean RQ = 1.05 















































Figure 5.2. Fold change mACVR2B expression (RQ). Analysis across A. Patient groups, no significant 
difference across groups, P = 0.746. B. Grades of HIE, no significant difference across grades of HIE, P 
= 0.468. Bar graphs represent fold change of RQ mean, and error bars represent standard error of the 





5.4.3 Activin A and mACR2B in Neurodevelopmental Outcome 
This patient population included 70 infants followed-up with neurodevelopmental 
assessment. The activin A outcome analysis had follow-up on fifty-six infants, 
including normal, n = 43, abnormal, n = 10, and severely abnormal outcome, n = 3; 
on analysis of ELISA results there was no statistically significant difference observed 
across the normal (median pg/ml = 795.37 (IQR = 431.45-1358.98)), abnormal 
(608.57 (333.32-1074.25)) and severely abnormal outcome groups (433.87 (322.49-
1042.04)), P = 0.550 (figure 5.3A). 
The mACVR2B expression analysis included follow-up on thirty-one infants, including 
infants with a normal, n = 25 and abnormal outcome, n = 6; there was no statistically 
significant difference observed across the normal (mean RQ = 0.91 (SD = 0.43) and 
abnormal outcome infants (1.05 (0.77)), P = 0.881 (figure 5.3B). 













































Figure 5.3. Neurodevelopmental outcome in Activin A and mACVR2B. Analysis in A. Activin A expression 
observed no differences across the outcome groups, P = 0.550. B. mACVR2B expression (RQ) observed 
no differences across the outcome groups, P = 0.881. Boxplots represent median, IQR and min-max. 
Bar graphs represent fold change of RQ mean, and error bars represent standard error of the mean. 






Activin A has been considered a potential biomarker of acute neuronal damage as it 
has shown to be increased in CSF following traumatic brain injury and increased 
across the cortical and hippocampal tissue of HIE rodent models (481, 482). Increased 
levels of activin A have also previously been reported in multiple clinical PA studies 
of umbilical cord plasma levels at birth, urinary levels in the first days of life, and in 
cerebrospinal fluid in the first day of life (194, 195, 478, 479). 
This study was part of a more extensive validation study performed to determine if 
previous findings from our BiHIVE1 cohort for severe HIE generalised to mild and 
moderate HIE (462). The original study identified mACVR2B as a predicted 
downstream target of the previously validated miR-374a, and demonstrated 
increased levels of umbilical cord whole blood mACVR2B in severe HIE; the original 
study also observed higher levels of umbilical cord serum activin A as the grade of 
HIE severity increased, but these trends were not significant. The current study, 
however, was unable to find any significant alterations across the groups. 
Activins signal via their receptors at the plasma membrane; and the ACVR2B 
receptors are considered constitutively active kinases. Activin type II receptors, 
ACVR2A and ACVR2B, are required for ligand-binding and for the expression of type 
I receptors, ALK4 and ALK5, which together form a stable complex, and activate 
downstream SMAD2 and SMAD3 molecules which control apoptosis, proliferation 
and differentiation (483, 484). Decreased ACVR2B expression has been associated 
with reduced neuronal apoptosis, where knockdown of expression deregulation 
programmed cell death in an avian model of embryonic neuronal development (485). 
The study has some limitations; although this study was recruited across two 
countries, it includes only mild and moderate HIE. Although previous studies have 
recognised changes in moderate HIE, animal models of HIE indicate that activin A is 
only altered in a severe HI insult, with no alterations observed in the moderate HIE 
model (486, 487). Future validations should include severe HIE although it remains 
challenging to recruit large numbers of infants with a severe grade of HIE. 





we have seen aninability to recruit a large number of infants with a severe grade of 
HIE is related to amalgamation of maternity services and the development of in-
house senior obstetric call. Most of the centre’s cases of severe HIE are thus outborn 
and so collection of UCB is not routinely possible. The use of mRNA as blood-based 
biomarkers is a continuously expanding field and the ability to detect accurately 
precise changes continues to be a challenge (286, 488). This study used the Tempus 
system for blood collection, which should contain both cellular transcripts from 
erythrocytes, leukocytes and platelets and extracellular transcripts from mRNA 
bound stably to both exosomes, microvesicles and proteins (278, 489-491). 
Therefore, it is difficult to decipher the original source of origin for mACVR2B, 
although highest levels of mACVR2B appear to originate from both the testis and 
brain, followed by the ovary and placenta (492) . 
The Activin A receptor mACVR2B appears to be another biochemical marker of 
severe encephalopathy only, which limits its ability to aid clinical decision-making. 
This study highlights the fact that although many studies report the ability of 
candidate biomarkers to predict moderate-severe encephalopathy, these findings 
may be driven by the cases with severe HIE who show a very different clinical and 
biochemical course (373, 493).  
The strengths of this validation multi-centre study involve the ability to recruit and 
analyse a large well-described infant population across two countries. The study also 
collected samples at delivery, all of which were processed according to strict 
standard operating procedures and stored in an ISO compatible biobank. This study 
used UCB, which was minimally invasive to both mother and infant and allowed a 
clear snapshot of placental-fetal circulation. 
This study focused on the umbilical cord serum activin A and umbilical cord whole 
blood mACVR2B as an early non-invasive biomarker that could be collected at birth, 
but neither biomarker could distinguish between mild and moderate grades of HIE; 
or predict mild or moderately abnormal developmental outcome. Other studies, 
have focused on urine and CSF in the postnatal days of life, these two biomarkers of 





studies should not consider umbilical cord serum levels of Activin A or mACVR2B as 











6.1 Description of Main Findings 
This research was conducted with the overarching aim of making novel contributions 
to the field of UCB-based biomarkers in neonatal brain injury. This thesis has also 
endeavoured to explore and validate a number of neonatal brain injury biomarkers 
using two independent cohorts and explore both diagnostic and prognostic potential. 
In Chapter 2, we identified UCB-based miRNA alterations in PA. The panel of miRNA 
explored in the discovery cohort consisted of both miRNA altered in a previous high 
-throughput microarray conducted by our group (see supplementary table 2.1 (213)), 
and also consisted of a selection of miRNA previously described in the literature 
focused on ischaemia, apoptosis, and microglial activation, all implicit in HIE injury 
(58, 434, 494). This allowed the study to conduct both the discovery vs validation 
approach and explore miRNA that may have gone undetected in the microarray 
(495). This was achieved with qPCR across two independent cohorts; with novel low-
throughput decreased expression of miR-376c in infants with PA in the BiHIVE1 
cohort and validated in the BiHiVE2 cohort. We also validated the decreased 
expression of miR-374a in infants with HIE compared to control infants across the 
BiHiVE2 cohort and explored the diagnostic potential of the decreased expression of 
miR-181b, across the two cohorts where it performed well compared to current 
markers of eligibility for TH. To date, altered expression of the three miRNAs have 
not been described in maternal or fetal circulation in the literature, but the three 
miRNAs are not-conserved to umbilical cord blood and have been described in the 
child and adult circulation previously; miR-374a and miR-181b have both been 
observed in the high abundance in the brain, when compared to placenta, testis, 
thymus, and prostate (496-498). 
In chapter 3, we explored the predicted downstream targets of miR-376c, miR-374a, 
and miR-181b associated with the Wnt pathway, mNFAT5 and mFZD4, with qPCR. 
The Wnt pathway was of interest due to previous research in neonatal brain injury 
(330). mFZD4 was significantly increased in infants with severe HIE, and in infants 
eligible for TH, and both mNFAT5 and mFZD4 were significantly increased in infants 





The mRNAs performed better than other biomarkers measured at birth as an 
indicator of poor neurodevelopmental outcome. 
In chapter 4, increased levels of IL-16 were observed in both PA and HIE in BiHiVE2 
validating previous findings from the original BiHiVE study. However, it was not 
reliable enough to differentiate between infants eligible for TH or constitute as a 
strong predictor of long-term outcome. This cytokine was not as reliable as current 
biochemical measurements at birth. The original BiHiVE study was the first to explore 
IL-16 in PA and HIE, prior to this, alterations have been seen in stroke, traumatic brain 
injury, ischaemic cerebrovascular dementia, astrocytic brain tumours and multiple 
sclerosis lesions, and IL-16 is expressed by microglial cells (454, 499-501).  
Finally, in chapter 5, we were unable to determine differences between the receptor, 
mACVR2B, a predicted target of miR-374a, in infants with moderate/severe HIE, and 
we were unable to determine these differences in the protein activin A, most likely 
due to the absence of severe HIE in the BiHiVE2 cohort. In addition, a direct 
correlation between miRNA and mRNA was not consistently seen when comparing 
miRNAs and their putative mRNA targets, such as mACVR2B and miR-374a, this may 
be due to the fragmented nature in which mRNA travels within the circulation, 
meaning that the mRNA may be more difficult to detect compared to the mature 
miRNAs which can exist within exosomes and microvesicles (278); additionally, it 
appears that although miRNA can be detected in PA (miR-376c) and HIE (miR-374a), 
and those eligible for TH (miR-181b), the mRNA are only detectable in those eligible 
for TH and infants that develop a severely abnormal long-term outcomes (mNFAT 
and mFZD4), see chapter 3. 
The purpose of the explored miRNA and mRNA in the circulation remains unclear, 
whether they have a mechanistic purpose or are being filtered from the blood as a 
form of clearance following apoptosis. One proposed mechanistic purpose could be 
that during a critical event, miRNAs are actively transported from the circulation into 
the cell to perform targeted mRNA repression - leading to a downregulation of 
miRNA in the blood. In the cell, the increased number of miRNAs may bind 
‘imperfectly’ to the target mRNA leading to translational repression of mRNA. Instead 





be degraded via exosome-mediated degradation - leading to an upregulation of 
mRNA in the blood. Beyond this, miRNA and mRNA can exist stably in extracellular 
vesicles, bound to proteins, and cellular based in the circulation, however, the origin 




6.2 Clinical Implications 
This thesis expands the field of biomarker research in neonatal brain injury, analysing 
miRNA, mRNA and proteins. It has elucidated novel UCB biomarkers of PA and has 
validated and failed to validate a number of proposed biomarkers associated with 
HIE. 
The miRNAs miR-374a, miR-376c have shown consistent decreased expression across 
high-throughput analysis (previously published microarray data (213)) and low-
throughput validation putting these candidates forward as altered miRNA. However, 
their potential as blood-based biomarkers remains difficult to discern; miR-181b, 
which is decreased in HIE infants eligible for TH, has shown promise with an 
extremely high NPV compared to current biomarkers but Apgar at 5 minutes 
continues to be a strong marker of infants eligible for TH. Further studies with a larger 
sample size would be necessary if this were to be considered further as a combined 
biomarker of HIE. However, rapid testing in qPCR is currently challenging with an 
approximate lead-time of 5 hours for RNA extraction and two-step qPCR, which is 
quite limited as a diagnosis of moderate/severe HIE is needed within 6 hours of 
delivery so TH can be implemented. Although decreased expression of miR-374a for 
HIE and decreased expression of miR-376c in PA have been observed, their future 
potential as point of care blood-based biomarkers is currently unclear. However, if 
altered levels of either miRNA have functional implications in future HIE studies, 
these could have a profound impact on how we approach the injury. 
Current diagnosis of the grade of HIE is subjective based on the modified Sarnat 
score, and it remains difficult to align subjective scores and objective biomarkers 
(502). HIE has been described as an evolving injury, and it may not be feasible to have 
a comprehensive biological snapshot of the injury prior to its full development which 
could be days or weeks after injury. It could also be proposed that if the injury has 
occurred at an early stage in utero, it may be too late for specific biomarkers to detect 
alterations. 
The mRNA, mFZD4, could distinguish infants with eligible for TH, similar to miR-181b, 





were merged to explore mRNA in a larger number of infants with long-term 
neurodevelopmental follow-up. mFZD4 performed better in PPV than current 
measurements at birth at distinguishing infants with poor neurodevelopmental 
outcome, and both mNFAT5 and mFZD4 performed well in NPV. These findings are 
of particular interest in the clinical setting, as the importance of rapid identification 
of these infants is not a necessity, as infants ineligible for cooling, i.e. PA or mild HIE 
could still experience a poor long-term outcome, and identification of infants with 
poor neurodevelopmental outcome may aid in clinical decision making over the first 
week of life. Further studies would need to be conducted with a larger sample size if 




6.3 Thesis Strengths 
The main strength of this thesis is the well-defined cohorts; and the uniqueness of 
the population. Alongside this, BiHiVE2 was conducted as a multi-centre study 
allowing recruitment and analysis of a large well-described infant population across 
two countries.  
The well-defined cohorts included demographical, biochemical, physiological, and 
clinical information. BiHiVE specifically included grading of HIE using a modified 
Sarnat score at 24 hours, and confirmed encephalopathy using continuous 
multichannel EEG which was interpreted by a trained and experienced 
neurophysiologist; it also included long-term neurodevelopmental follow-up at 18-
36 months with the validated BSID-III conducted by either a trained clinician or 
psychologist. 
UCB is used throughout as the medium for biomarker discovery, and it is an optimal 
source as it is non-invasive to both mother and infant; allowing simple collection of 
large volumes postpartum. All samples were processed according to strict standard 
operating procedures within 3-hours post-delivery, scanned and stored in a 
monitored ISO compatible biobank. Cases and controls were age-sex and birth 
weight matched across all studies to reduce biological variation. MIQE guidelines 
were followed for best practice in qPCR (313); miRNA and mRNA analyses were 
conducted in triplicate, including no enzyme controls, no template controls, spike-in 
controls to ensure optimal cDNA reverse transcription, monitoring melt curves, 
ensuring low CVs across samples, and samples were repeated when feasible to 
ensure accuracy. The miRNA, 374a and 376c, altered in chapter 2 of our study have 
been previously reported as altered using a high-throughput method (microarray 
(213)). 
Many questions arise around differences particularly in miRNA and mRNA across the 
blood-based mediums such as whole blood, serum, plasma, and buffy coat (126, 
132). For our HIE studies, we have focused on whole blood in Tempus tubes as they 
can be collected and stored rapidly without processing, and whole blood yields 





miRNA and mRNA in whole blood remains unclear compared to serum or plasma as 




6.4 Thesis Limitations 
The main difficulty to control for in this thesis is heterogeneity across patients, i.e. 
each neonatal brain injury can differ in timing and severity, meaning no injury is the  
No a priori sample size calculations were performed prior to recruitment of the 
BiHiVE cohorts, further to this a power calculation was completed post-hoc and 
demonstrated that the BiHiVE1 and BiHiVE2 cohort were powered at 0.78 and 0.75 
respectively indicating that both studies were adequately powered, although the 
subgroup analyses for miR-181b would require a larger moderate/severe HIE sample 
size for further validation, n = 21 (503). Recruitment of moderate/severe HIE was 
difficult across both studies, as recruitment remains difficult in middle- to high-
income countries, particularly in infants with severe HIE in BiHiVE2 which had n = 1 
UCB samples available; further to this larger sample sizes would be required before 
any biomarker could be readily translated to the cot side. 
Across the BiHiVE, BiHiVE2 and BASELINE cohorts mixed arterial/venous blood was 
collected with the aim of simplifying the collection process. However, this means it is 
unclear if the release or uptake of our biomarkers is reliant on venous or arterial 
blood, it is also unclear if mixed UCB is sufficient as a source for reflecting what's 
occurring in the neonatal brain. 
In the thesis the techniques used for miRNA expression analysis were not analysed 
within the 6 hour window needed to identify infants eligible for TH, the RNA isolation 
needed approx. 1.5 hours, the cDNA synthesis needed approx. 1.5 hours, and qRT-
PCR needed approx. 3 hours, followed by the statistical analysis. However, novel 
molecular biology techniques have been developed over the past 4 years such as 
one-step qPCR and fast qPCR products that could reduce the turnaround time to 
within 3 hours, so miR-181b expression would need to be tested with these novel 
procedures (504). 
Pre-analytical variables played a significant role across this thesis, as both fibrin clots 
and haemolysis can have negative impacts on both RNA and protein downstream 





if the sample became haemolysed due to collection technique at delivery, these 
samples could not be included in our analysis and needed to be excluded. Most whole 
blood RNA samples extracted had high quantities of RNA present after extraction 
from the Tempus tube, but some samples were unsuitable for extraction due to the 
failure of adequate mixing of the stabilising reagent with the blood at the collection. 
Limitations due to cost and time of experiments prevented further validation and 




6.5 Future Work 
Chapter 2 revealed decreased expression of 3 miRNAs, in PA (miR-376c), HIE (miR-
374c) and infants eligible for TH (miR-181b), putting forward several compelling 
questions: 
i. What are the proposed downstream targets of miR-181b, miR-374a, miR-
376c; and are these alterations observed in the circulation? 
Chapter 3, aided in answering part of this question, it focused on two mRNA targets 
associated with the Wnt pathway (mNFAT5 and mFZD4), but miRNA have hundreds 
of downstream mRNA targets and it’s unclear if further mRNA may be related to the 
miRNAs altered in chapter 2 (268, 506). Future work should consider, examining 
alternative pathways including mRNA associated with cell death pathways, which 
have been previously described in HIE, such as caspase signalling, as miRNA and 
mRNA may enter the circulation following apoptotic budding and crossing the BBB 
(44, 507). This work could be conducted by exploring predicted and validated 
downstream mRNA targets using miRBase, miRWalk, TargetScan and DIANA, see 
section 1.5.4.3.2. 
Additionally, in the cellular enrichment analysis of chapter 2, both miR-374a and miR-
376c were considered to play a role in postsynaptic specialisation; this is of interest 
as synaptic dysfunction has been considered in PA previously; which is occurring 
during development, formation, and maturation of the synapses, a process regulated 
by Wnt Signalling (51, 508-510). PA models have demonstrated a decrease in 
neuronal branching and synaptogenesis in the rat hippocampus, along with multiple 
studies describing thickening of postsynaptic densities, protein misfolding and 
ubiquitination post HIE injury (511, 512). One potential explanation is the miRNA are 
released via apoptotic budding or exosomal-mediated transport after microglial 
activation in the hippocampus during BBB leakage post-injury (513-515). 
ii. Are alterations seen in the cord blood reflected in the neonatal brain; and if 





This can be explored with both in vitro and in vivo animal models. The in vitro models 
could aid in understanding if the miRNAs are expressed in neuronal cells, i.e. rodent 
primary neurons, immortalised fetal brain cells, SH-SY5Y cells, and OPCs. These cells 
would be treated with hypoxic treatment, either cobalt chloride, oxygen glucose 
deprivation, or a hypoxic chamber (516, 517). Altered expression in the 3 miRNAs, 
and additionally the 2 mRNAs from chapter 3 (mNFAT5 and mFZD4), could be 
measured with qPCR and the functional effects of these miRNA-mRNA interactions 
could then be confirmed via luciferase assays (518). 
Further to this, a good in vivo animal model has the potential to give further insight 
into areas of the brain where the miRNAs may be present, and by extracting both 
brain tissue and blood from the in vivo models a direct comparison between miRNAs 
in the circulation and miRNAs in the brain post-hypoxia can be considered. 
Multiple animal models have been considered in HIE, with smaller models used for 
mechanistic understanding of the injury and larger animals for translational studies, 
and include rodents, piglets, lamb, rabbit and non-human primates (1, 519). The 
postnatal P7 rat is used to correspond with term newborn maturity, and uses 
unilateral carotid artery ligation combined with a hypoxic chamber, i.e. Rice-Vanucci 
model, or the more recent modified P3 rat which has a higher impact on cortical 
development (519, 520). The rodent model has been considered useful due to the 
large sample size with rodents compared to larger animals and the ability to conduct 
subsequent neurobehavioral studies; however, caveats in this model include failure 
to reproduce oxygenation-reperfusion and representative global HIE and systemic 
organ failure (521). Another consistently used model is the piglet model, which is 
considered optimal due to its human similarities in both the cerebrovascular system 
and the cardiovascular system, and its larger size compared to the rodent model 
allows it to be monitored at birth similar to the clinical condition (522-524). 
Unfortunately, although the piglet would be considered the optimal model it can be 
costly due to animal handling and instrumentation preventing it from largescale use 
across centres (521). Finally, the lamb model has also been widely studied and played 
a critical role in the development of TH, the insult is conducted with either 





representation of the insult and injury, but the neural maturity is considered beyond 
the term newborn making it difficult to make a comparison with neuronal tissue (1, 
2, 525). 
iii. Finally, can the miRNAs be manipulated to develop an RNA-drug delivery? 
Following detection and mechanistic understanding of miRNA function in the brain 
the use of in vitro and in vivo models can be used to explore miRNA manipulation 
using miRNA mimics and miRNA inhibitors to examine if these alterations can have 
positive effects on neuronal tissue post-injury; this will allow the potential for the 
development of miRNA-based drug delivery systems (526). 
In chapter 4, a cytokine biomarker was explored, and the alterations observed do not 
appear to detect clinically meaningful changes in IL-16 with the inability to 
differentiate between PA and HIE, or across HIE grades. In future work, it may be 
more useful to focus primarily on either the umbilical arteries (fetal cytokine release) 
or the umbilical vein (placental cytokine release) as this may provide novel 
information (527, 528). However, postnatal alterations or temporal alterations may 
also be promising as cytokine alterations develop and evolve over the first 72 hrs post 
injury. 
Currently, multiple pilot studies have been conducted in cytokine biomarkers, which 
have seen elevated expression of cytokines (IL-1β, IL-6, IL-8, IL-10, IL-13, IL-16, TNF-
α) across multiples mediums of biofluids (amniotic fluid, UCB, postnatal blood, CSF) 
with blood samples being both serum and plasma, postnatal bloods have also been 
explored temporally across the first days of life; the cytokine biomarkers have been 
correlated with brain injury in relation to MRI, graded injury, and studies have 
conducted long-term follow-up to examine neurodevelopmental outcome at 18-30 
months (52, 178-183, 208). Consistent elevation of these biomarkers across these 
smaller pilot studies warrant further validation studies; further to this as high 
sensitivity ELISA assays are developed these may provide more accurate detection of 
inconsistent results (153, 529, 530). 
The ideal animal model for studying cytokines would be a piglet HIE model due to its 





study which involves the collection of piglet plasma cord blood, temporal plasma 
postnatal bloods and CSF samples and postnatal piglet brain MRI and subsequent 
collection of postnatal brain tissue (531, 532). The bloods and CSF could be tested 
using a high-throughput cytokine panel that includes all cytokines in clinical studies 
to date; this study could be conducted in tandem with a large-scale clinical cohort, 
which would collect plasma cord blood and temporal postnatal plasma bloods and 
CSF samples and the infants would have MRI and long-term follow-up, and the bloods 
and CSF could be tested using a high-throughput cytokine panel that includes all 
cytokines in clinical HIE studies to date (533). This study would allow the researcher 
to compare piglet cytokine levels across the perinatal period with postnatal MRI, 
grade of injury and correlate cytokine levels with postnatal brain tissue; the study 
would also allow the measurement of infant cytokine levels across the perinatal 
period along with postnatal MRI and long-term follow-up; a well-powered clinical 
study would allow the researcher to move potential biomarkers to clinical practise 
and further to this it would allow the researcher to compare inflammatory 
differences between an in vivo model of HIE and a clinical study. 
Sex differences were not explored in the thesis as samples were matched for 
biological sex within the study, but currently HIE occurs more in males than females, 
and males go on to experience poorer long-term outcomes, this is considered to be 
a consequence of both endocrinology and genetics (534). Sex-differences in HIE have 
also been associated with microglial activation, one of the primary immune 
responses in HIE; previous research describes males exhibiting a higher cytokine 
response, and less neurogenesis compared to females, with these differences 
appearing later in the injury (70). Females also exhibit a more significant anti-
inflammatory response compared to males (535). Future studies could consider 
exploring sex-specific temporal inflammatory biomarkers in HIE. 
Throughout the thesis, the test that would be most beneficial based on all studies 
would be a rapidly available miRNA and mRNA combination of miR-181b and mFZD4, 
which could highlight both if the infant did not require TH and if the infant was not 
at high risk of poor neurodevelopmental outcome. These miRNA and mRNA both 





TH and inform parents that the child is not in the high-risk of severely abnormal 
outcome group. These miRNA and mRNA could both be analysed simultaneously as 
they can both be analysed using RNA isolated from whole cord blood, the timeframe 
would need to be reduced to allow rapid detection for infants eligible for TH, this 
may be possible with one-step qPCR or more novel point of care technologies (536). 
To design an ideal biomarker study in the future would involve the recruitment of a 
large multi-centre cohort study, across multiple developed and rapidly developing 
countries, to allow for population differences, and it should recruit sufficient infants 
so all subgroup analyses remain adequately powered throughout, i.e. 150 HIE infants, 
consisting of 50 severe HIE, 50 moderate HIE, and 50 mild HIE, 50 PA infants without 
encephalopathy, and 200 healthy age-sex matched controls. This would allow the 
cohort to be split 50:50 into a discovery cohort (n = 200), and validation cohort (n = 
200) and allow a 20% drop-off rate for the long-term outcome analysis. 
Umbilical cord blood would be collected arterially to ensure its an accurate reflection 
of the infant’s condition. The cord blood would be collected using Tempus tubes at 
birth, and postnatal platelet-poor plasma would be collected also on the first 3 days 
of life in the infant, plasma would be used as Tempus would be incompatible as it 
would require too much blood for a newborn. Following recruitment, the miRNA 
would be isolated, and quality tested and miRNA-seq (NGS) would be performed on 
75 HIE (25 mild, 25 moderate, 25 severe), 25 PA and 25 controls, to identify novel 
miRNAs which may have been discovered (n >2000) since the original microarray in 
2012 (n = 866) (213). 
Bioinformatic analysis would be conducted in DESeq2 and corrected for FDR (108). 
The top 40 miRNA would be validated on the discovery dataset with rapid one-step 
qPCR to test minimum time taken to analyse samples. Further validation of 
consistently altered miRNAs would be conducted on the validation-half of cohort. 
Temporal miRNA alterations would be tested on postnatal samples to identify if 
altered expression continues into the postnatal period, and if changes persist across 
different grades of HIE (351). Additionally, downstream mRNA targets would be 
identified and novel Olink proteomic technologies would be used to test a custom 





targets on postnatal samples to examine temporal alterations in circulating proteins 
post-injury, this would allow for a more functional understanding of changes 
occurring in the circulation, as altered mRNA may not correspond perfectly with 
altered protein function (537, 538). In vitro work could model the miRNA-mRNA 
interactions. The study would then analyse how the miRNAs and proteins correspond 
to long-term outcomes, and finish by the potential development of a robust 




6.6 Concluding Remarks 
This thesis highlights both the complexity and the potential of UCB-based diagnosis 
and prognosis in early infancy. Globally perinatal asphyxia is one of the primary 
causes of neonatal death with approximately 920,000 deaths each year. Early 
identification is critical to implement early intervention and for future treatments 
(34). To date no robust and reliable biomarker can rapidly distinguish HIE, grade of 
HIE, or long-term neurodevelopmental outcome; failure for early diagnosis means 
infants may miss early intervention strategies. Early and accurate prognosis would 
allow long-term treatment plans to be implemented to ensure best quality of life. 
This thesis has shown that 3 miRNAs are consistently decreased in the cord blood 
infants with PA (miR-376c), HIE (miR-374a) and infants eligible for TH (miR-181b); it 
has shown that downstream target mRNAs of the miRNAs altered are increased in 
infants with a severely abnormal outcome (mNFAT5 and mFZD4) at 18-36 months; 
and finally, it has validated (IL-16) a circulating cytokine increased in HIE, and 
invalidated a circulating protein marker (Activin-A) and its mRNA receptor 
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Appendix C. Cohort Identification 
C1.1 BiHIVE Discovery Cohort (2009-2011) 
Prof Murray was the Principal Investigator, and Prof. Boylan was the co-investigator 
steering this project. The study was established to identify a panel of biomarkers 
measurable in umbilical cord blood at birth that could predict severity of hypoxic-
ischaemic injury and predict neurodevelopmental outcome in a cohort of infants with 
signs of perinatal asphyxia at delivery. Promising biomarkers were to be identified 
using a multi-level approach with targeted and untargeted analyses across 
transcriptomics, metabolomics, and proteomics. It was proposed that an optimal 
panel of biomarkers determined by bioinformatics techniques would be developed 
into a point-of-care device to be used in the delivery suite, and this would contribute 
to the clinical decision-making process, treatment management, and prognosis. The 
study was conducted at Cork University Maternity Hospital and recruited between 
September 2009 and June 2011. Informed parental consent for UCB analysis, data 
collection, and neurodevelopmental assessment was a requirement in all cases, and 
the Cork Research Ethics Committee granted ethical approval for this study. 
Cases were identified if they met the following criteria: - 
• Infants having a gestational age ≥36 weeks and one or more of the following: 
o Apgar score ≤6 at 5 mins of life 
o Cord pH < 7.1 
o Required CPR or IPPV > 10 mins 
If the infant met the inclusion criteria, the attending midwives drew UCB, and filled 
2 serum vacutainers, 1 EDTA vacutainer and 1 Tempus blood RNA tube provided by 
a prepared study pack which were stored in a designated research fridge on the 
labour ward. Midwives then contacted the research team via an on-call phone 
number available 24/7 to inform them that blood had been collected. A designated 
researcher than processed the blood according to strict standard operating 





All infants had demographic and clinical data collected during their in-patient stay. 
All infants were assessed neurologically using the Thompson score on day 1, day 2, 
and day 3 of life, and at discharge depending on the length of in-patient stay. All 
infants requiring admission to the neonatal unit who developed hypoxic-ischaemic 
encephalopathy had a modified Sarnat score performed at 24 hours of life. 
Continuous multi-channel EEG application and therapeutic hypothermia were 
provided based on clinical requirement as determined by the consultant on duty. 
Neurodevelopmental outcome assessment was conducted between 18-36 months 
of age. Assessment consisted of the cognitive, language and motor scales of the 
Bayley Scales of Infant and Toddler Development (Edition 3). The parents were also 
asked to complete the social-emotional and adaptive behavioural Checklist (1.5 – 5 
years). 
The BiHiVE1 cohort recruited 112 cases, of these 40 developed HIE. The grade of HIE 
severity was broken down into 24 mild, 6 moderate and 10 severe. Fifty-two infants 




C2.1 BiHIVE2 Validation Cohort (2013-2015) 
Prof Murray was the Principal Investigator, and Prof Boylan and Dr Hallberg were the 
co-investigators steering this project, named BiHIVE2, a validation study of the 
original findings from the BiHiVE1 study. Informed parental consent was a 
requirement in all cases, and the local ethics boards in both countries granted ethical 
approval for this study. The study was a multi-centre study across two countries 
recruited across both Cork University Maternity Hospital, Ireland and Karolinska 
Huddinge, Sweden between March 2013 and June 2015. Informed parental consent 
for UCB analysis, data collection, and neurodevelopmental assessment was a 
requirement in all cases, and the local research ethics committees for each country 
in this study granted respective ethical approval. 
The inclusion criteria of the cases, methods for processing and neurodevelopmental 
follow-up were performed as in the BiHiVE1 study, described in full in D1.1. In the 
BiHiVE2 study, a prospective control population was recruited simultaneously with 
the cases. The parents were approached early in labour regarding their infants 
participating in the healthy control group. Infants were eligible as control infants if 
they met none of the cases inclusion criteria. 
The BiHiVE2 cohort recruited 353 cases, of these 48 developed HIE. The grade of HIE 
severity was broken down into 32 mild, 14 moderate and 2 severe. The healthy 
control population included 289 controls. Four-hundred and forty-nine infants had 








































C3.1 BASELINE Longitudinal Birth Cohort (2008-2016) 
Prof Murray was the Principal Investigator, and Prof. Jonathan Hourihane, Prof. 
Mairead Kiely, Prof. Alan Irvine, and Prof. Louise Kenny were the co-investigators 
steering this project, The Cork BASELINE Birth Cohort Study (Babies After SCOPE: 
Evaluating the Longitudinal Impact on Neurological and Nutritional Endpoints) 
recruited infants from 2008 to 2016 in Cork University Maternity Hospital. The SCOPE 
Ireland pregnancy cohort formed the basis of recruitment of infants to BASELINE, and 
additional infants were recruited post-delivery. Cork Research Ethics Committee 
granted ethical approval. 
BASELINE had three main aims: to investigate the effects of intrauterine growth 
restriction and early nutrition on metabolic health and neurodevelopment; to 
ascertain the incidence and determinants of food allergy and eczema in early 
childhood; and to describe early infant feeding, supplementation and nutritional 
status and their effects on physical and neurological growth and health outcomes. 
Infants were assessed on day 2 and at 2, 6, 12, and 24 months, and at 5-years of 
age(366). Blood samples were collected at birth, 24 months, and 5 years of age, 
processed according to strict standard operating procedures and biobanked at -80°C. 
The Baseline cohort recruited 1537 infants from SCOPE and an additional 600 infants 
on the postnatal ward. From the 2137 infants recruited 1954 continued after the 
initial assessment, 1537 infants were assessed at 2-years of age, and 759 infants were 
evaluated at 5-years of age. At the 2-year weight status 56 infants were obese (BMI 
> 98th percentile), 138 infants were overweight (BMI > 91st percentile), and 809 
infants were not overweight or obese. At the 5-year weight status 18 infants were 
obese (BMI > 98th percentile), 60 infants were overweight (BMI > 91st percentile), and 





















Appendix D. Extended Methodology 
Recruitment 
The PhD candidate was involved in the final recruitment stage for the BiHIVE2 cohort; 
this involved partaking in a 72-hour on call rota for processing and biobanking cases. 
Recruitment took place in two large single maternity hospitals, Cork University 
Maternity Hospital, Ireland and Karolinska Maternity Hospital, Sweden between 
March 2013 and July 2015. 
Sample Processing 
- (Adapted from BiHIVE Standard Operating Procedure) 
Once a case or control was born in BiHIVE2, cord blood was collected across four 
separate tubes in the delivery room; and transported to the research fridge in the 
NICU and the BiHIVE processing team was alerted, blood tubes were processed in the 
laboratory within 3 hours, and the four tubes were: 
• 6 ml red capped serum tube 
• 3 ml blue Tempus RNA tube 
• 6 ml lavender plasma EDTA tube 
• 6 ml additional red capped serum tube 
Serum 
Serum was allowed at least 30 minutes from collection for clot formation prior to 
processing. Samples were checked for clotting prior to centrifugation. Serums were 
centrifuged at 2,400 xg for 10 minutes at 4°C. Samples were pipetted to second spin 
tubes with Pasteur pipette, labelled with patient ID, and marked in red to represent 
serum and centrifuged at 3,000 xg for 10 min. at 4°C. Samples were then transferred 
in 250 μL aliquots into red-capped barcoded microtubules; scanned into the BiHIVE2 








Plasma was centrifuged immediately at 2,400 xg for 10 minutes at 4°C. Samples were 
then transferred in 250 μL aliquots into lavender-capped barcoded microtubules; 
scanned into the BiHIVE2 database and stored in -80°C freezer. 
RNA Whole Blood 
Three ml of blood was transferred directly into TEMPUS blood tube (Applied 
Biosystems, U.S.A.) until it reached the black mark on tube. Immediately after the 
TEMPUS tube was filled, the blood was stabilised with tubes reagents by shaking tube 




Total RNA was isolated from the Tempus system with the MagMAX™ for Stabilized 
Blood Tubes RNA Isolation Kit (Ambion, Life Technologies, U.S.A.), as per the 
manufacturer’s instructions. In summary, stabilised blood samples were thawed on 
ice, resuspended with phosphate buffered saline (PBS), centrifuged and washed to 
pellet crude RNA. Following resuspension and addition of TURBO DNase, the RNA 
was purified and eluted using RNA magnetic binding beads. The RNA concentration 
was quantified using Nanodrop 8000 spectrophotometer, and isolated RNA was 
labelled and subsequently stored in -80°C freezer. 
qPCR 
mRNA SYBR Green qPCR 
In summary, total isolated RNA and reagents were thawed, total isolated RNA was 
diluted to 20 ng/μL using nuclease-free water to form template RNA. Template RNA 
was prepared per sample using the Universal cDNA Synthesis Kit (Exiqon, Denmark; 
acquired by Qiagen, Germany), as per the manufacturer’s instructions. The cDNA was 
acquired with 2 μL of 5x Reaction buffer + 4.5 μL of nuclease-free water + 1 μL of 
enzyme mix + 0.5 μL of synthetic RNA spike in (UniSp6) + 2 μL of template RNA. The 





inactivation of the reverse transcriptase for 5 min. at 95°C and the cDNA template 
was stored in the freezer at -20°C. 
The cDNA template and reagents were thawed, and the template cDNA was diluted 
at 40x. The PCR working solution was acquired using ExiLERATE LNA qPCR, for mRNA 
and long non-coding RNA (Exiqon, Denmark; acquired by Qiagen, Germany), as per 
the manufacturer’s instructions. This was conducted with 5 μL of Exilent SYBR Green 
master mix + 1 μL of PCR primer set + 4 μL of diluted cDNA template. The PCR working 
solution was mixed thoroughly, and real-time PCR amplification was performed by a 
10 min. at 95°C polymerase activation/denaturation, followed by 40 amplification 
cycles for 10 sec. at 95°C, followed by 1 min. at 60°C, with optical read and 
subsequent melt curve analysis. Negative enzyme controls were performed, and 
negative template controls were performed across all primers. 
mRNA TaqMan qPCR 
In summary, total isolated RNA and reagents were thawed, total isolated RNA was 
diluted to 20 ng/μL using nuclease-free water to form template RNA. Template RNA 
was prepared per sample using the Universal cDNA Synthesis Kit (Exiqon, Denmark; 
acquired by Qiagen, Germany), as per the manufacturer’s instructions. The cDNA was 
acquired with 4 μL of 5x Reaction buffer + 8 μL of nuclease-free water + 2 μL of 
enzyme mix + 2 μL of template RNA. The cDNA was synthesised by an incubation step 
at 60 min. at 42°C, followed by heat-inactivation of the reverse transcriptase for 5 
min. at 95°C and the cDNA template was stored in the freezer at -20°C. 
The cDNA template and reagents were thawed, and the template cDNA was diluted 
at 20x. The PCR working solution was acquired using TaqMan Gene Expression 
Master Mix (Thermo Fisher Scientific, U.S.A.), as per the manufacturer’s instructions. 
This was conducted with 10 μL of TaqMan Gene Expression Master mix (including 
ROX dye) + 1 μL of TaqMan Gene Expression Assay + 9 μL of diluted cDNA template. 
The PCR working solution was mixed thoroughly, and real-time PCR amplification was 
performed by a 10 min. at 95°C polymerase activation/denaturation, followed by 40 





and subsequent melt curve analysis. Negative enzyme controls were performed, and 
negative template controls were performed across all primers. 
Protein Expression 
Sandwich ELISA - Activin A 
Human activin A was quantified with the DuoSet ELISA Development System (R&D 
Systems, U.S.A.), as per the manufacturer’s instructions. In summary, 100 μL of the 
diluted mouse anti-human activin A capture antibody was added to each well, this 
was sealed and incubated overnight. The next morning the plate was aspirated and 
washed; 300 μL of diluted reagent diluent was added to each well, the plate was 
sealed and incubated for 1 hr; this was followed by a subsequent aspiration and wash 
step. The recombinant human activin A standard was made up to 25.8 μL of stock 
and diluted with a seven-point standard curve using 2-fold serial dilutions in reagent 
diluent. Then 100 μL of samples and standards were added to the plate, followed by 
100 μL of 1M urea in PBS, the plate was sealed and incubated for 2 hrs. The wells 
were aspirated and washed and 100 μL of the biotinylated mouse anti-human activin 
A detection antibody was added to each well, the plate was sealed and incubated for 
2 hrs. The wells were aspirated and washed, and 100 μL of diluted streptavidin-
conjugated to horseradish-peroxidase was added to each well, the plate was sealed 
and incubated for 20 mins. The wells were aspirated and washed, and 100 μL of 
substrate solution was added to each well, the plate was sealed and incubated for 20 
mins. Finally, 50 μL of stop solution was added to each well, and the plate was read. 
Sandwich ELISA - IL-16 
IL-16 was quantified with the DuoSet ELISA Development System (R&D Systems, 
U.S.A.), as per the manufacturer's instructions. In summary, 100 μL of the diluted 
mouse anti-human IL-16 capture antibody was added to each well, this was sealed 
and incubated overnight. The next morning the plate was aspirated and washed; 300 
μL of diluted reagent diluent was added to each well, the plate was sealed and 
incubated for 1 hr; this was followed by a subsequent aspiration and wash step. The 
recombinant human IL-16 standard was made up to 25.8 μL of stock and diluted with 





μL of samples and standards were added to the plate, followed by 100 μL of 1M urea 
in PBS, the plate was sealed and incubated for 2 hrs. The wells were aspirated and 
washed, and 100 μL of the biotinylated goat anti-human IL-16 detection antibody 
was added to each well, the plate was sealed and incubated for 2 hrs. The wells were 
aspirated and washed, and 100 μL of diluted streptavidin-conjugated to horseradish-
peroxidase was added to each well, the plate was sealed and incubated for 20 mins. 
The wells were aspirated and washed, and 100 μL of substrate solution was added to 
each well, the plate was sealed and incubated for 20 mins. Finally, 50 μL of stop 





Appendix E. Systematic Review 
Mild Hypoxic-Ischaemic Encephalopathy: 
A Systematic Review 
Methods 
A systematic review of the literature was undertaken in June 2015 to assess the 
outcome of mild grade HIE infants after 18 months. 
Relevant literature reporting the outcome of mild HIE infants after 18 months that 
was published from 1980 was searched for in two electronic bibliographic 
databases:- Medline and ScienceDirect. The last search date was 22nd June 2015. 
Searches of the databases were conducted using the following strategies: 
i. Medline: 
(((((outcome) AND hypoxic ischemic encephalopathy) OR hypoxic-ischaemic 
encephalopathy) OR HIE) OR perinatal asphyxia) OR neonatal encephalopathy 
The search was restricted with the following “filters”: Journal articles only; Published 
in English; Human only. 
ii. ScienceDirect: 
"outcome" AND "hypoxic ischemic encephalopathy" OR "hypoxic-ischaemic 
encephalopathy" OR "HIE" OR "neonatal encephalopathy" OR "perinatal asphyxia”.  
The search was restricted with the following “limits”: Journal articles only. 
Eligibility criteria are outlined in figure E1. 
 





Process for Selecting Studies: 
A flow chart of the study selection process is shown in Figure E2. 





Table E1. Mild outcome in HIE studies. 





Outcome of Mild HIE Infants Follow-up 
1 Alderliesten 
(2011) 
81 2 0 Adverse outcome (Griffiths 
Mental Developmental Scale) 
18-46 mo 
2 Barnett (2002) 88 21 1 Mild hemiplegia/dystonia,  
(Touwen Examination (1979)) 
5.5-6.5 yrs 
3 Battin (2001) 40 11 1 Moderate hypotonic, 
developmental delay 
18 mo 
4 Belet (2004) 24 2 0 Adverse outcome 4 yrs 
5 Biagioni (2001) 25 8 1 Moderate outcome, mild 
quadriplegia 
24 mo 
6 Bjork (2013) 35 8 0 Adverse outcome 18 mo 
7 *El-Ayouty 
(2007) 
34 3 0 Adverse outcome  
8 Ferrari (2011) 34 9 2 Dystonic CP 24 mo 
9 Finer (1981)*     
10 Finer (1983)*     
11 Flisberg (2011) 21 1 0 Adverse outcome 18 mo 
12 Gardiner (2014) 65 13 2 Mild disability 24 mo 
13 George (2009)*     
14 Goergen (2014) 19 3 1 Below average BSID-III 24 mo 
15 Haiju (2008)*     
16 Hallioglu (2001) 47 17 0 Adverse outcome 24 mo 
17 Ilves (2004) 140 42 Mild/ 
Moderate 
7 Mild impairments, 3 severe 
disability 
18 mo 
18 Ishikawa (1987)     
19 Kontio (2013) 56 17 9 Moderate injury on MRI 9-10 yrs 
20 Lally (2014) 16 8 1 Abnormal vision 3.5 yrs 
21 Leijser (2007)*     
22 Maneru (2001) 56 6 0 Adverse outcome 8 yrs 





    
25 Mercuri (1999) 29 9 0 Adverse outcome 24 mo 
26 Murray (2010) 22 3 1 Motor delay 24 mo 
27 Murray (2009) 44 18 1 Hypotonic, gross motor delay, 
1 global developmental delay 
24 mo 
28 Murray (2009) 35 17 2 Abnormal outcome 18-24 mo 
29 Muttitt (1991)*     
30 Nagdyman 
(2003) 
49 15 2 Mild retardation, 1 severe 20 mo 
31 Perez (2013) 68 30 0 Adverse outcome 11 yrs 
32 Pisani (2009) 92 27 0 Adverse outcome 24 mo 
33 Polat (2013) 25 11 1 Adverse outcome 44-48 mo 
34 Precht (1993)*     
35 Robertson 
(1985)* 
    
36 Robertson 
(1988) 







    
38 Scalais (1998) 40 5 0 Adverse outcome 24 mo 
39 Shany (2006) 39 16 1 mildly abnormal, 1 severely 
abnormal 
31-67 mo 
40 Suppiej (2010) 59 21 0 Adverse outcomes 18-36 mo 
41 Ter Horst 
(2004) 
30 4 1 mildly abnormal 24 mo 
42 Thornberg 
(1995)* 
    
43 Thorngren-
Jerneck (2004) 
62 21 0 Adverse outcomes 18 mo 
44 Thorngren-
Jerneck (2001) 
20 6 0 Adverse outcomes 24 mo 
45 Van Handel 
(2010) 
126 33 3 TRF above clinical cut-off, 6 
CBCL above clinical cut-off 
9-10 yrs 
46 Van Kooij 
(2008) 
71 32 11 abnormal corpus callosum 
shape 
9-10 yrs 
47 Van Kooij 
(2010) 
80 6 3 Moderate/severe injury 9-10 yrs 
48 Van Schie 
(2010) 
32 7 1 Poor mental outcome 24 mo 
49 Van Schie 
(2015) 





46 10 0 Adverse outcomes 24 mo 
51 Walsh (2011) 44 19 0 Adverse outcomes 24 mo 
52 Wertheim 
(1994) 
37 10 1 Died 18 mo 
*Full-text unavailable. 
 Concluding Summary 
This systematic review identified a number of mild infants with poor 
neurodevelopmental outcome at 18 months. Following this systematic review, these 




Appendix F. Outcome in mUCHL 
Introduction 
This study explores mRNA of UCH-L1, as UCHL1 has previously been described as a 
target of miR-181b (350, 374). UCH-L1 is a highly neuronal and neuroendocrine-
specific enzyme involved in regulating protein degradation (375, 376). 
Methods 
As described in chapter 3. 
Results 
The patient population is as described in chapter 3. 
mRNA Expression in Neurodevelopmental Outcome 
From the population, the neurodevelopmental outcome was available in sixty-three 
infants from both the BiHIVE1 and BiHIVE2 cohort, from this group seven infants 
were excluded as they were tested in a language that was not their first language. 
The neurodevelopmental outcome group included infants with a normal outcome, n 
= 38, a mildly abnormal outcome, n = 11, and a severely abnormal outcome, n = 7. 
Increased levels of mUCHL1 were observed in severely abnormal (median RQ = 2.27 
(IQR = 1.32-2.63)) vs normal outcome infants (0.75 (0.47-1.57)), P = 0.009, and in 
severely abnormal (2.27 (1.32-2.63)) vs mildly abnormal outcome infants (0.78 (0.45-



































Figure F1. RQ levels in messenger RNA assessing neurodevelopmental outcome. The analysis 
included normal outcome, n = 38, mildly abnormal outcome, n = 11, and severely abnormal outcome, 
n = 7. *P < 0.05. Bar graphs represent fold change of RQ mean, and error bars represent standard 
error of the mean. RQ = relative quantification. 
Discussion 
UCH-L1 is a highly abundant and specific neuronal and neuroendocrine 
deubiquitinating enzyme (410). UCH-L1 acts as a marker of prior activation of 
memory T-cells and a determinant of cell survival maintaining axonal integrity after 
brain injury (411, 412). Increased levels of blood-based UCH-L1 is a recognised 
marker for severity of brain injury, with highest levels seen in those patients who do 
not survive (413, 414); it has been described in a number of studies as a possible HIE 
biomarker (415, 416). UCH-L1 can be affected by both long non-coding RNAs and 
miRNA and has been further defined in studies of miR-181b (374, 417-419). Increased 
mUCHL1 is increased in infants with severely abnormal long-term outcome. 
